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Abstract 
 
Background The elderly population in sub-Saharan Africa 
(SSA) is increasing rapidly, with a consequent rise in non-
communicable disease (NCD). The prevalence of stroke 
disease is already known to be higher in SSA than in high-
income countries (HICs). There are currently no community-
based data on the prevalence of atrial fibrillation (AF) or 
hypertension (HTN) specifically in elderly SSAs. 
Design Cross-sectional community-based observational study, 
with case-control sub-group analysis. 
Methods Approximately one quarter of the population (n=2232) 
aged 70 and over of a demographic surveillance site in the 
rural Hai district of Northern Tanzania underwent screening for 
AF by 12-lead electrocardiography (ECG), in addition to a sub-
group undergoing ambulatory cardiac monitoring looking for 
paroxysmal AF (n=232). Demographic data were also collected 
along with disability level, body mass index and blood pressure 
(BP). The gender-specific prevalence of AF, paroxysmal AF 
and hypertension in each 5-year age band was determined. 
ECGs were examined digitally, and P wave indices in this 
population were described. 
Results There were only 15/2232 (12 female) participants with 
AF, giving an age-adjusted prevalence of 0.64%. 6/233 (2.6%) 
had at least 1 paroxysm of AF, suggesting a total overall 
prevalence of AF as high as 3.2%.1553/2232 had a BP 
≥140/90, giving an age-adjusted prevalence of hypertension of 
69.7%. Women had a higher mean systolic (166.0 vs. 
154.3mmHg) and diastolic (89.3 vs. 83.1mmHg) BP.  
Conclusions The prevalence of AF is much lower in this 
population than elsewhere in the world and points towards 
potential protective genetic and environmental factors and 
some differences in risk factor profile. However, the low 
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prevalence of AF is particularly interesting in the setting of a 
prevalence of hypertension and stroke that is similar to African-
Americans in HICs. 
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Chapter 1. Introduction 
 
1.1 Atrial Fibrillation 
 
AF is a cardiac arrhythmia characterised by seemingly 
disorganised atrial depolarisations without effective atrial 
contraction (1). Control of the heart rhythm is taken away from 
the sinus node by rapid electrical activity in the atria. It is the 
most common cardiac rhythm disturbance and contributes 
significantly to cardiac morbidity and mortality worldwide (2).  
 
1.1.1 Pathophysiology 
There have been multiple theories as to the initiation and 
propagation of AF, and thus multiple therapies aimed at 
combating the disease based on these theories. Initially it was 
thought that AF was caused by simultaneous, rapidly 
discharging ectopic atrial foci (3), or by single circuits of 
electrical re-entry (4). Over the past fifty years, multiple-circuit 
re-entry has been the dominant conceptual model of AF, 
heavily influenced by work done with regard to the effect of 
multiple re-entry wavelets on the perpetuation of AF (5), and 
wavelengths of re-entry (6). 
Over the past 15 years however, our understanding of AF 
pathophysiology has advanced significantly through an 
increased awareness of the role of ‘atrial remodelling’ (7). Any 
change in structure or function of the atria constitutes atrial 
remodelling and this remodelling is the dominant reason for AF 
perpetuation, leading to a direct relationship between time 
spent in AF and difficulty in restoring sinus rhythm (i.e. ‘AF 
begets AF’). 
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For the initiation of AF, there needs to be present both trigger, 
as well as susceptible tissue and electrophysiological substrate 
that perpetuates it (dual substrate paradigm) (8). Examples of 
vulnerable substrate include atrial tissue that is acutely 
ischaemic, inflamed or dilated (7). It is now understood that 
most AF is initiated by rapidly firing ectopic foci often located in 
the muscular sleeves of the pulmonary veins (9), or less 
frequently from the proximal superior vena cava (10), ligament 
of Marshall (11), or other parts of the left or right atria (as 
previously suggested by Engelman). 
The principle mechanisms of ectopic activity generation include 
phase 4 depolarisations, delayed after-depolarisations (DADs) 
and early after-depolarisations (EADs) (7). Phase 4 
depolarisation establishes the time required to reach threshold 
potential and generate a spontaneous action potential. If this 
occurs in the atrial cells of an ectopic focus at a faster rate than 
in the sinus node cells, then ectopic beats and sustained 
tachycardias may occur. Abnormalities in cellular calcium 
handling, particularly calcium overload, can cause DADs, 
spontaneous hump-shaped depolarisations occurring just after 
full repolarisation. When they become large enough to reach 
threshold potential, they cause cell firing either as a single 
ectopic beat or a sustained tachycardia. EADs occur when 
action potentials become abnormally prolonged, allowing L-
type calcium channels to recover from inactivation and 
generate abnormal depolarisations at plateau potentials. Both 
phase 4 depolarisations (12) and EADs (13) have been shown 
to be related to atrial tachyarrhythmias, yet their relation to AF 
and atrial remodelling specifically is not fully understood. DADs 
are thought to be promoted by congestive heart failure through 
cellular calcium loading (14), a strong candidate mechanism to 
underlie AF-generating ectopic foci (7). Again, how they relate 
to triggered activity in AF is controversial (15) (16). 
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The maintenance of AF is facilitated by the presence or 
development of abnormal tissue substrate that allows multiple 
re-entrant wavelets of excitation (as mentioned by Moe et al) to 
propagate within the atrial myocardium, through atrial 
remodelling. 
There are two components to atrial remodelling – electrical and 
structural. Electrical remodelling develops within hours of onset 
of AF and includes the electrophysiological alterations of 
shortening of the atrial effective refractory period (AERP), 
action potential duration (APD) and wavelength (WL) (7) (8). 
The AERP is directly related to APD, as sodium channels that 
govern cardiomyocyte excitability inactivate when cells are 
depolarised, and require repolarisation to approximately -60mV 
before they become active again (7). Therefore, the shorter the 
APD, the quicker the sodium channels become reactivated and 
thus the shorter the AERP. APD itself is governed by the 
balance of inward calcium currents (keeps cells depolarised) 
and outward potassium currents (repolarises cells). In atrial 
remodelling it has been shown that sustained rapid atrial 
activation, as occurs in AF, reduces inward L-type calcium 
current and enhances outward potassium currents (17) thereby 
shortening APD. This has been shown to be a major contributor 
to clinically relevant AF promotion (18) (19). Reduced 
wavelength is also an important factor in electrical remodelling. 
Wavelength is the distance travelled by an impulse in one 
refractory period, and is given as the product of refractory 
period and conduction speed (7). It approximates the shortest 
path length for re-entry and determines the size of functional 
re-entry circuits. Consequently, reduced atrial wavelength 
decreases re-entry circuit dimensions and thereby increases 
the potential number of simultaneous circuits and augments the 
probability of AF maintenance (7).  
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Structural remodelling is a slower process involving myocyte 
degeneration, myocardial fibrosis, left atrial enlargement, and 
results in heterogeneity of conduction (8).  It is an important 
contributor to the AF substrate (20).  
The main driver of structural remodelling is sustained atrial 
tachycardia. Evidence suggests it suppresses expression of the 
atrial selective connexin-40 (21), which provides electrical 
coupling between cells and minimises lateral dissipation of 
current, essential to normal impulse conduction and thus 
leading to heterogeneity of conduction (7). It also reduces 
sodium current (22), which provides the source and energy for 
conduction, and is the other essential part of normal impulse 
conduction. 
Atrial tachycardia impairs atrial contractility, principally by 
causing calcium handling abnormalities (23) which causes 
atrial dilatation(24), further promoting re-entry. Atrial dilatation 
increases the amount of atrial tissue that can accommodate re-
entry circuits, and atrial dimensions are a particularly important 
determinant of the occurrence of multiple-circuit re-entry (25). 
In addition, atrial tachycardia up-regulates the expression of 
pro-fibrotic factors such as angiotensin II (26), and transforming 
growth factor 1 (27), and evidence is growing for the roles of 
platelet derived growth factor (20) and connective tissue growth 
factor (28), both of which activate fibroblasts and hence 
encourage atrial fibrosis. AF is known to enhance oxidant 
stress(29, 30) which also enhances fibrosis through cell death 
and pro-inflammatory pathways(7). 
Both electrical and structural remodelling create a susceptible 
substrate that has been implicated in the perpetuation of AF 
(8). 
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1.1.2 Classification 
Clinically, it is reasonable to distinguish five types of AF based 
on the presentation and duration of the arrhythmia: first 
diagnosed, paroxysmal, persistent, long-standing persistent, 
and permanent AF (31). 
(1) Every patient who presents with AF for the first time is 
considered a patient with first-diagnosed AF, irrespective of the 
duration of the arrhythmia or the presence and severity of AF-
related symptoms. 
(2) Paroxysmal AF (PAF) is self-terminating, usually within 48 
hours. Although AF paroxysms may continue for up to 7 days, 
the 48-hour time point is clinically important—after this the 
likelihood of spontaneous conversion is low and anticoagulation 
must be considered. 
(3) Persistent AF is present when an AF episode either lasts 
longer than 7 days or requires termination by cardioversion, 
either with drugs or by direct current cardioversion (DCCV). 
(4) Long-standing persistent AF has lasted for ≥1 year when it 
is decided to adopt a rhythm control strategy. 
(5) Permanent AF is said to exist when the presence of the 
arrhythmia is accepted by the patient (and physician). Hence, 
rhythm control interventions are, by definition, not pursued in 
patients with permanent AF. Should a rhythm control strategy 
be adopted, the arrhythmia is re-designated as ‘longstanding 
persistent AF’. 
This classification is useful for clinical management of AF 
patients, especially when AF-related symptoms are also 
considered. Many therapeutic decisions require careful 
consideration of additional individual factors and co-morbidities. 
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Silent AF (asymptomatic) may manifest as an AF-related 
complication (ischaemic stroke or tachycardiomyopathy) or 
may be diagnosed by an opportunistic ECG. Silent AF may 
present as any of the temporal forms of AF. 
 
1.2 Epidemiology 
Prevalence and incidence rates of AF vary around the world 
according to region and ethnicity. There have been many large 
studies conducted in the developed, high income countries of 
Europe and the United States of America (USA), whilst fewer 
studies have been performed in developing countries, 
particularly in SSA. AF prevalence rates are thought to be 
underestimated overall due to the fact that AF often remains 
undiagnosed for long periods of time (‘silent AF’) (32) and 
many patients with AF never present to hospital (33). 
Examining the literature, there appears to be a consistent 
theme in differences in incidence and prevalence between 
Caucasians (higher prevalence) and African-Americans (lower 
prevalence). This is despite an increased prevalence of 
'traditional' risk factors for AF in African-Americans and 
suggests there must be other contributing factors. It has 
previously been suggested that AF prevalence is particularly 
underestimated in certain ethnic groups (e.g. African-
Americans in the USA) with poorer access to health care (34), 
and this theme may well be extrapolated to low income 
countries with poor healthcare infrastructure. However, this is 
unlikely to be the whole explanation, with genetics and 
environment both likely to be playing significant parts. The 
following AF prevalence studies are summarised in Table 1. 
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1.2.1 Europe and North America 
A large community-based study (15,406  participants) in the 
West of Scotland by Stewart et al (35) looking at the 
prevalence and incidence of AF in 45-64 year olds found an 
overall prevalence of AF in this population of 0.65%. The 
prevalence was higher in males (0.8%) than females (0.5%), 
and prevalence not only increased with age, but the disparity 
between male and female prevalence increased from 0.3% vs. 
0.35% in those aged 45-49 up to 1.5% vs. 0.8% in those aged 
60-64 years. Incident AF in this study followed a similar pattern, 
with overall incidence of 0.54 cases / 1000 patient years, and a 
higher incidence in males versus females (0.9 / 1000 vs. 0.25 / 
1000). Again, this was true throughout the age bands, and 
disparity increased with age, from an incidence of 0.65/1000 in 
males versus 0.2/1000 in females aged 50-54, up to 1.8/1000 
versus 0.7/1000 in males and females respectively, aged 60-64 
years. 
Another study by Sudlow et al (36) in the North-East of England 
looked at community-based prevalence of AF in 4843 people 
aged 65 years and older. They found an overall prevalence of 
4.7%, which increased with age and had preponderance for 
male sex. In the 65-74 year old group, prevalence was 3.5% in 
men and 2.4% in women, rising to 10.0% in men 75 years or 
older and 5.6% in women in the same age bracket. 
These two studies make no mention of the ethnic background 
of participants and this is probably because it was exclusively 
Caucasian. However, a study by Lip et al (33) looking at AF in 
those aged 50 years and over in a general practice setting in 
Birmingham contained small numbers of different ethnic 
groups. Of 4522 patients studied, 111 (2.4%) had AF of whom 
2.7% were Afro-Caribbean, 0.9% Asian and 0.9% mixed-race, 
whilst the majority (77.5%) were Caucasian. The mean age of 
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the patients was 76.6, and the prevalence increased 10-fold 
between the ages of 50-55 (3.6%) and over 80 (36.9%). It was 
noted that 73% of patients had chronic AF and 27% had 
paroxysmal AF. 
A European study by Heeringa et al (37) looked at the 
prevalence, incidence and lifetime risk of AF using a large 
(6808 participants) population-based prospective cohort of 
people aged 55 years and above. This suggested a higher 
prevalence than UK studies of 5.5% overall with a higher 
prevalence in men than women (6.0% vs. 5.1%), but higher 
absolute numbers in women (207 vs. 169). As with previous 
studies, prevalence of AF increased markedly with age, from 
0.7% in the 55-60 year age group, to 17.8% in those aged 85 
years and above. Incidence tended to follow this trend, with an 
overall level of 9.9 cases/1000 person years, increased 
incidence across all age groups in men, and a rising incidence 
level with age (1.1/1000 in the 55-60 age group up to 18.2/1000 
in the 85 and above age group). Lifetime risk of AF was fairly 
similar between sexes, being 23.8% for men aged 55 and 
22.2% for women at the same age. This risk was fairly stable 
until the age of 75, when lifetime risks decreased steadily 
independent of gender. It was noted that at follow-up of the 
same cohort after two and 7 years, the prevalence of AF had 
increased from 6.1% at baseline to 6.7% and 8.3% 
respectively. This was felt to be due to both increased 
awareness of AF by practitioners and ageing of the cohort. 
Studies based in North America suggest similar patterns of AF 
prevalence and incidence to those based in Europe. As part of 
the Framingham study, Kannel et al (38) reported the 
prevalence of AF to be 0.5% at aged 50-59 years, with 
prevalence increasing to almost 9% at age 80-89 years. The 
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odds ratio for developing AF if male as opposed to female was 
1.5. 
 A large study by Go et al (39) looked at the prevalence of 
diagnosed AF in adults (aged 20+ years) in California (USA) in 
a population of 1.89 million, finding 17974 people with AF. The 
overall prevalence was 0.95%, with 45% of AF sufferers aged 
75 or over. AF was again more common in men than women 
(1.1% vs. 0.8%) and prevalence increased with age (0.2% men 
/ 0.1% women aged <50, to 11% men / 9.1% women aged 
85+). The study included ethnicity status in 89% of patients, 
and 84.7% of the study population were white, 3.6% were black 
and 2.5% were Hispanic / Latino, with 9.1% classified as other / 
multiple. Overall, AF was more common in whites than blacks 
(2.2% vs. 1.5%) with this disparity persisting with age (5.2% vs. 
4.4% in the 70-79 age group and 9.9% vs. 7.7% in those aged 
80+).  
The findings of reduced prevalence of AF in black people is 
further supported in a study by Upshaw et al (40) looking at the 
prevalence of AF using electrocardiography in people 
presenting to an urban hospital in Georgia (USA). There was a 
fairly even mix of white (1201) and black (922) patients. The 
overall prevalence was found to be 7.8% in white patients, but 
only 2.5% in black patients. Again, prevalence increased with 
age, but the increase was steeper in whites (2.0% in 50-59 age 
group up to 19.3% in the 90-99 age group) than blacks (0.7% 
50-59 up to 7.0% 90-99). The difference between men (5.6%) 
and women (5.5%) was minimal. 
In the Large Health Survey by Veteran Enrollees Study by 
Borzecki et al (41), 664,754 males responded to a health 
questionnaire. Overall prevalence of AF was 5.3%. By race, the 
age-adjusted prevalence was 5.7% in whites, 3.4% in blacks, 
3.0% in Hispanics, 5.4% in native Americans/Alaskans, 3.6% in 
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Asians and 5.2% in Pacific Islanders (p<0.001). The OR of a 
white male having AF versus a black male was 1.84, despite a 
higher prevalence of hypertension in black males. 
This racial difference in prevalence appears to extend to 
patients with heart failure. Ruo et al (42) studied 1,373 HF 
patients (223 African Americans, 1,150 Caucasians), finding an 
overall prevalence of AF of 36.9%. African-Americans were 
again more likely to be hypertensive, but also to be younger 
and more likely to have been previously diagnosed with heart 
failure. Despite this, the prevalence of AF was significantly 
lower in African-Americans (19.7%) than Caucasians (38.3%). 
The Cardiovascular Health Study by Furberg et al (43), 
reported the prevalence of AF in 5201 elderly patients aged 65 
years and over. The prevalence of AF was 4.8% in women and 
6.2% in men, with prevalence being strongly associated with 
advanced age in women. Another study by Feinberg et al (44) 
in Arizona (USA) looked at recent epidemiological studies in 
the US and estimated that 2.2 million people in the US had AF, 
with a prevalence of 2.3% in those aged 40+ and 5.9% in those 
aged 65+. The absolute number of men and women with AF 
was found to be roughly equal, with about 60% of AF sufferers 
aged 75+ being female.  
A study by Miyasaka et al (45) in Minnesota (USA) reported 
trends in AF incidence over a 20-year period between 1980 
and 2000. They report that the age- and sex- adjusted 
incidence of AF was 3.04 per 1000 person-years in 1980 and 
rose to 3.68 in 2000. This was a statistically significant rise in 
incidence over 21 years, and suggested a relative increase in 
incidence of 12.6%. The authors suggest that if this increase in 
incidence continues, then the number of persons with AF by 
2050 would be 15.9 million, rather than the 12.1 million as 
projected by the US Census Bureau. This study is in line with 
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other studies (39) (46) that suggest the prevalence of AF is 
increasing. 
Another study in Manitoba, Canada, by Krahn et al (47) looked 
at the incidence of AF in 3983 male air crew recruits over 44 
years of follow-up. 299 (7.5%) developed AF during 154,131 
person-years of observation, with the incidence of AF rising 
from 0.5 / 1000 person-years in those aged <50, to 9.7 / 1000 
in those aged >70. 
 
1.2.2 Elsewhere in the World 
A study by Lake et al (48) in Busselton, Western Australia, 
looked at the prevalence of AF in 1770 people aged 60+, and 
found similar results to those found in elderly Caucasian 
populations elsewhere in high-income countries. The 
prevalence increased with age, from 1.7% overall in the 60-64 
age group, up to 11.6% in those aged 75+, and AF was more 
common in men than women (5.6% vs. 4.2% overall). 
The majority of epidemiological work on AF outside Europe and 
the USA comes from Asia. A large study by Inoue et al (49) in 
Japan looked at data from 630,138 subjects aged 40 years and 
over. The overall prevalence of AF was 0.56%, lower than rates 
reported in Europe and the USA. However, similar to Europe 
and the USA, AF was more common overall in men than 
women (1.35% vs. 0.43%) and increased with age, although 
not by as much as seen elsewhere (4.4% in men aged 80 
years and over but only 2.2% in women in the same age 
range). The prevalence of AF in Japan is expected to almost 
double from 0.56% currently to 1.09% in 2050. Another 
Japanese study by Iguchi et al (50) looked at 41,436 people 
aged 40 years and over, finding a higher prevalence rate of 
1.6% overall, closer to that found in a Western population. As 
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part of the follow-up from this study, Iguchi et al (51) also 
produced incidence figures for 30,449 people assessed at 
follow-up. Of these, 278 (0.9%) developed AF over 1 year 
follow-up, giving an incidence rate of 9.3 / 1000 person-years. 
A large study across 13 provinces in mainland China by Zhou 
et al (52) looked at 29,079 adults aged 30 years and over. The 
overall prevalence rate was 0.65%, similar to rates found in the 
study by Inoue et al in Japan, yet lower than Europe and the 
USA. Men had a higher prevalence rate than women (0.91% 
vs. 0.65%) and again, prevalence increased with age. This 
pattern was repeated in another study of 1839 Chinese 
residents of Singapore aged 55 years and older (53). 
In a study of 14,540 adults aged 40 years and over in Korea by 
Jeong et al (54), the overall prevalence rate was 0.7%, again 
similar to other Asian studies. This rate rose to 2.1% in those 
aged 65 years and older, and AF was more common in men 
than women (1.2% vs. 0.4%). 
There has also been prevalence research done in the Middle 
East. A study by Habibzadeh et al (55) looked at 463 people 
aged 50-79 years at a primary care centre in Iran. The mean 
age of participants was 64.0 years and the overall prevalence 
of AF was 2.8%. The prevalence was noted to be higher in 
women than men (4.3% vs. 1.3%), unlike elsewhere in the 
world. It was also noted that the prevalence increased ten-fold 
between the ages of 50-59 (0.6%) and 70-79 (6.4%). 
A study in Turkey by Uyarel et al (56) looked at 3450 adults 
with a mean age of 52.0 years, with an overall prevalence rate 
of 1.25% and incidence of 1.35 / 1000 person-years. Again, 
unlike elsewhere, prevalence and incidence rates for women 
were higher in all age groups. 
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There have been two AF prevalence studies of note in Latin 
America, both based in Sao Paulo, Brazil. The first, by De 
Carvalho Filho et al (57), found a prevalence of 4.8% of chronic 
atrial fibrillation in a geriatric out-patient clinic, with AF sufferers 
having a mean age of 76.1 years. The second, by Kawabata-
Yoshihara et al (58) looked at electrocardiographic findings of 
1524 people aged >65 years as part of the Sao Paulo aging 
and health study. They found an AF prevalence rate of 2.4% 
overall (men 3.9%, women 2.0%), slightly lower than that found 
in Europe and the USA. 
 
1.2.3 Sub-Saharan Africa 
There are very few published data regarding AF in SSA, 
particularly community-based studies. Most reports are either 
hospital-based or focus on the prevalence of stroke risk factors. 
A study by Sliwa et al (59) in South Africa looked at the 
spectrum of heart disease as part of the Heart of Soweto study 
at Baragwanath Hospital in Johannesburg. Of 1593 new 
presentations (mean age 52.8 years) to this tertiary hospital, 
102 (7%) had AF. 59% were women, and all had concomitant 
presentations with heart failure, hypertension, valve disease or 
coronary artery disease. 
Another study by Sliwa et al (60), again as part of the Heart of 
Soweto study, looked at incident AF in a hospital population. Of 
5328 consecutive cardiac cases presenting to the hospital, 246 
(4.6%) had AF. This translated to an estimated 5.6 cases / 
100,000 population / annum. Mean age was younger than in 
epidemiological studies elsewhere in the world at 59.0 years, 
but as with other areas incidence rose with age, from 0.78 / 
100,000 in the 15-24 year age group up to 49.6 / 100,000 in 
those aged 75+. 61% of total cases were found in women, and 
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this higher rate was seen in every age group for women over 
the age of 25 years. Peak incidence for men was in the 55-64 
age group. 
A study by Lodenyo et al (61) looking at cardiovascular disease 
in an elderly hospital population in Nairobi, Kenya, evaluated 
200 consecutive in-patients aged 60+. Their findings are 
reported in a rather confusing manner in that they report 6 out 
of 200 ECGs (3%) showing AF, yet subsequently say that of 43 
patients with arrhythmia (out of the same study population of 
200), 11 (5.5%) had AF. Therefore their exact prevalence rate 
is difficult to determine but is either 3% or 5.5%. 
A study by Connor et al (62) looked at the prevalence of stroke 
risk factors in a general practice population in South Africa. The 
study sent questionnaires out to 200 general practices, with 
9133 questionnaires analysed. Mean age of participants was 
50.7 years, with 73% in the age range 30-59 years. 59% were 
white, 23% black, 10% Asian and 7% of mixed race. The 
prevalence of AF was reported to be highest in white South 
Africans at 5%, 4% in those of mixed race, and 2% in both the 
black and Asian population. 
Finally, a study by Ntep-Gweth et al (63) looked at clinical 
characteristics of AF in an out-patient population in Cameroon. 
172 AF patients (56% female) were included from 10 
cardiologists’ out-patient clinics, with a mean age of 65.8 years. 
The prevalence of paroxysmal, persistent and permanent AF 
was 22.7%, 21.5% and 55.8% respectively.
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Author / Country / Year Study Population Size / 
Location 
Study Population Ethnicity Age Range Studied AF Prevalence Other Important Findings 
Stewart et al, UK, 2001 15,406 
Community-based 
Not stated 45-64 Men 0.8% 
Women 0.5% 
Overall 0.65% 
Prevalence increases with age 
and AF is more common in men 
than women 
Murphy et al, UK, 2007 362,155 
Community-based 
Not stated Overall  
 
65+ 
 
75+ 
 
85+ 
Men 0.9% / women 0.8% 
 
Men 5.3% / women 4.0% 
 
Men 7.5% / women 5.8% 
 
Men 8.4% / women 6.6% 
Prevalence increases with age 
and AF is more common in men 
than women. 
Prevalence decreases with 
increasing socioeconomic 
deprivation  
 
Majeed et al, UK, 2001 1.4 million 
Community-based 
Not stated 70-74 
 
75-79 
 
85+ 
Men 4.6% / women 3.3% 
 
Men 9.1% / women 7.2% 
 
Men 10.6% / women 10.9% 
Prevalence increases with age 
and AF is more common in men 
than women. 
Sudlow et al, UK, 1998 4843 
Community-based 
Not stated 65 – 74 
 
75+ 
Men 3.5% / Women 2.4% 
 
Men 10.0% / Women 5.6% 
Prevalence increases with age 
and AF is more common in men 
than women 
 
Lip et al, UK, 1997 4522 
Community-based 
77.5% Caucasian 
2.7% Afro-Caribbean 
0.9% Asian 
50+ 
 
50-55 
 
85+ 
2.4% overall 
 
3.6% overall 
 
36.9% overall 
Prevalence increases with age 
and AF is more common in men 
than women. Suboptimal use of 
anticoagulation 
Heeringa et al, Netherlands, 
2006 
6808 
Community-based 
Not stated 55+ 
 
70-74 
 
75-79 
 
80-84 
 
85+ 
Men 6.0% / women 5.6% 
 
Men 6.9% / women 5.4% 
 
Men 13.0% / women 6.5% 
 
Men 15.2% /women 12.7% 
 
Men 17.9% /women 17.5% 
Prevalence increases with age 
and AF is more common in men 
than women 
Friberg et al, Denmark, 2003 8606 
Community-based 
Not stated 50-89 Men 3.3% / Women 1.1% Prevalence increases with age, is 
increasing over time and AF is 
more common in men than 
women 
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Wolf et al, USA, 1991 5070 
Community-based 
Not stated 50-59 
 
60-69 
 
70-79 
 
80-89 
0.5% 
 
1.8% 
 
4.8% 
 
8.8% 
Prevalence increases with age 
and increases risk of stroke 
Kannel et al, USA, 1998 4731 
Community-based 
Not stated 65 – 84 Men 9.1% 
Women 4.7% 
Prevalence increases with age, is 
increasing over time and AF is 
more common in men than 
women 
Go et al, USA, 2001 1.89 million 
Community-based 
84.7% white 
3.6% black 
2.5% Hispanic 
20+ 
 
70-79 
 
80+ 
White 2.2%, black 1.5% 
 
White 5.2%, black 4.4% 
 
White 9.9%, black 7.7% 
Prevalence increases with age 
and AF is more common in black 
Americans than white in all age 
groups 
Upshaw et al, USA, 2002 2123 
Hospital admissions 
(consecutive) 
57% white 
43% black 
Age range 20-99 
 
70-79 
 
80+ 
White 7.8%, Black 2.5% 
 
White 9.3%, black 2.4% 
 
White 15.7%, black 8.2% 
Prevalence increases with age 
and AF is more common in black 
Americans than white 
Borzecki et al, USA, 2008 664,754 males Veteran Enrollees  Whites 5.7% 
Blacks 3.4% 
Hispanics 3.0% 
Asians 3.6% 
Pacific Islanders 5.2% 
 
Ruo et al, USA, 2004 1373 F patients 223 African-Americans 
1150 Caucasians 
Mean age 67 
 
Mean age 74 
Blacks 19.7%  
Whites 38.3% 
Overall 36.9% 
 
Furberg et al, USA, 1994 5201 
Community-based 
94.7% white 
4.7% black 
Overall 65+ 
 
70-79 
 
80+ 
Men 6.2% / women 4.8% 
 
Men 5.8% / women 5.9% 
 
Men 8.0% / women 6.7% 
Prevalence increases with age 
and AF is more common in men 
than women overall 
Philips et al, USA, 1990 2122 
Community-based 
Not stated 65-74 
 
75+ 
Men 6.0% / Women 3.0% 
 
Men 16.1%/Women 12.2% 
Prevalence increases with age 
and AF is more common in men 
than women overall 
Feinberg et al, USA, 1995 14,163 
Review of 4 large prevalence 
studies 
Not stated 70-74 
 
75-79 
 
5.0% 
 
7.0% 
 
Prevalence increases with age 
and is higher in men, yet absolute 
numbers in older age groups 
higher in women. 70% AF 
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80+ 10.0% (arbitrarily chosen due to 
low numbers) 
sufferers aged 65-85 
 
Lake et al, Australia, 1989 1770 
Community-based 
Not stated 70-74 
 
75+ 
Men 8.6% / Women 5.5% 
 
Men 15.0% / Women 8.4% 
Prevalence increases with age 
and AF is more common in men 
than women overall. AF cases 
had increased mortality from any 
cause incl. stroke 
Inoue et al, Japan, 2009 630,138 
Community-based 
Not stated 40+ overall 
 
70-79 
 
80+ 
Men 1.35% / women 0.4% 
 
Men 3.4% / Women 1.2% 
 
Men 4.4% / Women 2.2% 
Prevalence increases with age 
and AF is more common in men 
than women overall, but is lower 
than in the USA 
Iguchi et al, Japan, 2008 41,436 
Community-based 
Not stated 40+ overall 
 
60-79 
 
80+ 
Men 2.4% / Women 1.2% 
 
Men 2.3% / Women 1.0% 
 
Men 3.5% / women 2.5% 
Prevalence increases with age 
and AF is more common in men 
than women overall. AF cases 
had lower cholesterol levels than 
non-AF cases 
Jeong et al, Korea, 2005 14,540 
Community-based 
Not stated 40+ overall 
 
70-74 
 
75-79 
 
80+ 
Men 1.2% / Women 0.4% 
 
Men 2.5% / Women 1.1% 
 
Men 3.4% / Women 0.5% 
 
Men 4.5% / Women 3.5% 
Prevalence increases with age 
and AF is more common in men 
than women overall 
Zhou et al, China, 2008 29,079 
Community-based 
Not stated 30+ overall 
 
70-74 
 
75-79 
 
80-84 
 
85+ 
Men 0.9% / women 0.65% 
 
Men 3.0% / women 2.6% 
 
Men 4.8% / Women 2.6% 
 
Men 5.0% / Women 7.0% 
 
Men 15.4% / Women 8.6% 
Prevalence increases with age 
and AF is more common in men 
than women overall. Similar rates 
overall to other Asian studies, but 
higher rates in older age groups 
Habibzadeh et al, Iran, 2004 463 
Community-based 
Not stated 50-79 
 
50-59 
 
70-79 
Men 1.3% / women 4.3% 
 
0.6% overall 
 
6.4% overall 
Prevalence increases with age 
and AF is more common in 
women than men overall 
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Table 1. Summary of AF Prevalence Studies Worldwide
Uyarel et al, Turkey, 2008 3450 
Community-based 
Not stated 32-59 
 
60-69 
 
70-79 
0.46% 
 
2.09% 
 
2.49% 
Prevalence increases with age 
and AF is more common in 
women than men overall 
De Carvalho Filho et al, Brazil, 
1991 
49 
Hospital – based 
Geriatric out-patient clinic 
Not stated 66-87 4.8% Prevalence increases with age 
Kawabata-Yoshihara et al, 
Brazil, 2009 
1524 
Community-based 
Not stated 65+ Men 3.9% / women 2.0%  
Connor et al, South Africa, 
2005 
9133 
Community-based 
59% white 
23% black 
10% Asian 
7% mixed race 
Mean age 50.7 years White 5% 
Black 2% 
Mixed race 4% 
Asian 2% 
AF more common in white and 
mixed race than black and Asian 
people 
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1.2.4 The ‘African-American paradox’ – potential genetic factors influencing 
epidemiology 
As can be seen from my literature review, a clear pattern emerges, such that 
there appears to be significant differences in the prevalence of AF in different 
racial and ethnic groups. The most widely studied groups in high-income 
countries are Caucasians and African-Americans and despite the literature 
suggesting that African-Americans not only have higher rates of 'traditional' 
risk factors for AF (discussed in detail in next section), such as hypertension 
and obesity, but also significantly increased problems with sequelae of AF, 
such as stroke (discussed in section 1.5.1), they appear to have a much 
lower prevalence of AF itself. Thus, a paradox is present, one which has as 
yet remained unexplained although there have been several suggestions as 
to the potential reasons for this paradox. These include differential access to 
healthcare and therefore population bias, disease subtypes such as 
paroxysmal AF being more common in African Americans and therefore 
inadequately sensitive diagnostic methods (64), and survival bias i.e. 
exclusion of people from epidemiological surveys who die from their AF (65).  
However, there is growing evidence that these factors cannot explain the 
paradox fully, and that there are also potentially influential genetic factors. 
The evidence for a genetic predisposition to AF has been growing and a 
report by Fox et al (66) from the Framingham Heart Study suggested that if 1 
parent had AF, their offspring had an OR of 1.85 of developing AF. This OR 
rose to 3.23 if the parent had developed AF <75 years of age, and most 
'genetic evidence' for familial AF has arisen in studies of families with 'lone 
AF' (i.e. AF at a young age with no structural heart disease) (67-69). Current 
attention has turned towards the renin-angiotensin-aldosterone system 
(RAAS). Evidence is accumulating that RAAS may be an important risk 
factor for AF and inactivating RAAS through the use of angiotensin 
converting enzyme inhibitors may help prevent AF. There are known to be 
differences in the expression of genes coding for RAAS between white and 
black people (70) and, whilst most studies have been undertaken to show 
genetic polymorphisms that increase risk of AF, there of course must be 
polymorphisms that potentially protect against AF development. A study by 
Shreieck et al (71) looked at the C825T polymorphism in the coding region of 
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the G-protein β3-subunit (GNB3), which modulates atrial inward rectifier 
potassium current. Their study reported a 54% decrease in AF in people with 
this polymorphism. There is a paucity of genetic data in African-Americans 
although the Vanderbilt-Meharry AF registry seeks to fill this knowledge gap 
(72). I could find no data on the genetics of AF in a SSA population.  
 
1.3 Aetiology and Risk Factors 
 
1.3.1 Hypertension 
Hypertension (HTN) is the most common condition associated with AF in 
population-based studies (73). The suggested pathophysiological 
mechanism is adverse left atrial (LA) remodelling (dilatation and fibrosis) 
because of decreased ventricular compliance, increased ventricular stiffness 
and increased left ventricular (LV) diastolic filling pressures. This is one of 
the particular reasons for looking at hypertension in this elderly Tanzanian 
cohort (see chapter 7). 
In the Framingham study (38) it was reported that HTN was responsible for 
more AF in the population (14%) than any other risk factor. It conferred an 
odds ratio for the development of AF of 1.5 for men and 1.4 for women after 
adjustment for other risk factors. In another study by Psaty et al (74), for 
every 10mmHg increase in Systolic blood pressure (BP), the relative risk of 
incident AF was 1.11. In the Manitoba Follow-up study (47), the risk of AF 
was increased by 1.42 times in men with a history of hypertension. The 
Women’s Health Study (64) looked at systolic and diastolic BP in 34,221 
women and subsequent risk of incident AF. They studied 34,221 women and 
found there was a statistically significant trend in increasing systolic and 
diastolic BP with incident AF.  
Interestingly, a study by Schnabel et al (75) looked at risk factors for AF in 
whites versus African-Americans using data from 3 large population-based 
studies (Framingham, Cardiovascular Health Study and Age, 
Gene/Environment Susceptibility-Reykjavik Study), including 1552 African-
Americans. Of these, 35.8% were men with a mean age of 75.3 years. The 
study reports that whilst HTN was more prevalent in African-Americans and 
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derived similar hazard ratios to whites (1.17 vs. 1.14/1.14/1.18) this did not 
translate into an increased incidence of AF and thus suggests that HTN may 
not be such an important risk factor for AF in African-Americans. In the 
previously mentioned Heart of Soweto study (59), HTN was only present in 
12 of the 102 (12%) AF cases. 
 
1.3.2 Ischaemic Heart Disease 
In the Manitoba Follow-up Study (47), risk for AF was not only higher in 
participants with previous myocardial infarction (MI) (RR 3.62) and known 
angina (RR 2.84), but also in those with ST and T wave abnormalities on 
their ECG in the absence of overt ischaemic heart disease (IHD) (RR 2.21). 
It was noted that the RR for AF was strongest at the onset of IHD and 
diminished over time. In the Framingham study, only men with previous MI 
suffered increased risk (OR 1.4). However, in the Renfrew/Paisley study (35) 
it was reported that the odds ratio of incident AF was higher for women with 
myocardial ischaemia than men (OR 5.6 vs. 2.2, 4.5 overall). Chronically 
ischaemic myocardial tissue is an ideal substrate for AF perpetuation. 
However, risk of AF is not only increased in chronic IHD, but also in acute 
MI, reported to complicate 6-21% of all MIs in a review by Schmitt et al (76). 
The underlying mechanisms suggested in the acute setting include atrial 
ischaemia or infarction, right ventricular infarction, pericardial inflammation, 
acute hypoxia or hypokalaemia, and haemodynamic impairment secondary 
to LV dysfunction (77, 78). 
Interestingly, it has previously been noted that black Africans suffer less IHD 
than do white people. Bertrand et al (79) reported that IHD accounted for 
only 6% of all forms of cardiovascular disease (CVD) in black Africans, and a 
study by Walker et al (80) in South Africa reported that IHD was responsible 
for <1% deaths. This compares to a prevalence of IHD in the general 
population in the USA of 6.9%, with IHD responsible for 20% of all deaths in 
the USA in 2003 (81). 
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1.3.3 Age 
Advancing age has consistently been shown to be a risk factor for the 
development of AF. Please see epidemiology section (1.2) where age as a 
risk factor for AF is discussed with specific reference to the appropriate 
literature. 
 
1.3.4 Cardiac Failure   
The Framingham study (38) showed there to be 4.5x risk in men of AF if they 
had heart failure and a 5.9x risk in women. Diastolic dysfunction associated 
with increased LV filling pressures is common in the elderly and has also 
been shown to increase risk of AF by 5.26x in one study by Tsang et al (82). 
In a review of papers looking at AF risk factors by Schnabel et al (75), 
prevalent heart failure provided a hazard ratio for incident AF of 1.78 – 4.45 
in whites (dependent on study) and 3.21 in black Americans. 
The EuroHeart Failure survey conducted in 2000 - 2001 in 24 countries in 
Europe has reported that up to 45% of patients with congestive heart failure 
(CHF) also presented with intermittent or established AF (83). According to 
this survey, the overall prevalence of new onset AF in patients hospitalised 
for CHF is 13%, ranging from 8% to 36% in different European regions. The 
prevalence of AF generally depends on the severity of the underlying 
pathology, between 10% and 20% in mild to moderate CHF and up to 50% in 
patients with more advanced disease (84). Patients with CHF due to diastolic 
dysfunction have the same prevalence of AF as their counterparts with LV 
systolic dysfunction. AF was present in 29.1% of patients with an ejection 
fraction <40% enrolled in the Candesartan in Heart Failure Assessment of 
Reduction in Mortality (CHARM)-Preserved trial (85) and in 23.4% patients 
with an ejection fraction <50% who participated in the New York Heart 
Failure Consortium Registry (86). 
Further studies have shown heart failure to be a common concomitant 
diagnosis with AF. Murphy et al (87) reported that heart failure was 
concomitantly diagnosed in 15.3% of men and 19.8% of women with AF in a 
community-based study of general practices in Scotland. Sliwa et al (59) 
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reported heart failure concomitantly in 48 of 102 (47%) consecutive cases of 
AF in a hospital-based setting in South Africa. 
Because of the nature of the two conditions occurring together it is difficult to 
ascertain in the majority of cases which came first, AF or heart failure. In the 
majority of cases it is likely that heart failure predisposes to AF rather than 
the other way around although, in the Manitoba Follow-up study (47), whilst it 
was noted that congestive cardiac failure (CCF) was a risk factor for AF, AF 
itself increased the risk for CCF (RR 2.98). 
 
1.3.5 Atrial Enlargement 
The Framingham study (38) reported increased LA diameter as a risk factor 
for AF, with a 39% increase in risk with each 5mm incremental rise in LA 
diameter. This finding was supported by the Cardiovascular Health Study 
findings (43), and by data from the Olmsted County study (88) that showed a 
30% increase in LA size was associated with a 48% higher risk of AF.  
As discussed previously, atrial dilatation and structural remodelling not only 
changes ionic currents through atrial myocytes (23) but also the process of 
an enlarged LA means there is simply a bigger volume for micro re-entry 
circuits to flourish (25). 
 
1.3.6 Intra-Cardiac Conduction Abnormalities  
PR interval (79) and sinus node dysfunction (80) are known to increase the 
risk of AF. RR increases with increasing PR interval length, and previously 
published studies suggest chronic AF occurs in up to 11% of SSS cases at 
19 months, 16% at 5 years, and 28% at 10 years. 
Wolf-Parkinson-White Syndrome (WPW), a syndrome in which an accessory 
conduction pathway between atria and ventricles is present, also confers 
increased risk of development of AF. AF occurs in a fifth to a third of WPW 
patients, and can continue to occur in up to 24% even following ablation of 
the accessory pathway (89). 
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1.3.7 Obesity and Metabolic Syndrome 
Obesity in both women (82) and men (83) has been shown to increase risk of 
AF development. The Women’s Health Study in the USA showed a 4.7% 
increase in risk with each kg/m2.  
A study by Rosengren et al (90) looking at 6903 men (mean age 51.5 years) 
in Sweden showed recalled increased body surface area (BSA) at age 20, 
increased BMI at assessment and the increase in weight over time all had a 
positive correlation with risk of AF. 
A recent meta-analysis found that obesity increased the risk of developing 
AF by 49% in the general population and the risk escalated in parallel with 
increased BMI (91). 
The Metabolic Syndrome (≥3 of abdominal obesity, elevated triglycerides, 
low HDL cholesterol levels, elevated blood pressure and impaired glucose 
tolerance) has also been shown to increase risk of AF, with obesity being the 
most significant contributor to AF risk (85). 
Another study, by Chamberlain et al (92) looked at 15,094 participants in the 
ARIC study, which was notable for its significant percentage of African-
Americans included. 45.7% of blacks and 39.6% whites at baseline had 
metabolic syndrome. Over a mean follow-up of 15.4 years, 1238 cases of AF 
were identified. Age-adjusted incidence rates were higher in those with 
metabolic syndrome than without (60/10,000 person-years vs. 36). Hazard 
ratio for incident AF was 1.67 for those with metabolic syndrome vs. those 
without and there was no significant inter-racial difference. The population 
attributable risk was 22% (i.e. 22% of AF events could have been prevented 
with elimination of metabolic syndrome). HTN and obesity appeared to 
confer greatest increased risk, their respective multivariable-adjusted hazard 
ratios being 1.95 and 1.4. Other components measured were low high-
density lipoprotein (HDL) (HR 1.2), impaired fasting glucose (1.16) and 
elevated triglycerides (0.95). Increasing number of components of metabolic 
syndrome conferred increasing risk of AF, with a hazard ratio of 4.40 for 
those with all 5 components vs. those with none. 
Reasons suggested for the trend of increased AF incidence in people with 
increased body size include the fact that as body size increases, so does LA 
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size/volume (87), in addition to the correlation between obesity and IHD and 
thus, potentially, heart failure (86).  
 
1.3.8 Hyperthyroidism 
Whilst the prevalence of hyperthyroidism in the elderly ranges from 0.4-2.0% 
(93) and is thus not high, studies have shown increased prevalence (88) and 
incidence (89) of AF, with biochemical abnormalities more pronounced in 
those hyperthyroid patients with AF (92). 
 
1.3.9 Electrolyte Abnormalities 
AF is more common in patients with primary aldosteronism (93), post cardiac 
surgery in patients with low potassium levels (94) and in patients with 
diuretic-induced hypomagnesaemia (95) 
Suggested mechanisms for increased AF in patients with hypokalaemia and 
hypomagnesaemia centre around the ideas that reduced levels of K+ and 
Mg2+ not only increase automaticity by increasing premature atrial complexes 
(PACs) (through increased intra-cellular Ca2+) but also shorten AERP and 
increase wavelet dispersion, thereby creating a substrate for the initiation 
and propagation of AF (94). 
 
1.3.10 Valve Disease 
The Framingham study (38) reported an odds ratio for AF development in 
patients with valvular heart disease of 1.8 in men and 3.4 in women. This 
finding is supported by other large population-based studies in North 
America such as the Cardiovascular Health Study (43) and the Manitoba 
follow-up study (47). Aortic stenosis (97) and aortic regurgitation (98) have 
been shown to be related to AF, particularly in the elderly. Left ventricular 
hypertrophy (LVH) results from a ventricle contracting against a stenosed 
aortic valve, and LV dilatation results from a regurgitant aortic valve. Both 
eventually lead to increased LV diastolic filling pressures and decreased LV 
compliance, meaning increased LA pressure and atrial remodelling. 
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Whilst the aetiology of valve disease in these studies is primarily likely to be 
related to chronic degeneration and the result of other co-morbidities such as 
MI leading to functional valve incompetence, the situation in SSA is very 
different. In SSA, valvular disease is encountered in the young, not 
infrequently in children of school-going age or young females of child-bearing 
potential, and with a course that is much more rapid. This is usually as a 
result of infectious disease, either directly through infective endocarditis or 
indirectly as in the case of acute rheumatic fever. The incidence of acute 
rheumatic fever (in large part secondary to Group A streptococcus infection) 
has been said to be 100 times greater in SSA (data from Sudan) than in 
high-income countries. The prevalence of chronic rheumatic heart disease 
(RHD) has been estimated mainly from surveys of school-going children and 
varies from 2.7/1000 in Nairobi to 14.3/1000 in Kinshasa (95). In a survey of 
12,050 black school children in Soweto, South Africa, in 1975, McLaren et al 
(96) found a prevalence of 6.9/1000 with a maximum of 20/1000 in seventh- 
and eighth-grade children. With an improvement in the standards of living in 
the Soweto population, a distinct decline in the incidence of acute rheumatic 
fever presenting to Baragwanath Hospital has been observed (97), although 
chronic rheumatic valve disease remains commonplace. 
The Heart of Soweto study (60) found that valve disease was a common 
concurrent diagnosis in incident AF cases, occurring in 107/246 (43%) 
cases. A primary diagnosis of valve disease was made in 71 of these cases, 
with the remaining 36 as a result of other cardiac pathology leading to 
valvular dysfunction (e.g. ischaemic cardiomyopathy leading to functional 
mitral regurgitation). 51 cases were diagnosed as rheumatic (of which 43% 
were mitral stenosis), with the other 20 degenerative, perhaps highlighting 
the different underlying aetiology of valvular heart disease in SSA. Potential 
reasons for the fact that mitral valve disease increases risk of AF include the 
idea that both mitral stenosis and mitral regurgitation increase left atrial 
pressure, thus causing atrial dilatation and structural atrial remodelling over 
time. There are very little data on valve disease in the elderly in SSA, 
potentially this is a result of a combination of the majority dying at a young 
age and that same age group being an understudied demographic. 
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1.3.11 Pulse Pressure 
In a study by Mitchell et al (98), pulse pressure and systolic pressure were 
both associated with a higher risk of developing AF, with an odds ratio of 
1.23 for pulse pressure and 1.14 for systolic BP, although their population 
was one of almost exclusively Caucasian background and there is little data 
in different racial groups. Elevated pulse pressure is used as a surrogate for 
increased proximal aortic stiffness (98) and has been shown to predispose to 
increased LA size chronically (99) as well as being thought to increase LA 
distending pressure (and thus provide substrate for AF initiation)when 
pulsatile load increases acutely (100). 
 
1.3.12 Other Risk Factors 
Pulmonary embolus (106), sepsis (107, 108), atrial myxoma (109-111), atrial 
septal defect (112, 113), the post-cardiac surgery state (31) (due to a 
number of mechanisms including acute atrial distension, atrial inflammation 
from surgical trauma or pericarditis, ischemic injury caused by cardioplegia, 
and electrolyte and volume shifts during bypass that can alter atrial 
repolarization (101)) have all been shown to increase risk of AF. AF is less 
common in patients following non-cardiac surgery but can still be a potential 
problem and, as one might expect, has been noted to be more common in 
those with underlying cardiovascular disease (115, 116). 
 
1.4 Associations 
1.4.1 Diabetes 
AF prevalence is significantly greater among patients with diabetes mellitus 
(DM) and a study looking at 17,000 diabetic patients with an equivalent 
number of age- and sex-matched controls showed an exaggerated increase 
of AF incidence over time in diabetic vs. non-diabetic patients, particularly in 
women (117). Newly-diagnosed AF is also more likely to occur in diabetics 
than non-diabetics (118), translating into a 40% increase in risk of AF in 
those with treated DM. This is primarily thought to be due to increased 
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diastolic dysfunction and thus LA pressure, chronic inflammation and cardiac 
autonomic neuropathy. 
 
1.4.2 Cognitive Function 
There have been many studies looking at the association between AF and 
cognitive function, often reporting conflicting results. A systematic review 
(120) and a meta-analysis (121) of the current literature (with some overlap 
in studies analysed) found similar results in the general population in that 
there remains uncertainty of a link between AF and dementia. However, the 
meta-analysis looked at studies involving patients having had a stroke (7 out 
of 15), with the association much more convincing, with an OR of 2.4 
(p<0.001) in patients with AF and stroke for developing dementia compared 
with patients without AF or stroke.  
 
1.4.3 Chronic Kidney Disease 
Two reasonably-sized studies looked at the association of AF with CKD, one 
including 50% African-Americans finding that in CKD patients the prevalence 
of AF was 18% overall, higher than in previous studies (123-126). The 
REGARDS study more recently found a prevalence of AF of only 1.0% 
although the prevalence did increase significantly with worsening renal 
function (127). 
 
1.4.4 Pericardial Fat 
CT-estimated pericardial fat volume (128) has been linked to an increased 
risk of AF, patients with persistent AF having been shown to have a greater 
volume than paroxysmals, who in turn have a higher volume than those in 
sinus rhythm (129).  
 
1.4.5 Obstructive Sleep Apnoea 
Incident AF is higher in patients with obstructive sleep apnoea (OSA) (130). 
OSA is more prevalent in patients undergoing DC cardioversion (DCCV) 
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versus those controls without past / current AF referred to a cardiology OPC 
(131) and AF is more likely to recur in patients with OSA who have 
undergone DCCV who are not treated with nocturnal CPAP versus those 
who are (132). 
 
1.4.6 Diet (Caffeine, Alcohol and Fatty Acids) 
A recent systematic review by Gronroos and Alonso (102) reviewed the 
evidence regarding the influence of dietary factors on risk of AF. The review 
identified 4 factors that have been looked at in relation to subsequent AF – 
alcohol, caffeine, fish-derived n-3 polyunsaturated fatty acids (n-3 PUFAs) 
and ascorbic acid. Alcohol appears to increase risk of AF, particularly heavy 
drinking (134-137), whilst n-3 PUFAs may decrease risk by as much as 85% 
in 1 study (138). Caffeine intake showed a U-shaped curve in 1 study (139), 
whereby moderate caffeine intake may have a protective effect, and ascorbic 
acid may be protective in high doses post-cardiac surgery (140). 
 
1.4.7 Inflammation and Inflammatory Conditions 
It remains controversial as to whether inflammation is the initiating event in 
the development of AF or, conversely, if it occurs as a consequence of AF. 
Evidence implicating inflammation in the initiation of AF include the increased 
incidence of AF in the setting of inflammatory states such as cardiac surgery 
and the observation that baseline CRP levels predict future occurrence of AF 
(103). On the other hand, the observation of decreasing highly sensitive CRP 
levels following restoration of sinus rhythm has led some to believe 
inflammation is a consequence rather than a cause of AF (104). 
Chung et al were the first to report an association between AF and elevated 
CRP in non-postoperative AF (105). The association between elevated CRP 
and presence of AF was further supported with the findings from a large 
population-based cohort study of 5,806 elderly individuals followed for a 
mean of 6.9 years (103). CRP was not only associated with the presence of 
AF but, in patients without AF at baseline, elevated CRP levels were 
significantly and independently associated with the future development of 
AF. In one study, every 1 mg/dL increase in serum CRP was associated with 
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a 7-fold increased risk of recurrent AF and a 12-fold increased risk of 
permanent AF compared with controls (106). Raised CRP has also been 
associated with failed DCCV in those with persistent AF (107) and also with 
recurrence of AF post-DCCV (108). 
The exact mechanism for increased serum CRP in AF patients is uncertain.  
It has been suggested that it may contribute to cellular membrane 
dysfunction and therefore have a direct effect (109) or may just be a marker 
of systemic inflammation and reflect underlying disease processes 
associated with AF. Raised Interleukin-6 (IL-6) has also been shown to be 
related to presence / duration of AF and LA diameter (110), and IL-8 was 
found to be elevated in AF patients in a small study (111). 
 
1.5 Sequelae 
1.5.1 Stroke and Thromboembolism 
A study by Wolf et al (112) looked at 34 years of follow-up in 5070 (almost 
exclusively) Caucasian patients from the Framingham study. They assessed 
AF as an independent risk factor for stroke and found that there was a five-
fold excess of stroke in patients with AF. In persons with IHD or heart failure, 
AF doubled the stroke risk in men and trebled the risk in women. The 
attributable risk of stroke in AF sufferers increased from 1.5% in those aged 
50-59 to 23.5% in those aged 80-89 years. The data suggest the elderly are 
particularly vulnerable to stroke when AF is present. 
In a report by the Stroke Prevention in AF Investigators (1992), 568 AF 
patients were followed up for a mean of 1.3 years. They looked at the 
incidence of stroke in AF patients with and without three clinical predictors 
(recent CCF, HTN and previous thromboemboli). Risk of stroke was 2.5% 
per annum in AF patients with none of these predictors, rising up to 17.6% 
per year with 2 or 3 of the clinical predictors. 
In a population based study (113) looking at long term (20 year) risks, AF 
was a strong independent risk factor for stroke (in women OR 3.2 and in men 
OR 1.8).   In another study one in six strokes occurred in a patient with AF 
(114). In the Framingham study ischaemic stroke occurring with AF was 
almost twice as likely to be fatal as stroke not associated with AF, with 
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recurrence more frequent and functional deficits more severe in survivors 
(115). Lone AF increases the risk of stroke 4-fold while AF associated with 
mitral RHD increases the risk 17-fold. The prevalence of AF in patients with 
ischaemic stroke may be increasing independently of age and gender (116). 
It has been noted in other previous studies in high-income countries that AF 
and AFl account for about 10% of all strokes and 50% of cardioembolic 
strokes (117) and about 35% of AF patients will experience ischaemic stroke 
during their lifetime (118) (119) (120). 
Risk of stroke in lone AF is less certain. Whilst data from the Framingham 
study suggest a four-fold increase in stroke risk with lone AF (121), a study 
by Kopecky et al (122) looked at 97 patients with lone AF (aged ≤60 at 
diagnosis) and followed them up for a mean of 14.8 years. They found a low 
risk of stroke in these younger patients with no structural heart disease, with 
only 1.3% of patients suffering stroke during follow-up. 
There are currently fewer data on the role of AF in stroke in blacks. A study 
by Yuan et al (123) of 4 million Medicare recipients in the USA, followed for 4 
years, showed that compared with those without AF, black men and women 
had 4.3 and 7.3 times the risk of embolic stroke, and 1.4 and 1.7 times the 
risk of non-embolic stroke respectively. 
There are data on the contribution of AF to cardioembolic stroke in SSA. In a 
South African study 21% of ischaemic strokes were cardioembolic (124) with 
13% due to RHD and AF present in 7%. In Zimbabwe, 19% of ischaemic 
strokes were cardioembolic due to AF, cardiomyopathy or valvular heart 
disease (125). In one hospital series, AF was found in 2% of strokes (126), in 
5-7% of strokes in hospital series using imaging (127) (128) and in 7% of a 
hospital cohort in the Gambia (129). 
Paroxysmal AF is thought to confer a very similar risk of stroke to permanent 
AF. A study by Friberg et al (130) looked at 855 patients with paroxysmal AF 
and 1126 patients with permanent AF with respect to their stroke incidence 
over a 3.6 year follow-up period. They found the incidence of stroke in 
paroxysmal AF patients to be 26 / 1000 person-years, versus 29 / 1000 
person-years in those with permanent AF. The multivariable-adjusted HR for 
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ischaemic stroke in paroxysmal AF vs. permanent AF was 1.07, and for all 
strokes (ischaemic and haemorrhagic) was 0.89. 
Atrial Flutter is thought to confer a similar risk of stroke as AF, although the 
evidence for this is not as clear-cut. A study by Lelorier et al (131) followed 
881 patients with AF / AFl from the Canadian Registry of Atrial Fibrillation 
(CARAF) for an average of 6.9 years. They found a stroke incidence of 1.33 / 
100 patient-years in the AF group, versus 1.24 / 100 patient-years in the AFl 
group. A retrospective study by Wood et al (Wood K, 1997) suggests a 3% 
annual risk of stroke with AF and a series by Seidl et al (132) suggests it may 
be as high as 7%. However, it is noted in the Lelorier study that 28% of AFl 
patients did convert to AF over time, thus suggesting perhaps AFl patients 
also suffered AF that was the ultimate catalyst for stroke. 
 
1.5.2 Heart Failure and Tachycardiomyopathy 
It is well recognised that chronic tachycardia in patients with AF and fast 
venticular response may result in extensive changes in ventricular function 
and structure (tachycardiomyopathy) (133). Importantly, 
tachycardiomyopathy with proper ventricular rate control is completely 
reversible.  
Our present understanding of tachycardia-induced cardiomyopathy relies 
mainly on experiments in animal models. Sustained rapid atrial or ventricular 
pacing can produce severe biventricular systolic and diastolic dysfunction in 
animals. The heart failure is characterized by elevated ventricular filling 
pressures, impairment of left and right ventricular systolic function, increased 
left and right end-systolic and end-diastolic volumes, reduction of cardiac 
output, and elevation of systemic vascular resistance. Subsequently, the 
plasma atrial natriuretic peptide, epinephrine, norepinephrine, renin activity, 
and aldosterone levels are markedly elevated. AF is also known to reduce 
cardiac output by 10-20%, irrespective of ventricular rate (133).  
In large population-based studies, AF has been shown to increase risk of 
subsequent heart failure. In a 20-year follow-up study by Stewart et al (113) 
AF was a strong independent risk factor for heart failure, with an OR of 3.1 in 
women and 3.4 in men. In support of these findings, Krahn et al (47) found in 
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the Manitoba follow-up study that AF independently increased the risk of 
heart failure with an OR of 2.98. 
 
1.5.3 Impaired Quality of Life 
AF can be a highly symptomatic arrhythmia, with patients reporting 
palpitations, dizziness, breathlessness, exercise intolerance and fatigue. 
These symptoms can be particularly troublesome in the elderly (134). 
Therefore it is unsurprising to find that several studies have reported AF 
patients to have a reduced quality of life (QOL) compared with an age- and 
sex- matched general population in sinus rhythm (135-137).  
A systematic review by Thrall et al (138) looking at the impact of AF on QOL 
found that in the domains of general health, vitality, physical, social and 
emotional role functions, AF patients have poorer QOL than age-matched 
healthy controls. However, it was noted that there was significant 
improvement in all these domains as patients’ symptoms were alleviated 
through various rate and rhythm control methods.  
Symptomatic relief may involve multiple psychological factors. In addition to 
the obvious effect of the medical or surgical intervention, it has been 
suggested that patients may report fewer symptoms because they believe 
their treatment has been successful. Furthermore, perhaps simply being 
informed that their heart rate is beating in a ‘normal’ rhythm may reduce 
patient anxiety and increase psychological well-being (139). Clearly, 
symptom control is a key factor in determining QOL in AF patients and many 
current management strategies for AF are very much ‘symptom driven’. 
 
1.5.4 Mortality and Medical Costs 
There is a significant mortality burden from untreated AF. Risk of death was 
shown to increase by 1.5 times in men with AF, and 1.9 times in women, 
after adjustment for pre-existing cardiovascular conditions as reported by 
Framingham study investigators (2). Another study from Australia (48) 
reported that relative mortality for those with AF versus those without was 
1.92 for all causes, 1.82 for death from cardiovascular causes (excluding 
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stroke) and 3.78 for deaths from stroke. In the Manitoba follow-up study (47) 
total mortality rate in AF patients was increased 1.31 times compared to that 
of the background population. Cardiovascular mortality including and 
excluding fatal stroke was also increased (RR 1.41 and 1.37 respectively). A 
four-year follow-up of patients in the Marshfield Clinic Epidemiologic Study 
Area population also showed a 2.4-fold increased risk of death even after 
adjustments for sex, age, and other cardiovascular risk factors in patients 
with AF or Afl (140). 
AF imposes a substantial cost burden on the healthcare system due to 
therapeutic interventions intended to reduce morbidity and mortality. Based 
on data from the National Hospital Discharge Survey, the number of AF-
related hospitalizations almost tripled in 2000 compared with two decades 
ago (141). A good estimate of the involved costs was provided by a large 
UK-based survey that revealed that the direct cost of managing AF increased 
from 0.6–1.2% of the total National Health Service (NHS) budget in 1995 to 
0.9–2.4% by 2000 (142). A study from France showed similar figures, with a 
significantly higher number of hospitalizations and deaths in patients with 
persistent or permanent AF compared with those with paroxysmal AF (143), 
AF-associated heart failure, coronary disease, use of class III antiarrhythmic 
drugs, hypertension, and metabolic disease were significantly associated 
with higher costs. Based on retrospective analyses of three federally funded 
databases in the US (2001 data), total annual costs for treatment of AF were 
estimated at US$6.65 billion, including US$2.93 billion (44%) for 
hospitalizations for AF, US$1.95 billion (29%) for the incremental inpatient 
cost of AF as a co-morbid diagnosis, US$1.53 billion (23%) for outpatient 
treatment of AF, and US$235 million (4%) for prescription drugs (144). A 
recent study by Kim et al (145) looking at medical costs of AF versus non-AF 
controls in the US showed mean annual inpatient costs per patient were 
$7841 versus $2622 (incremental cost, $5218), outpatient medical costs 
were $9225 versus $5629 ($3596), and outpatient pharmacy costs were 
$3605 versus $3714 (−$109) (all p<0.001). The total incremental cost of AF 
was $8705 per patient. The national incremental cost of AF was $26.0 billion 
(AF, $6.0 billion; other cardiovascular, $9.9 billion; non-cardiovascular, $10.1 
billion). 
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1.6 Risk Stratification 
1.6.1 CHADS2 and Other Risk Stratification Tools 
As has been shown previously, AF is a significant risk factor for stroke, but 
the presence or absence of other clinical factors in AF patients and the 
application of a validated risk stratification tool allows their stroke risk to be 
more accurately calculated. There have been many risk stratification tools 
produced and compared for validity (146) but the one which has gained most 
acceptance for general use, partly because of its reliability but also its ease 
of use, is the CHADS2 score. In non-valvular AF patients, it stratifies stroke 
risk based on a points-scoring system. 1 point is scored for each of ‘C’ for 
congestive heart failure / LV dysfunction (EF ≤40%), ‘H’ for hypertension, ‘A’ 
for age ≥75 and ‘D’ for diabetes mellitus. 2 points are scored for the patient 
having had a previous stroke (‘S’) or TIA. The maximum score is 6 and the 
higher the score the higher the stroke risk, from a 1.9% stroke risk per year 
in a patient with a CHADS2 score of 0 up to 18.2% per year with a score of 6 
(147). This risk stratification tool, as with others, allows the patient to be 
stratified (albeit artificially) as low, intermediate or high risk and thus 
determines how the patient should be treated. Traditionally with the CHADS2 
scoring system, a score of 0 was low risk and aspirin or no treatment 
recommended, a score of 1 intermediate risk and aspirin or warfarin 
recommended and a score of >1 high risk and warfarin recommended if no 
contraindications.  
 
1.6.2 CHA2DS2-VASc 
The 2010 European Society of Cardiology (ESC) guidelines (31) have 
encouraged physicians to move away from categorising AF patients as either 
low, intermediate or high risk and see risk as a continuum. An attempt at 
refining and improving on the CHADS2 score has been made in the form of 
the CHA2DS2-VASc score where more importance is placed on age ≥75 
years (the first ‘A’ scoring 2 points). Furthermore, female sex (‘Sc’ for sex 
correlate) is recognised as a risk factor in its own right, providing a RR of 1.6 
for thromboembolism, as is known vascular disease (‘V’) such as previous MI 
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and peripheral vascular disease (148). Age 65-74 is also known to increase 
stroke risk, although less so than the 75 and over group. 
These risk stratification tools are currently somewhat arbitrary with respect to 
treatment decisions in rural Tanzania and most of SSA given the lack of 
infrastructure for safe anticoagulant use and monitoring. However, I feel 
these tools are helpful to demonstrate just how high the risk of stroke is in 
the majority of my AF cases and these risk scores highlight a situation in my 
Study Population which needs to be addressed. 
 
1.6.3 Assessment of Bleeding Risk 
As with any medication, a risk-benefit profile should be considered prior to 
commencement. With respect to AF patients and their risk of bleeding prior 
to commencement of oral anti-platelet / anti-coagulant therapy, this comes in 
the form of the HASBLED tool. Again, the patient scores 1 point for each of 
hypertension (H) with a systolic BP >160mmHg, abnormal renal and liver 
function (A) with 1 point for each, stroke (S), previous bleeding (B), labile 
INRs (L), elderly (E) >65 years and drugs / alcohol (D) again scoring 1 point 
each. This gives a total score of 9, with a score of ≥3 considered high-risk of 
having a major bleed. ESC guidelines (31) recommend caution and regular 
review in these high risk patients. 
The HASBLED scoring system was derived from a ‘real world’ cohort of 3978 
Euro Heart Survey AF patients (149). Again, whilst some of the scoring 
system is less relevant to risk assessment in SSA (i.e. labile international 
normalised ratios (INRs) and liver dysfunction more relevant to warfarin than 
aspirin), it has also been noted previously that in the elderly the risk of major 
bleeding is similar with either aspirin or warfarin treatment (150). Therefore it 
was useful to my study in order to assess bleeding risk in AF patients to 
whom I was considering prescribing aspirin. 
 
1.7 P wave predictors of atrial fibrillation 
The P wave morphology, if abnormal, can provide information on disease 
processes involving the atria and traditionally the P wave area (PWA) has 
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been used as a surrogate for atrial size. There is growing evidence of the 
importance of the P wave on 12-lead electrocardiogram, not only in 
assessing immediate electrical function of the atria but also in predicting 
future problems such as AF and stroke. P wave duration (PD), P wave 
dispersion (PDISP) (i.e. maximum P wave duration – minimum P wave 
duration), PWA, PWTF in lead V1 and P-R interval have all been looked at in 
more detail to assess their ability to predict PAF, future AF and stroke. 
However, it has been noted that PD, PWA and PR interval show a significant 
circadian variation in healthy individuals and the relationship between P area 
/ RR, PR / RR, and P duration / RR also demonstrate a significant diurnal 
pattern (151). This variation has also been demonstrated on a seasonal 
basis, with a study by Kose et al (152) demonstrating that P wave maximum 
duration and PDISP were significantly shorter in summer than in winter in 
523 healthy male army recruits. Multiple physiological factors are suggested 
to play a part in these variations, including changes in left atrial volume, left 
atrial pressure, autonomic tone and atrial conduction characteristics (151). It 
is also noted that apart from the paper by Soliman et al (153), most of the 
other papers involve small numbers of participants and further work is 
suggested in this area. 
 
1.7.1 P wave duration 
Studies have shown prolonged PD to be more common in patients with PAF 
(195), to predict recurrence of AF (196), but also that a small minimum PD 
was more prevalent in PAF (197), suggesting that extremes of P wave 
measurement (either very long or very short) may be the important factor in 
predicting AF. PD ≥110ms correlates well with LA enlargement when 
compared to CT-derived LA volume and index (154). 
In another study by Soliman et al (153) looking at the ethnic distribution of 
ECG predictors of AF as part of the ARIC (Atherosclerosis Risk In 
Communities) study, 15,429 participants’ (27% black) ECGs were analysed. 
The study found not only that, overall, black Americans had more evidence 
of ECG predictors of AF but also, importantly to this section, that maximum 
PD and PD in lead II (upper 5th percentile vs. first 95th percentile) were the 
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most strongly associated predictors of incident AF (HR 4.07 and 3.90 
respectively after adjustment for demographic and clinical variables).  
 
1.7.2 P wave Dispersion 
Increased PDISP has been shown to be more common in people with PAF 
(195) and to predict the development of AF, both in the general population 
(199) and following cardiac surgery (200). 
 
1.7.3 P wave Area 
In the Soliman paper (153), mean and maximum PWA were both significantly 
associated with incident AF, with HRs of 2.83 and 2.61 respectively. In 
addition, as predictors of incident ischaemic stroke the respective HRs were 
1.11 and 1.13 after adjustment for demographic and clinical variables. 
 
1.7.4 P wave Terminal Force (V1) 
Again, in the Soliman paper (153),PWTF had a HR of 1.9 for incident AF and 
1.22 for incident ischaemic stroke. This was the strongest ECG predictor of 
incident stroke in their population of 15,429. In another study by Ishida et al 
(155), 78 patients with LA overload (based on a PWTF in V1 of ≥0.12mV/sec) 
were chosen from 102,065 in the database. During a mean follow-up of 43 
months, 15 patients developed AF whilst 63 did not. There was no significant 
difference in the PWTF but there was a significantly larger mean PW initial 
force in V1 in the AF group, giving a HR after multivariate analysis of 4.02. 
 
1.7.5 P-R interval 
A study by Cheng et al (156) looked at 7575 individuals from the 
Framingham study with >30 years follow-up. When examining PR interval on 
the ECGs, they found that for each 20ms increase of PR interval, HR of 
developing AF was 1.11. For participants with 1st degree AV block (i.e. PR 
interval >200ms), HR of AF development was 2.06. 
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In the Soliman paper (153), 1 standard deviation of change in PR duration 
resulted in a HR for development of AF of 1.41 after adjustment for 
demographic and clinical variables but there was no significant difference in 
the effect on incident ischaemic stroke (HR 1.00). 
 
1.8 Pharmacological Management 
There are many pharmacological treatments currently available for the 
management of acute and chronic AF. In this next section I will concentrate 
particularly on the chronic management of atrial fibrillation given that my AF 
Study Population was community-based. Treatment options in SSA are 
limited to basic reduction in stroke risk and control of ventricular rate to help 
reduce symptoms and heart failure risk. 
 
1.8.1 Anti-platelets 
Eight independent randomized controlled studies, together including 4876 
patients, have explored the prophylactic effects of anti-platelet therapy, most 
commonly aspirin compared with placebo, on the risk of thrombo-embolism 
in patients with AF (157). When aspirin alone was compared with placebo or 
no treatment in seven trials, treatment with aspirin was associated with a 
non-significant 19% (95% CI –1% to –35%) reduction in the incidence of 
stroke. There was an absolute risk reduction of 0.8% per year for primary 
prevention trials and 2.5% per year for secondary prevention by using 
aspirin. The bulk of the positive results came from one large trial, SPAF-1, 
that compared aspirin 325mg / day versus placebo and showed a 42% RRR 
in the risk of stroke. Pharmacologically, near-complete platelet inhibition is 
achieved with aspirin 75 mg. Furthermore, low-dose aspirin (<100 mg) is 
safer than higher doses (such as 300 mg), given that bleeding rates with 
higher doses of aspirin are significant. Thus, if aspirin is used, it is 
reasonable to use doses in the lower end of the allowed range (75–100 mg 
daily) (31). 
However, having said this, there is a small amount of evidence that aspirin 
may be detrimental to stroke prevention in some AF patients, particularly 
those with no obvious underlying structural cardiac disease. In the Japan 
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Atrial Fibrillation Stroke Trial (150), patients with lone AF were randomized to 
an aspirin group (aspirin at 150– 200 mg/day) or a control group without anti-
platelet or anticoagulant therapy. The primary outcomes (3.1% per year) in 
the aspirin group were worse than those in the control group (2.4% per year), 
and treatment with aspirin caused a non-significant increased risk of major 
bleeding (1.6%) compared with control (0.4%). 
 
1.8.2 Anti-coagulants 
In a meta-analysis, the RR reduction with Vitamin K antagonists (such as 
Warfarin) versus placebo was highly significant and amounted to 64%, 
corresponding to an absolute annual risk reduction in all strokes of 2.7% 
(157). When only ischaemic strokes were considered, adjusted-dose Vitamin 
K antagonists use was associated with a 67% RR reduction. Direct 
comparison between the effects of Vitamin K antagonists and aspirin has 
been undertaken in nine studies, demonstrating that Vitamin K antagonists 
were significantly superior, with a RR reduction of 39% (31). It was also 
noted in the BAFTA (Birmingham Atrial Fibrillation Treatment of the Aged) 
study that there was no increase in major haemorrhage in the Warfarin group 
(158), but in studies prior to BAFTA, risks of intracranial haemorrhage were 
doubled when results were taken together (although absolute risk increase 
was small at 0.2% / year). 
In the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of 
Vascular Events–Warfarin arm (ACTIVE W) trial, anticoagulation therapy 
was superior to the combination of clopidogrel plus aspirin (RR reduction 
40%; 95% CI 18–56), with no difference in bleeding events between 
treatment arms (159, 160). 
The major problem with warfarin treatment is the need for regular monitoring 
of levels using the INR. This is a particular stumbling block to anticoagulation 
in rural SSA, given poor access to health care and sporadic compliance with 
medication. However, several new anticoagulant drugs - broadly in two 
classes, the oral direct thrombin inhibitors (e.g. dabigatran etexilate and 
AZD0837) and the oral factor Xa inhibitors (rivaroxaban, apixaban, 
edoxaban, betrixaban, YM150, etc.) - are being developed for stroke 
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prevention in AF (of which Dabigatran has just been granted a licence in the 
US by the FDA). These newer anticoagulant drugs are novel in that they do 
not require regular monitoring and perhaps provide hope for the treatment of 
AF and other conditions requiring anticoagulation in SSA in the future (where 
there is little infrastructure for INR monitoring away from large urban 
centres). These agents are showing good early promise in terms of being at 
least as good as warfarin from a thromboembolism protection perspective, 
whilst not unduly increasing bleeding risk, with some results suggesting 
reduced overall (and particularly intracranial) bleeding risk (205-207).  
 
1.8.3 Rate Control Versus Rhythm Control 
Control of ventricular rate versus restoration of sinus rhythm has long been a 
contentious issue in the treatment of AF, particularly with regard to outcomes 
in terms of morbidity, mortality and quality of life. In SSA, with the lack of 
drug availability and affordability, it is the cheaper generic rate control drugs 
that are most prevalent. There is good evidence to suggest that a rate control 
strategy is non-inferior in terms of hard outcomes such as morbidity and 
mortality (208-210), as well as suggestions that symptomatic quality of life 
may differ very little also (208-212). 
In terms of rate control treatment, -blockers and non-dihydropyridine 
calcium channel antagonists are normally used as first-line rate control 
therapy. They have been shown to control ventricular rate (on exertion and at 
rest) quickly and effectively (161). Digoxin has also been shown to control 
resting pulse rate well. 
What is deemed acceptable rate control is still open to some debate. The 
AFFIRM trial suggested that resting PR should be 60-80bpm with PR on 
moderate exertion 90-115bpm. However, this has been deemed somewhat 
strict by the more recent RACE II (Rate Control Efficacy in permanent atrial 
fibrillation) trial that randomised 614 patients to either lenient rate control 
(resting PR <110bpm) or strict rate control (resting PR <80bpm) (162). 81 
patients (38 lenient, 43 strict) reached the primary endpoint including CV 
death, stroke, heart failure hospitalisation and pacemaker insertion, proving 
non-inferiority for a more lenient rate control approach. 
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1.8.4 Other Upstream Therapies 
Upstream therapy to prevent or delay myocardial remodelling associated 
with hypertension, heart failure or inflammation (e.g. after cardiac surgery) 
may defer the development of new AF (primary prevention) or, once 
established, its rate of recurrence or progression to permanent AF 
(secondary prevention) (163). Treatments with angiotensin-converting 
enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), 
aldosterone antagonists, statins, and omega-3 polyunsaturated fatty acids 
(PUFAs) are usually referred to as ‘upstream’ therapies for AF. Again, many 
of these therapies are unavailable in SSA and are not discussed, but ACEIs 
and ARBs are worth mentioning. ACEIs and ARBs have been shown to 
inhibit the arrhythmogenic effects of angiotensin II, which include stimulation 
of atrial fibrosis and hypertrophy, uncoupling gap junctions, impaired calcium 
handling, alteration of ion channels, activation of mediators of oxidative 
stress, and promotion of inflammation. There is good experimental evidence 
of anti-fibrillatory and anti-fibrotic actions of ACEIs and ARBs in various AF 
models (31). I saw evidence of them being used for the treatment of 
hypertension in Tanzania and, although they remain expensive and not 
recommended as first-line therapy in the treatment of hypertension in black 
people of African descent / origin (164), they may well have a role to play in 
controlling BP and therefore potentially reducing the incidence of AF in SSA. 
 
1.9 Further Management 
The field of invasive management for the treatment of AF is growing rapidly. 
Atrio-ventricular node ablation (31), catheter ablation (31, 216, 217), surgical 
ablation (31) and left atrial appendage occlusion devices (218) have all been 
shown to have some benefit in either reducing AF burden or reducing the 
symptoms and incidence of sequelae associated with the disease. However, 
these interventions currently have no place in the management of AF in SSA, 
particularly in rural areas, and therefore they are not discussed in more 
detail.  
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1.10 Background Information about Tanzania and the Hai District 
Tanzania is situated in sub-Saharan East Africa at 6°S and 35°E and has a 
population of 41.8 million. It covers an area of 947,300 square km. It has a 
very pyramid-shaped population profile (see figure below) in that 43% of the 
population are <15 years old, 54.1% are between 15-64 years, and only 
2.9% are aged 65+. The median age is 18.3 years and the life expectancy at 
birth for men is 50.99 years and for women 54.03 years. Estimated 
population growth rate in 2010 was 2.03% per year.   
 
Figure 1: Tanzanian Population Pyramid in 2005 
 
The birth rate as of 2010 was 33.44 live births / 1000 population and the 
death rate was 12.31 / 1000 population. The net migration rate was -0.81 
migrants / 1000 population. The sex ratio of male to female is 1.03:1 at birth, 
and 0.98:1 overall. In the elderly population (65+) the ratio is 0.77:1. The 
infant mortality rate remains high at 68.13 deaths / 1000 live births and 6.2% 
of adults are HIV positive. 25% of the population live in urban areas, with the 
rate of urbanisation 2005-2010 estimated at 4.2% / year. The literacy rate for 
men is 77.5% and for women 62.2%. 
Independence from colonial rule was achieved on 9th December, 1961, and 
the current President of the Republic of Tanzania, Jakaya Kikwete, has been 
in office since 21st December 2005. Tanzania remains one of the poorest 
countries in terms of per capita income, although 7% gross domestic product 
(GDP) growth per year between 2000 and 2008 as a result of tourism and 
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gold production has resulted in slow improvement. The economy depends 
heavily on agriculture, which accounts for more than one-fourth of GDP, 
provides 85% of exports and employs about 60% of the work force (165). 
The Hai District, covering an area of 13,000 square km, is situated in north-
eastern Tanzania on the south-western slopes of Kilimanjaro and the 
surrounding plains (see arrow in Figure 2 below). The district has 4 
administrative divisions, 11 wards, and 61 villages. The Hai demographic 
surveillance site (DSS) lies between latitudes 3.13° and 3.46°S and 
longitudes 37.11° and 37.36°E, and it covers three of the four divisions of the 
district. The DSS contains 56 villages.  
A recent census completed in June 2009 revealed the DSS population to be 
161,119, of whom 8869 (5.50%) were aged 70 years and above. The 
Chagga are the predominant tribe and most work in agriculture, either on 
subsistence farms or ‘shambas’, or for larger companies that own coffee 
plantations. The two main religions are Christianity (79%) and Islam (20%), 
with most of the population speaking Kiswahili (official language) in addition 
to their local tribal language. There is not a large population flux overall and 
most villagers live their whole lives in the same village. There is slightly more 
movement in the lower-lying villages close to the main road from Moshi to 
Arusha. 
The Hai District comprises three distinct ecological zones. The two lower 
zones are populated.  The lowland zone lies between 750 and 1000m above 
sea level (asl), with minimal rainfall (about 325 mm a year), moderate to high 
temperatures and sparse population density (about 70 people per km2).  The 
midland zone lies between 1000 and 1600m asl and has higher rainfall 
(about 1560 mm a year), moderate temperatures and higher population 
density (about 150–160 per km2).  The highest zone is above 1600m and is 
uninhabited, with heavy rainfall, cool temperatures, and mountain forests and 
grasslands. It constitutes the largest water source (from rainfall and glacial 
runoff) and forest reserve in Kilimanjaro. Multiple springs and rivers flow from 
this zone supplying water to both the midland and lowland zones. These are 
sometimes used as a drinking water source, although piped water from 
higher up the mountain is available in most villages from the Hai district 
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water supply. Water is plentiful in the highland and midland zones but is 
often polluted with microbes, toxic minerals and agricultural chemicals.   
The Hai District has 3 district hospitals in Machame, Kibongoto and 
Boman’gombe (the district capital), with 2 further government health centres, 
39 dispensaries and 61 village health posts. There is disparity in the services 
available at each of these but most offer basic assessment and treatment. 
The main tertiary referral hospital, Kilimanjaro Christian Medical Centre 
(KCMC), is situated in Moshi, approximately 20km from Boman’gombe. 
However, the nearest specialist cardiological opinion is 600km away in Dar-
es-Salaam. 
The district has 139 primary schools, 13 secondary schools (both public and 
private) and 5 post-primary technical schools. About 85% of children below 
the age of five are vaccinated against five major communicable diseases. 
Community-based data show that main causes of death in the district are 
HIV/AIDS, cancer, perinatal causes, acute febrile illness including malaria, 
pneumonia, diarrhoeal diseases, injuries (both intentional and unintentional), 
nutrition and maternal causes. 
Wood is the main source of fuel. 36 of the 61 villages have electricity but the 
use of this source of energy is limited because of the costs and even in those 
villages with electricity this power source extends to very few households. 
There are 710 kilometres (km) of road and an international airport (The 
Kilimanjaro International Airport) 10km from the nearest border. Most roads 
are unpaved and are often impassable for vehicles during the rainy season.   
As a DSS, the Hai study area has permanent delineated boundaries, 
recognizable on the ground (for example, rivers, roads, and clearly 
demarcated administrative boundaries). In this thesis the Hai DSS study area 
is the same as the project study area, so all references to Hai are in relation 
to the geographical DSS. 
The majority of the Hai District has been a DSS as part of the Adult Morbidity 
and Mortality Project (AMMP) since 1992, initially as part of a project set up 
between the Tanzanian Ministry of Health and Newcastle University (funded 
through the Department for International Development – DFID). This project 
developed an infrastructure in the District from the District Medical Officer 
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(DMO) in Boman’gombe to the 5 Assistant Medical Officers (AMOs) who act 
as supervisors within the community (in addition to them acting as medical 
translators from Kiswahili to English for the purposes of the project), through 
to the village enumerators (usually nurses, teachers and village leaders) who 
identified patients for the study from the census which they helped to perform 
in their respective villages (in addition to translating local tribal languages). 
Without this established infrastructure and the blessing of local politicians 
(through the DMO) it would not have been possible to conduct this research. 
In addition to this, the study employed a nurse who acted as a further 
translator and received additional training in the management of AF and 
related cardiovascular problems. 
 
 
Figure 2: Map of Tanzania 
 
1.11 Healthcare in Tanzania and Patient Access to Treatment 
There is no National Health Service in Tanzania and there are major 
disparities in accessibility, availability and quality of health care across 
Tanzania. Even within the Hai District, which is considered a reasonably 
‘affluent’ rural district, there are major disparities between villages with 
regard to the quality and staffing of local health centres and the availability 
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and prescribing practices of essential medicines. There were 5 ways of 
obtaining health care and, particularly pertinent to this project concerning 
chronic disease, repeat medication prescriptions: 
1. Being (or having a family member who was) a government employee 
allowed free access to healthcare and prescriptions. 
2. A yearly fee of 10,000 Tanzanian Shillings (TzS) (around £5 or the 
equivalent of one chicken) would provide an exemption card for the person 
and their family from prescription charges and free repeat prescriptions. 
3. If over the age of 65 years, applying to the village council and then, if 
subsequently approved, to the district medical officer, for an exemption card 
providing free repeat prescriptions for chronic disease medications. As may 
be envisaged, this was often a laborious process entailing much bureaucracy 
and was supposedly means-tested. 
4. Paying a ‘contribution’ to repeat prescriptions (usually around 2500TzS 
or just >£1). This tended to work out more expensive than option 2 for tablets 
needed to be taken daily as it was very dependent on medication stocks at a 
particular health centre which dictated how many tablets a repeat 
prescription would buy. Often hypertensive patients (who may have walked 
for several hours to get to the health centre) would be given only a 1 week 
supply of Bendrofluazide. This was due not only to meagre drug supplies but 
also inadequate understanding and education on the part of the dispensary 
workers. 
5. Buying medication from private dispensaries at full value. This meant 
that one could buy as many tablets as one wanted but often meant patients 
were not always advised to buy the cheapest, even if it was the most 
effective. 
One of my more difficult tasks during the project would be to educate 
patients and health care workers on the importance of managing chronic 
diseases and taking daily medication for diseases such as hypertension, that 
were often completely without symptoms. Another would be to raise the 
profile of non-communicable disease and particularly the hypertension 
epidemic to the DMO, and encourage the reduction in disparities across the 
district with regard to availability of medication and quality of prescribing 
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habits. This was not helped just as we were departing Tanzania by a 
government announcement confirming a 33% health budget cut (166). 
 
1.12 Importance of Non-Communicable Disease Research in SSA 
In May 2009 the non-communicable disease (NCD) Alliance was formed 
(bringing together 4 international federations: the World Heart Federation, 
the International Diabetes Federation, the Union for International Cancer 
Control, and the International Union against Tuberculosis and Lung 
Disease), with the aim of “putting non-communicable diseases on the global 
agenda”. A campaign has resulted in a United Nations summit on NCDs that 
took place in New York in September. In preparation for the summit, the 
WHO released its Global Status Report on NCDs that states that of the 57 
million deaths worldwide in 2008, 36 million were due to NCDs. The burden 
is growing fastest in low income countries, imposing large, avoidable costs in 
human, social and economic terms (167). Despite this, NCDs did not feature 
in the millennium development goals and account for <3% of global health 
aid (168). The Lancet’s NCD Action Group has identified five priority 
interventions for NCDs as follows (169): 
1. Tobacco Use: accelerated intervention of WHO Framework 
Convention on Tobacco Control 
2. Dietary Salt: Media campaigns and voluntary action by food industry to 
reduce consumption 
3. Obesity, unhealthy diet and physical inactivity: Media campaigns, 
food taxes, subsidies, labelling and marketing restrictions 
4. Harmful alcohol intake: Tax increases, advertising bans and 
restricted access 
5. Cardiovascular risk reduction: combination of drugs for people at 
high risk 
Total cost for the implementation of all 5 interventions per person per year 
has been estimated to be US$1.72 in China, US$1.52 in India and US$4.08 
in Russia (169).  
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Prior to focusing well-needed resources on these interventions, accurate 
data on the scale of the problem are needed. One of the intentions of my 
research is to demonstrate the urgent need to document prevalence rates of 
such NCD, and hopefully to attract appropriate resource allocation. A recent 
article in the BMJ (170) highlighted the importance of improved surveillance 
of NCDs and their risk factors in low and middle income countries (LMICs). 
Whilst the figures tell us that NCDs are on the increase in LMICs, it should 
also be acknowledged that if population health is good and people are 
enabled to live into old age, then most people will die of NCD (171). 
Therefore, naturally, as life expectancy increases, so will mortality rates from 
NCD. It is thus important to clarify premature deaths as opposed to timely 
deaths from NCD and concentrate resources on the former rather than the 
latter. Additionally, the UN summit should take care to establish realistic 
rather than misplaced risk factor thresholds. For instance, in the treatment of 
hypertension, if they employ ‘Western’ values of 140/90mmHg as a cut-off, it 
risks diverting resources from the sick to the well and the poor to the rich 
(171). With my hypertension patients, I have employed a 160/100mmHg cut-
off for treatment in order to identify those most at risk, in addition of course to 
education and awareness of what non-pharmacological measures may be 
taken to reduce BP. In resource-poor countries these will be the most 
important measures taken as steps such as stopping smoking and reducing 
dietary salt are free interventions and merely rely upon education and a 
change in attitude rather than potentially costly infrastructures for the delivery 
and monitoring of medication. 
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Chapter 2. General Methodology 
 
This section covers general methodology and logistics of the project. More 
specific methodology with regard to the 4 main results chapters (prevalence 
of AF, prevalence of PAF, PWI analysis and prevalence of hypertension) can 
be found in the specific chapter. 
 
2.1 Inclusion and Exclusion Criteria 
To be included in the study, participants had to: 
 
1. Be alive and living in the Hai District in one of the 12 randomly selected 
study villages on the prevalence date of 1st January 2010. 
 
2. Be aged 70 years or over on 1st January 2010. 
 
3. Have given informed consent to take part in the study (or informed 
assent by a family member if participant was unable). 
  
People excluded from the study were: 
 
1. Either dead, or not living in one of the 12 randomly selected study 
villages on 1st January 2010. 
 
2. Not aged 70 years and over on 1st January 2010. 
 
3. Not providing informed consent (or assent from family member). 
 
2.2 Prevalence Studies 
The prevalence of a disease in a population is defined as the number of 
people in that population who have that disease at a defined point in time. It 
is usually expressed as the number per 100,000, although can be per 1000 if 
the disease is more common. There are a number of different ways to 
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determine prevalence, including case-finding studies, pharmacy searches 
and door-to-door surveys. 
Case-finding studies involve looking through medical notes to assess the 
prevalence of a particular disease and identify cases. This approach, whilst 
efficient in countries where people have good access to healthcare and there 
is an infrastructure for recording and treating disease, is impractical in SSA 
given that few people have reasonable access to health care, or can afford 
treatment. This therefore means that there will be potentially many previously 
undiagnosed cases in the community. 
Pharmacy searches entail searching for cases through medication 
prescriptions for drugs only used for the condition being searched for. There 
are two problems with this method in searching for AF cases in SSA. Firstly, 
there are many different treatments available for AF most, if not all of which, 
are used for treating other conditions as well (e.g. aspirin – previous stroke, 
propranolol - hypertension, digoxin – heart failure), so the search would be 
non-specific. Secondly, and more specifically to SSA, there is a lack of 
infrastructure for a pharmacy database in SSA. In the Hai District, there are 
many governmental dispensaries, often with very limited drug supply and run 
by dispensary workers with very little knowledge of treating medical disease. 
These compete with private dispensaries, often with adequate drug stocks 
but selling treatment (not always correct) at inflated prices. Again, many 
people do not present to drug dispensaries for treatment of their condition 
because of access and price. 
Door-to-door surveys are seen as expensive and time-consuming for 
population-based research. However, in order to accurately define 
community burden of a disease and to identify previously undiagnosed 
cases, they are seen as the gold-standard approach. A two-tiered approach 
has been advocated to increase efficiency, whereby non-medically trained 
personnel perform an initial screening test to determine whether a person 
may have a disease, and then medically trained personnel perform more in-
depth assessment of the identified patients. In the case of AF, the screening 
test was an ECG, which the non-medically trained personnel (the village 
enumerators) were taught to perform at a workshop prior to study 
commencement. However, it quickly became clear that it would not be 
sufficient simply to see AF patients, as all of the elderly participants wanted 
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to see me, and I needed to see most of them in order to prescribe treatment 
for HTN, osteoarthritis etc. Therefore, to maximise case ascertainment in 
each village (fewer people were turning up when I was absent from the 
health centre) and to ensure all participants received appropriate treatment, I 
decided to adopt a one-tiered approach in that I saw all study participants 
regardless of whether they had AF or not. This approach was at the expense 
of overall numbers for my study. 
 
2.3 Case-Control Studies 
Within my prevalence study, there was a nested case-control study that was 
designed to enable me to look at the characteristics of, and risk factors for, 
AF, by comparing known risk factors in those diagnosed with AF on 12-lead 
ECG, versus an age and sex-matched group of controls. Case-control 
studies are often inexpensive and can be performed by a small research 
team / single researcher in a confined time period, unlike more structured 
experimental studies / prospective cohort studies. They are often used as a 
preliminary study where little is known about the association between the risk 
factor and disease of interest. Whilst this is not the case with AF risk factors 
in high-income countries, it remains the case in SSA. Difficulties with case-
control studies include determining a person's risk factor exposure over time, 
and the presence of realised and unrealised confounding factors. 
 
2.4 Timing of the study 
This study ran in conjunction with another study investigating the prevalence 
of neurological disorders in the same study population. This used a 
screening questionnaire and therefore a pilot study was performed in one 
village (Mudio) prior to the main study. The village enumerators in Mudio 
were trained separately in ECG and BP measurement, prior to the main 
study workshop at the end of January 2010, when the study was rolled out 
across the other villages. The majority of data collection took place from 
January – June 2010, with initial follow-up of AF patients and controls 
through July 2010 (meaning an interval of 1-6 months between initially being 
seen and follow-up). 
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Date Literature 
review and 
study 
development 
Data 
Collection 
Initial 
Follow-up 
Writing 
up MD 
thesis 
Further 
Follow-up 
October 2008 – 
October 2009 
     
November 2009 
– January 2010 
     
January 28th  Workshop    
January 2010 – 
June 2010 
     
July 2010      
August 2010 – 
October 2011 
     
October 2011      
 
Figure 3: Timeline of Study 
 
 
2.5 Identification of Study Population 
The Study Population was identified via census details of those aged 70 
years and over and through village enumerators (as mentioned in section 
1.10), who invited people known to have reached 70 years between the 
census and our data collection period. Collecting accurate information on 
patient age can be difficult in SSA as few people have a birth certificate 
(172). Age was calculated from birth year and confirmed using memory 
prompts (e.g. age at independence) where necessary. This method has been 
previously validated (173).  
I planned to assess approximately one-quarter of the 70 years and over 
population in the DSS. I visited 12 villages, with a total census population of 
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2419. Our final cohort consisted of 2232 people and cohort assembly is 
shown below. 
 
Figure 4. Identification of the study population 
 
 
  
Population Identified Via Census 
 
n=2419 
Refused 
n=148 
Moved 
n=128 
Died 
n=154 
Too Young 
n=33 
Not 
Known 
n=17 
Admitted 
Hospital 
n=1 
Appeared 
Twice 
n=7 
Total on Census Not Seen 
 
n=488  
Census Population 
 
n=1931 
Population Turned 70 After Census 
Conducted 
n=301 
Total Study Population 
 
n=2232 
 
 
2.6 Choosing the study villages 
Villages were chosen using a random number generator, with stratification to 
allow a representative spread of upland and lowland villages. In the Hai DSS, 
of those aged 70 years and over, 76.5% live in upland areas and 23.5% in 
lowland areas. We studied eight upland villages (n = 1683, 75.4%) and four 
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lowland villages (n = 549, 246%), giving a final cohort of 2232 people. The 
breakdown by village is shown in the table below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Breakdown of Chosen Study Villages 
 
 
2.7 Workshop and Training 
The main workshop took place in Boman’gombe on January 27th 2010. It 
was a full day workshop and was designed to educate village enumerators, 
AMOs and the DMO not only to teach specific skills to enumerators in order 
that they could help with screening, such as performing ECGs and BPs, but 
also to outline what I was trying to achieve with my research. Village 
enumerators from all DSS villages were invited to the initial sessions 
highlighting the diseases I was hoping to find and treat to raise the profile of 
these NCDs in the Hai District. The more detailed sessions later in the day 
were for the enumerators of the 12 villages that had been randomly chosen 
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Mudio  277 344 -67 Upland  39 22 21 12 0 0 5 99 32 
Roo  265 305 -40 Upland  10 14 14 2 0 0 0 40 0 
Saawe  192 185 7 Upland  1 11 6 0 0 0 0 18 25 
Kyuu  118 121 -3 Upland  3 4 10 0 0 0 0 17 20 
Mbweera  194 194 0 Upland  1 1 7 0 0 0 0 9 9 
Lukani  115 117 -2 Upland  10 4 12 2 0 0 0 28 26 
Nshara  386 411 -25 Upland  47 3 32 3 0 0 0 85 60 
Urori  136 142 -6 Upland  5 4 2 5 0 0 2 18 6 
Kware  148 189 -41 Lowland  12 13 12 4 0 0 0 41 0 
Kwasadala  83 79 4 Lowland  2 10 12 0 0 0 0 24 28 
Shirumgungani  182 120 62 Lowland  2 2 6 0 0 0 0 10 72 
Boman’gombe  136 218 -82 Lowland 22 40 20 5 17 1 0 105 23 
Total  2232 2425 -193 N/A 154 128 154 33 17 1 7 494 301 
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for my study and concerned performing the screening tests that would 
identify AF cases and risk factors for AF. The training and standardisation 
procedures undertaken for study measurements are discussed in more detail 
in the relevant chapters. 
 
2.8 Developing the Proforma 
The proforma was designed to record data in the field that was accurate, 
efficient and in a format that was subsequently relatively easy to enter into a 
Microsoft ExcelTM spreadsheet for analysis. The proforma recorded important 
data pertaining to demographics, associated symptoms, examination and 
echocardiographic findings. It was also where treatment decisions were 
initially recorded. There were 2 parts to the proforma. The first part 
concerned demographic details (see appendix 2a), was performed on all 
2232 study participants and was primarily completed by village enumerators. 
The second part concerned more in-depth detail regarding symptoms, 
examination and echocardiographic findings and blood sampling (see 
appendix 2b) and was performed on AF patients and controls and was 
completed by me, with the aid of an AMO acting as a medical translator for 
the history and examination components. This will be discussed in more 
detail in Chapter 4. In addition to this, a follow-up proforma was subsequently 
developed (see appendix 3), based on collecting data on whether patients 
had had an improvement in their symptoms, had had any side-effects from 
medication, whether they were still taking their medication, what their BP was 
and whether there was any change to their initial management plan.  
 
2.8.1 Demographic details 
This recorded important information such as name, age and year of birth. 
Other information recorded on the demographic details sheet can be found in 
Appendix 2a. It will be noted that there is space for answers to a ‘screening 
questionnaire’. This was for the prevalence of neurological disorder study 
that ran in parallel as previously mentioned. In addition, BP measurements 
were recorded for 2232 participants in this section, and a 12-lead ECG was 
recorded at the same time. 
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2.9 General Critique of study design 
In this section I will only mention a few general limitations and strengths to 
the study design. More specific limitations and strengths are mentioned in 
relevant results and discussion chapters.  
 
2.9.1 Limitations 
The methodology was limited by a number of factors. The choice of controls 
and participants willing to wear an ambulatory ECG monitor was not entirely 
at random and was based more on a pragmatic approach for the reasons 
explained previously.  
Precision in the history was sometimes an issue. There are not as many 
descriptive medical words in Swahili as there are in English. One word in 
Swahili may mean several different things in English with regard to a 
patient’s symptoms. I tried to minimise this effect by educating the translators 
as to exactly what I was looking for. 
Ideally, the echo machine would have had a video loop recorder such that I 
could ask a second independent observer to report a random selection of my 
echocardiograms. However, this was not the case and I had to report the 
echocardiograms at the time knowing whether the patient had AF or not. 
Methodologically it would have been better if I had been blinded to whether 
the echo was on an AF case or control when reporting so that it did not bias 
my assessment of LV function. However, given a rhythm strip along the 
bottom of the echo screen blinding would have been impossible. 
When identifying risk factors such as hypertension, I only had one 
opportunity to decide on whether the patient required treatment or not. In 
normal clinical practice patients would have several readings over the course 
of months to decide if BP was consistently high. To try to combat this 
limitation and target those at highest risk, I only initiated treatment in patients 
with very high BP (>160/100) at the time. In those with Grade I hypertension, 
I recommended they get their BP re-checked in another month. 
 
2.9.2 Strengths 
There were also many strengths to the study design. As the team of 
enumerators and supervisors employed within this study had previously 
worked on a stroke incidence study, a PD prevalence study and an epilepsy 
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prevalence study in the same area with the same principal investigator, the 
basic infrastructure was robust.  The hierarchy and chain for passing of 
information was well used and had been tried and tested over the past 7 
years.  This meant that the population were used to being approached for 
censuses or research and had developed trust in the people involved. Also, 
apart from myself and the research doctor from the neurological disorder 
study (FD), all of the other day to day people involved in the study were 
Tanzanian and local to the area and many worked in health care centres in 
the villages or at the local hospital.  This added to the acceptability of the 
project to the local community. 
The study villages were chosen at random yet reflected well the spread of 
the population living in upland and lowland areas. The AF cases and controls 
were seen and assessed by the same doctor every time, and I performed all 
the echocardiograms, reducing inter-rater variability. Identification of cases 
was by the currently accepted gold standard in epidemiological studies, the 
12-lead ECG, and I maximised ascertainment of cases by using the door-to-
door survey method.   
 
2.10 Ethical Considerations 
Ethics committee approval was sought from the Newcastle and North 
Tyneside Health authority Joint Ethics Committee in the UK, Tumaini 
University Ethics Committee locally in Tanzania and the National Institute of 
Medical Research (NIMR) ethics committee nationally in Tanzania. Ethical 
approval was granted from Tumaini University and NIMR. The UK committee 
deemed it unnecessary to be considered as all the research was being 
carried out it Tanzania. All patients were given an information sheet in 
Kiswahili.  Any patient who could not speak Kiswahili had the information 
sheet translated verbally into their tribal language. All patients signed written 
consent forms in Kiswahili (or in the case of those who could not write, a 
thumb print was obtained) and were free to withdraw from the study at any 
stage should they wish to do so.  All information sheets and consent forms 
were translated by the Cardiology Nurse Specialist and then back translated 
by another specialist research nurse to ensure accurate translation. See 
appendices for consent forms and information sheets. 
There were several important ethical points that arose from the study: 
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1. Treatment offered to patients for AF / hypertension etc. should be 
treatment that is available at government dispensaries and health centres in 
the Hai District, that is, cheap (as in the majority of cases the patients had to 
pay themselves) and effective (e.g. ACE-I not as good as thiazide diuretics at 
controlling BP in black Africans). 
2. Prescribing practices in the elderly in rural Tanzania were very ethically 
challenging at times. I had to balance the potential benefit of initiating 
treatment with risks of side-effects and inability to access healthcare easily. 
Hypertension treatment was a particular challenge, given that I quickly found 
most dispensaries were fortunate if they had 1 anti-hypertensive available 
(usually bendrofluazide) and most patients struggled to remember 
instructions for taking more than 1 medication, coupled with the challenges of 
economic viability and availability. Bendrofluazide was the only widely 
available anti-hypertensive and was significantly cheaper than nifedipine (at 
an effective dose), the next most available. I decided prior to the start of the 
study that it was clinically reasonable to begin treatment immediately if 
average BP was >160/100mmHg. If BP was very high (>180/100) then a 
higher dose of bendrofluazide (5mg rather than 2.5mg) would be instituted. 
This is a dose that would not be used in the UK (where there are freely 
available effective alternatives) due to side-effects, but is recommended by 
the Tanzanian Ministry of Health Prescribing Guidelines due to a slightly 
better BP lowering effect (174). I decided on balance, taking into account the 
very high BPs of some patients (and therefore the very high risk of stroke), 
the added BP lowering effect of 5mg (albeit minor), the lack of additional / 
alternative drugs and also in keeping with national prescribing policy, that 
patients could be given 5mg bendrofluazide provided they were given 
additional ‘safety net’ advice and monitored any side-effects closely. 
3. There would be a way of referring patients on for other tests at the local 
hospital if they presented with something that could not be dealt with in the 
community. This was done through the development of a prescription / 
investigation sheet on which a ‘referral’ of sorts was written (see Appendix 
4). Also, an agreement was made that I could refer patients with cardiac 
abnormalities that required follow-up to the OPD at KCMC. 
4. Blood results should be returned in good time to AF cases and controls 
following analysis in the UK. This was done within 2 months of return, and 
60 
 
abnormalities were highlighted and followed-up by one of the study nurses in 
Tanzania. 
5. With regard to ambulatory monitoring, patients were identified with 
significant brady or tachyarrhythmias either symptomatic or asymptomatic. 
Fortunately, no patients were identified with significant ventricular 
arrhythmias, but several people were identified with varying degrees of heart 
block, the most significant of which was an asymptomatic man with 9 second 
ventricular standstill on his 24-hour tape. He was asymptomatic as it was 
nocturnal but would be a class Ia indication for pacing in the UK/USA (175). 
Pacemakers were prohibitively expensive and the closest place they were 
available was in Nairobi, Kenya. All I could do was advise what would be 
done in the UK, ask about potential sources of funding that he may have 
(e.g. through the church) and refer him in the usual way. Ultimately, it was 
the patient’s decision after that as to what course of action to take. 
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Chapter 3. Census and Demographic Details 
 
3.1. Results 
 
3.1.1 The Census 
The Hai District DSS census was completed on the 1st of June 2009, with the 
population of the Hai district DSS being 161,119. 83,180 (51.63%) were 
women and 77,939 (48.37%) were men. 8869 (5.50%) were aged 70 and 
over, 103025 (63.94%) were aged 15 and over and 58,093 (36.06%) were 
aged less than 15. 3159 (1.96%) were 70-74, 2531 (1.57%) were 75-79, 
1447 (0.90%) were 80-84 and 1732 (1.07%) were aged 85 and over. Of the 
70 and over population 4844 (54.62%) were women and 4025 (45.38%) 
were men. Age and sex divisions are detailed in the table below. 
 
Table 3 Age and Sex divisions In the Hai District DSS from the 01/06/2009 
census 
AGE GROUPS FEMALE % MALE % TOTAL (MALES 
AND FEMALES) 
% 
0-14 28794 34.62 29299 37.59 58093 36.06 
15-19 8114 9.75 8648 11.10 16762 10.40 
20-24 5225 6.28 4719 6.05 9944 6.17 
25-29 5487 6.60 4467 5.73 9954 6.18 
30-34 5381 6.47 4961 6.37 10342 6.42 
35-39 5216 6.27 4852 6.23 10068 6.25 
40-44 4800 5.77 4234 5.43 9034 5.61 
45-49 4156 4.99 3630 4.66 7786 4.83 
50-54 3727 4.48 2986 3.83 6713 4.17 
55-59 2911 3.50 2437 3.13 5348 3.32 
60-64 2390 2.87 1949 2.50 4339 2.69 
65-69 2135 2.57 1732 2.22 3867 2.40 
70-74 1684 2.02 1475 1.89 3159 1.96 
75-79 1351 1.62 1180 1.51 2531 1.57 
80-84 824 0.99 623 0.80 1447 0.90 
85+ 985 1.18 747 0.96 1732 1.07 
TOTAL 83180 100 77939 100 161119 100 
 
This is demonstrated pictorially in the following graph. 
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Graph 1 Age and Sex Divisions In the Hai District DSS from the 01/06/2009 
census 
 
 
Division of the Census Population by village 
The number of patients aged 70 and over, as well as the population and 
geographical location of each village (highland or lowland) in the Hai district 
is shown in Table 5. The villages highlighted in bold are those 12 that were 
randomly selected to take part in the study. They represent approximately 
1/4 of the 70 and over population of the Hai District DSS. The population of 
these villages recorded on the census was slightly different from the 
population seen as part of the study due to reasons detailed in Figure 4 
(page 92). 
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Table 4 Division of the Hai District DSS population by village demonstrating 
representation from the 70 and over population  
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BOMAN’GOMBE 11558 7.2 216 2.4 136 1.53 LOWLAND 995 
FOO 3969 2.5 394 4.4 N/A N/A UPLAND 1565 
ISUKI 1853 1.2 126 1.4 N/A N/A UPLAND 1399 
KAWAYA 2722 1.7 88 1.0 N/A N/A LOWLAND 851 
KIA 1501 .9 16 .2 N/A N/A LOWLAND 919 
KIKAVU CHINI 3743 2.3 116 1.3 N/A N/A LOWLAND 805 
KILANYA 1848 1.1 151 1.7 N/A N/A UPLAND 1588 
KIMASHUKU 2452 1.5 79 .9 N/A N/A LOWLAND 909 
KWA SADALA 3018 1.9 78 .9 83 0.94 LOWLAND 1033 
KWARE 3251 2.0 189 2.1 148 1.67 LOWLAND 1071 
KWATITO 1083 .7 28 .3 N/A N/A LOWLAND 909 
KYEERI 2959 1.8 195 2.2 N/A N/A UPLAND 1670 
KYUU 1778 1.1 120 1.4 118 1.33 UPLAND 1396 
LEMIRA KATI 1514 .9 139 1.6 N/A N/A LOWLAND 1420 
LENGOI 2013 1.2 62 .7 N/A N/A LOWLAND 833 
LOSAA 1345 .8 77 .9 N/A N/A UPLAND 1560 
LUKANI 1272 .8 116 1.3 115 1.30 UPLAND 1594 
LYAMUNGO KATI 2254 1.4 190 2.1 N/A N/A UPLAND 1520 
LYAMUNGO SINDE 1869 1.2 138 1.6 N/A N/A UPLAND 1315 
MAMBA 1952 1.2 157 1.8 N/A N/A UPLAND 1340 
MASHUA 2394 1.5 137 1.5 N/A N/A UPLAND 1353 
MBATAKERO 669 .4 18 .2 N/A N/A LOWLAND 940 
MBORENI 1371 .9 86 1.0 N/A N/A UPLAND 1330 
MBOSHO 1740 1.1 139 1.6 N/A N/A UPLAND 1295 
MBWEERA 3297 2.0 194 2.2 194 2.19 UPLAND 1330 
MIJONGWENI 3681 2.3 130 1.5 N/A N/A LOWLAND 820 
MKALAMA 2605 1.6 91 1.0 N/A N/A LOWLAND 864 
MTAA WA SHABAHA 1023 .6 33 .4 N/A N/A LOWLAND 915 
MTAKUJA 1685 1.0 43 .5 N/A N/A LOWLAND 920 
MUDIO 5522 3.4 345 3.9 277 3.12 UPLAND 1257 
MULAMA 1824 1.1 123 1.4 N/A N/A UPLAND 1274 
MUNGUSHI 7884 4.9 184 2.1 N/A N/A LOWLAND 1050 
MUROMA 1874 1.2 119 1.3 N/A N/A UPLAND 1296 
NGIRA 2234 1.4 160 1.8 N/A N/A UPLAND 1275 
NGOSERO 968 .6 35 .4 N/A N/A LOWLAND 822 
NGUNI 2498 1.6 159 1.8 N/A N/A UPLAND 1580 
NKUU NDOO 2038 1.3 222 2.5 N/A N/A UPLAND 1620 
NKUU SINDE 2132 1.3 234 2.6 N/A N/A UPLAND 1314 
NKWANSIRA 2080 1.3 133 1.5 N/A N/A UPLAND 1240 
NRONGA 2299 1.4 287 3.2 N/A N/A UPLAND 1670 
NSHARA 7805 4.8 411 4.6 386 4.35 UPLAND 1170 
ROO 5308 3.3 305 3.4 265 2.99 UPLAND 1250 
RUNDUGAI 7686 4.8 225 2.5 N/A N/A LOWLAND 861 
SAAWE 2609 1.6 185 2.1 192 2.16 UPLAND 1476 
SANYA STATION 3219 2.0 91 1.0 N/A N/A LOWLAND 933 
SHARI 3611 2.2 318 3.6 N/A N/A UPLAND 1390 
SHIRI NJORO 2841 1.8 111 1.3 N/A N/A LOWLAND 1018 
SHIRIMGUNGANI 3090 1.9 118 1.3 182 2.05 LOWLAND 860 
SONU 2926 1.8 257 2.9 N/A N/A UPLAND 1306 
TELLA 2692 1.7 163 1.8 N/A N/A UPLAND 1241 
TINDIGANI 1250 .8 25 .3 N/A N/A LOWLAND 915 
UDURU 2289 1.4 167 1.9 N/A N/A UPLAND 1296 
URORI 2825 1.8 142 1.6 136 1.53 UPLAND 1086 
USARI 2231 1.4 134 1.5 N/A N/A UPLAND 1190 
USWAA 3218 2.0 269 3.0 N/A N/A UPLAND 1190 
WARI 3745 2.3 401 4.5 N/A N/A UPLAND 1440 
Total 161119 100.0 8869 100.0 2232 25.2 N/A  
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The table and graph below highlights geographical variations in the study 
population. It clearly shows that more elderly live in upland villages. There is 
no documented reason for this although we can speculate that this may be 
due to either younger people migrating towards more low-lying villages 
closer to main transport links (and therefore work), or that those living in 
lowland villages may die earlier. The table and graph also demonstrate that 
the studied population is representative of the 70 and over population in the 
whole of the Hai District DSS with regard to the percentage of people that 
come from upland and lowland areas. 
 
Table 5 Representations from geographical areas in the whole Hai District 
DSS population, the whole 70 and over population, and the 70 and over 
population in the studied villages   
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Lowland 69456 43.1% 2115 23.8% 601 24.8% 549 24.6% 
Upland 91663 56.9% 6754 76.2% 1818 75.2% 1683 75.4% 
Total 161119 100.0% 8869 100.0% 2419 100.0% 2232 100.0% 
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Graph 2  
 
 
3.1.2 Demographic Details 
Detailed below are results of the demographics part of the questionnaire. 
Values do not always add up to 100% due to missing data. 
Age  
The mean age of 976 men was 77.9 (95% CI 77.4 to 78.3), and of 1256 
women was 77.7 (77.3 to 78.1). The proportions of patients aged 70 and 
over in the different age brackets are demonstrated in the table and graphs 
below. This is expressed as a percentage of the 70 and over population and 
as a percentage of the whole Study Population and can be compared to the 
percentage of people in the age brackets in the overall Hai District DSS. It 
demonstrates age-wise that the Study Population is representative of the 
whole DSS population. 
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Table 6 Demonstration that the age breakdown of the 70 and over 
population in the study was representative of the whole Hai District DSS 
population 
 
Age 
Divisions 
People 
in the 
Study 
Percentage 
of the 70 
and over 
population 
in the 
Study 
Percentage 
of the 
whole 
population 
in the 
Study 
People 
in the 
whole 
Hai 
District 
DSS 
Percentage 
of the 70 
and over 
population 
in the 
whole Hai 
District 
DSS 
Percentage 
of the 
whole 
population 
in the 
whole Hai 
District 
DSS 
70-74 877 39.3 1.71 3159 35.62 1.96 
75-79 625 28.0 1.22 2531 28.54 1.57 
80-84 344 15.4 0.67 1447 16.32 0.90 
85+ 386 17.3 0.75 1732 19.53 1.07 
Total 2232 100.0 4.35 8869 100.0 5.50 
 
Graph 3 
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Graph 4 
 
 
Table 7 Demonstration of the further Divisions of the older age bracket in the 
Study Population 
Age Divisions Frequency Percentage 
70-74 877 39.3 
75-79 625 28.0 
80-84 344 15.4 
85-89 221 9.9 
90-94 89 4.0 
95-99 40 1.8 
100+ 36 1.6 
Total 2232 100.0 
 
Gender 
The proportion of men and women in the Study Population was also 
representative of the background Hai District DSS population.  
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Table 8 Demonstration of the comparable breakdown of the 70 and over 
population by sex in the Study Population and the Hai District DSS 
population 
Sex People Aged 
70 and over 
in the Study 
Percentage of 
the 70 and 
over of the  
Study 
Population 
People Aged 70 
and over in the 
Hai District DSS 
Percentage of 
the 70 and over 
in the Hai 
District DSS 
population 
F 1256 56.3 4844 54.6 
M 976 43.7 4025 45.4 
Total 2232 100.0 8869 100.0 
 
Graph 5 
 
 
 
Age structure by Gender 
There is no difference between men and women in terms of the age structure 
of the participants despite there being more women than men in the Study 
Population. 
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Table 9 Demonstration of the comparable age structure of males and 
females in the Study Population  
Sex Age Frequency of 
participants in 
the Study 
Population 
Percentage of 
the 
participants in 
the Study 
Population 
Men 70-74 384 39.3 
75-79 285 29.2 
80-84 135 13.8 
85+ 172 17.6 
Total 976 100.0 
Women 70-74 493 39.3 
75-79 340 27.1 
80-84 209 16.6 
85+ 214 17.0 
Total 1256 100.0 
 
Graph 6 
 
 
Tribe 
The majority of participants were from the Chagga tribe. The Maasai tribe 
was under-represented in the Study Population as compared to the overall 
Hai district DSS population but otherwise the tribal breakdown was similar. 
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Table 10 Tribal representations of the Study Population  
Tribe Number of People in each 
Tribe aged 70 and over in 
the study 
Percentage in each 
tribe aged 70 and over 
in the study 
MZARAMO 6 0.3 
MNDENGEREKO 4 0.2 
MCHAGGA 2033 91.1 
MMASAI 7 0.3 
MPARE 38 1.7 
MNYAMWEZI 7 0.3 
MSUKUMA 2 0.1 
OTHER 135 6.0 
Total 2232 100.0 
 
Religion 
The religious divisions were representative. This was particularly important 
when considering health-seeking behaviour. 
 
Table 11 Religious Representations of the Study Population  
Religion Number of People in each 
Religion aged 70 and over 
in the Study Population 
Percentage in each 
Religion aged 70 and 
over in the Study 
Population 
CHRISTIAN 1763 79.0 
MUSLIM 466 20.9 
PAGAN 3 0.1 
Total 2232 100.0 
 
Marital Status 
1103 (49.4%) were married, 1050 (47.0%) were widowed, 32 (1.4%) were 
separated, 27 (1.2%) were single and 20 (0.9%) were divorced. The main 
reason for divorce was that the woman was unable to have children. 
 
 
 
 
 
 
 
 
 
71 
 
Age When Married  
 
Table 12 The age of first marriage of the Study Population 
Age Categories (years) Number of people 
aged 70 and over in 
the Study Population 
Percentage of people 
aged 70 and over in the 
Study Population 
10-14 13 0.6 
15-19 431 19.3 
20-24 670 30.0 
25-29 481 21.6 
30-34 246 11.0 
35-39 59 2.6 
40+ 76 3.4 
Missing Entry including 
N/A as the person was 
not married 
256 11.5 
Total 2232 100.0 
 
Graph 7 
 
 
Number of Children 
The number of children each study participant had is demonstrated in the 
table below. Men often had more than 1 wife and therefore the total number 
of children they fathered with all their wives is recorded.  
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Table 13 The number of children born to each study participant of the Study 
Population  
Number of children Number of people 
aged 70 and over in 
the Study Population 
Percentage of people 
aged 70 and over in 
the Study Population 
0 46 2.1 
1 28 1.3 
2 45 2.0 
3 66 3.0 
4 103 4.6 
5 175 7.8 
6 290 13.0 
7 348 15.6 
8 345 15.5 
9 305 13.7 
10 265 11.9 
11 84 3.8 
12 63 2.8 
13 19 0.9 
14 14 0.6 
15 10 0.4 
16 3 0.1 
18 1 0.0 
20 1 0.0 
24 1 0.0 
26 1 0.0 
38 1 0.0 
Missing Entry 18 0.8 
Total 2232 100.0 
 
Graph 8 
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Mortality level of the children of the Study Population  
This data was collected to look at social support and family size of study 
participants. As can be seen from the table below, only approximately half of 
the Study Population (n=1078) were asked about how many children they 
had and also how many of their children were dead (n=1083).  
 
Table 14 The mortality level of the children of the Study Population  
Number 
of 
children  
Frequency 
in the Study 
Population 
Percentage 
in the Study 
Population 
Number 
of 
children 
who had 
died 
Frequency 
in the 
Study 
Population 
Percentage 
in the Study 
Population 
0 46 2.1 0 98 4.4 
1 32 1.4 1 305 13.7 
2 58 2.6 2 271 12.1 
3 89 4.0 3 197 8.8 
4 157 7.0 4 83 3.7 
5 171 7.7 5 56 2.5 
6 169 7.6 6 30 1.3 
7 139 6.2 7 18 0.8 
8 115 5.2 8 13 0.6 
9 56 2.5 9 8 0.4 
10 26 1.2 10 2 0.1 
11 9 0.4 11 0 0.0 
12 6 0.3 12 0 0.0 
13 1 0.0 13 1 0.0 
14 3 0.1 14 0 0.0 
15 0 0.0 15 1 0.0 
21 1 0.0 21 0 0.0 
Total 1078 48.3 Total 1083 48.5 
Missing 
Entry 
1154 51.7 Missing 
Entry 
1149 51.5 
Total 2232 100.0 Total 2232 100.0 
 
Household Composition 
As a further representation of the level of social support for the elderly the 
participants were asked who they lived with. Their household compositions 
are demonstrated in Table 16 and Graph 9. In the majority of cases the 
“other” category represented cohabiting with siblings, with a small minority 
living with employees. 
 
 
74 
 
Table 15 The household composition of the Study Population  
Household composition Number of People in 
each household 
situation in the Study 
Population 
Percentage of 
people in each 
household 
situation in the 
Study Population  
Lives Alone 217 9.7 
Lives with spouse only 368 16.5 
Lives with spouse and others 627 28.1 
Lives with children only 593 26.6 
Lives with grandchildren 295 13.2 
Lives with children and 
grandchildren 
100 4.5 
Other 30 1.3 
Total 2230 99.9 
Missing Entry 2 0.1 
Total 2232 100.0 
 
Graph 9 
 
 
Where the Study Population was seen 
I attempted to see participants in a place of convenience for them. In the 
majority of cases it was possible and practical for them to come to the village 
health centre or dispensary. When the village was large, people were seen at 
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other convenient central locations, e.g. a private house or a local church. If 
the person was unable to travel to a central location they were seen in their 
own home. The fact that I saw patients in their own home is likely to have 
increased my case ascertainment and the validity of my conclusions. 1530 
(68.5%) people were seen in local health centres, 355 (15.9%) were seen in 
their own homes, 330 (14.8%) were seen in central large private houses and 
17 (0.8%) were seen in a local church.  
 
Distance to the Health Centre 
Nearly everyone had to walk to their nearest health centre / hospital and 
clearly health-seeking behaviour will be affected by a patient’s ability to 
access healthcare and for how long they have to travel. 99 (4.4%) had to 
travel for 0-29 minutes, 344 (15.0%) travelled for 30-59 minutes, 362 (16.2%) 
for 60-89 minutes, 100 (4.5%) for 90-112 minutes, 99 (4.4%) for 120-149 
minutes, 32 (1.4%) for 150-179 minutes and 61 (2.7%) had to travel for 3 
hours or more. 
 
Proportion of the Study Population that was born in and that had ever 
lived outside the Hai District DSS 
The population of the Hai District DSS and the Study Population are fairly 
static especially with reference to the 70 and over population.  The majority 
of the people (83.9%) in the Study Population were born within the Hai 
District DSS and only 26.7% had ever lived outside the Hai District DSS. 
 
3.2 Discussion 
The census was undertaken by experienced enumerators who had 
performed several previous censuses in their respective villages in the Hai 
District. The data were subsequently analysed by analysts in Dar-es-Salaam 
who again had worked successfully and accurately on previous censuses in 
the area. 
There was a six month time period between completion of the census (end of 
May 2009) and my point prevalence date (1st January 2010), during which 
time 301 more people from my surveyed villages turned 70. This was 
ascertained simply by asking patients their year of birth using memory 
prompts as for the rest of the census, rather than the exact date, and so may 
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have introduced a small degree of error with ages. However, this method 
remains the best validated (173) method in countries where the majority of 
people do not have birth certificates. 
The 12 villages were chosen at random, yet stratified to reflect accurately the 
spread of upland and lowland villages across the whole Hai District (and thus 
the tribal mix). The enumerators for each village were residents in their own 
village and this was beneficial because they spoke both Swahili and the local 
tribal language, were respected within their village (as they were educated 
and normally either teachers, nurses or local businessmen/women), and 
knew the location of houses and inhabitants very well. The benefit to my 
study was great, as, with these enumerators, my ascertainment was 
maximised. 
The AMOs, supervising the enumerators and co-ordinating data collection, 
provided intermediary communication between me, the enumerators, and the 
DMO. They were invaluable not only to relay logistics information but also to 
act as medical translators during the data collection. 
 
3.3 Conclusions 
The census was performed robustly and accurately to allow for precise 
identification of a proportion of an elderly Tanzanian population to produce 
accurate results based on reliable methodology. This has allowed me to 
accurately identify prevalence rates of AF and hypertension in the 
community-dwelling elderly population.
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Chapter 4.  
Prevalence of AF and Clinical Correlates - a Case-Control 
Study 
 
4.1 Methods 
In addition to the general methodology mentioned in Chapter 2, the 
ascertainment of AF cases and controls is described in more detail below. 
 
4.1.1 History Findings 
Please see Appendix 2b for full proforma. 
 
4.1.1.1 Presenting Symptoms 
Common, important symptoms relating to AF and cardiac problems were 
recorded in this section. Chest pain was classified as cardiac or non-cardiac, 
and further delineated if it was thought to be potentially of cardiac origin 
using the Canadian Cardiovascular Society Angina Classification (176). 
Breathlessness was graded according to the New York Heart Association 
Classification of heart failure (177). These scales were chosen for their ease 
of use and their common acceptance elsewhere in the world. Other 
symptoms of heart failure and AF were recorded such as orthopnoea and 
paroxysmal nocturnal dyspnoea, and palpitations, pre-syncope, syncope, 
tiredness and reduced exercise tolerance. 
 
4.1.1.2 Other History 
Other history I felt it was important to record included whether the 
participants had sought medical help for their symptoms and whether they 
had been to a health centre / hospital in the previous 12 months or to a 
traditional healer ever, in order to assess not only health-seeking behaviour, 
but also the gap in diagnosis and treatment of AF and other conditions such 
as hypertension. The past medical history concentrated particularly on risk 
factors for AF and other cardiac conditions, and another assessment (in 
addition to the Barthel Index (BI) score within the demographics section) of 
ADLs was made particularly related to stroke. 
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4.1.2 Examination Findings 
4.1.2.1 Cardiac 
The examination for AF cases and controls focused mainly on cardiovascular 
findings, particularly auscultation of the praecordium, assessment of 
peripheral pulses and systemic stigmata of cardiac disease. See appendix 
2b for Proforma. 
 
4.1.2.2 Other 
Other important signs related to risk factors for AF were assessed and 
recorded e.g. fundoscopy was performed for signs of hypertensive 
retinopathy, lung bases were auscultated for signs of LV failure and 
pulmonary oedema. Incidental findings that were of interest or cause for 
concern from a medical perspective were also recorded and appropriate 
advice or treatment was given (or prescribed if not immediately available). 
 
4.1.3 The Electrocardiograph and standardisation of measurements 
The machine used for recording 12-lead ECGs was a MAC 1200 TM (GE 
Healthcare, UK). The study had the use of 2 machines (one of which was 
already in Tanzania as it was used in a previous study, and one that was 
purchased with grant money). These machines were introduced to the village 
enumerators in a 2-hour session, with an initial demonstration of how the 
machine worked, and then an opportunity to practise recording ECGs on a 
volunteer and address any queries. The enumerators were provided with a 
printed sheet, detailing steps in recording ECGs in Kiswahili and a diagram 
to remind them about electrode placement (see appendix 1). The machines 
had rechargeable batteries to ensure they were readily usable in health 
centres / homes without electricity and to minimise AC interference from 
mains supply. The machines were set-up to record at a paper speed of 
50mm/s, with a sensitivity of 10mm/mV, as is standard practice in the UK. 
The machines were capable of storing up to 40 ECGs digitally, for 
subsequent download to PC. I aimed to perform 12-lead ECGs on all 
participants. 
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4.1.4 Blood Pressure Measurements in AF Cases 
Blood pressure was measured as in Section 7.1.1. It is well known that 
accurate BP measurement in patients with arrhythmias is difficult, particularly 
if the arrhythmia is irregular and consequently there is beat-to-beat variation 
in stroke volumes. The current ESC guidelines (178) states: 
 
"Irrespective of what guidelines are agreed upon, blood pressure measurement in 
atrial fibrillation, particularly when the ventricular rhythm is highly irregular, will at 
best constitute a rough estimate, the validity of which can perhaps be improved 
upon only by using repeated measurements or direct intra-arterial measurement". 
 
In following these guidelines, I accept that the BP measurements may not be 
as accurate as the recordings in the participants in sinus rhythm, but aimed 
to maximise accuracy by repeating measurements and ensuring that 
consecutive BPs were within a range of each other (see 7.1.1). Intra-arterial 
measurements were clearly not an option. 
 
4.1.5 Case definition of AF 
AF was diagnosed according to the definitions provided by the ESC 
guidelines (31). AF is defined as a cardiac arrhythmia with the following 
characteristics: 
 
(1) The surface ECG shows ‘absolutely’ irregular RR intervals (AF is 
therefore sometimes known as arrhythmia absoluta), i.e. RR intervals that do 
not follow a repetitive pattern. 
(2) There are no distinct P waves on the surface ECG. Some apparently 
regular atrial electrical activity may be seen in some ECG leads, most often 
in lead V1. 
(3) The atrial cycle length (when visible), i.e. the interval between two atrial 
activations, is usually variable and <200 ms (>300 bpm). 
 
Any arrhythmia that has the ECG characteristics of AF and lasts sufficiently 
long for a 12-lead ECG to be recorded, or at least 30 seconds on a rhythm 
strip, should be considered as AF. 
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For the purposes of this study, cases of atrial flutter (AFl) were included 
under the umbrella heading of AF. AFl can usually be distinguished from AF 
on 12-lead ECG, because it tends to be a more organised supra-ventricular 
arrhythmia, and thus results in characteristic ‘saw-toothed’ F waves of 
constant amplitude and frequency, with a cycle length ≥200ms (≤300bpm), 
and often a regular RR interval. However, as has been mentioned previously, 
several studies have reported a similar risk profile in Afl patients to that 
observed in AF patients (131) (179) (132). 
 
4.1.6 Risk stratification for treatment purposes 
With regard to persistent / permanent AF, risk stratification has been 
previously discussed and I employed the CHA2DS2-VASc tool. As all of my 
patients were 70 years of age or older, they all scored at least 1 point with 
the tool. This meant, as warfarin was not available in this setting, that all of 
my patients were given aspirin 75mg per day if there was no contra-
indication. I did not increase the dose of aspirin in higher risk patients as I did 
not want to increase bleeding risk. I used EF ≤40% or evidence of clinical 
LVF as a cut-off for deciding whether a patient scored 1 point for 'C', and 
used the WHO criteria for diagnosis of Diabetes Mellitus (random plasma 
glucose ≥11.1mmol/L. I did not use fasting glucose due to inability to ask 
participants to come and see me fasted and did not have the finances to 
perform HbA1c). I did not test all study participants for Diabetes Mellitus, only 
patients with AF and the pool of controls, as this was felt to be outside the 
scope of this study. I may have underestimated risk scores as diagnosis of 
vascular disease relied solely on symptoms and palpation of peripheral 
pulses. 
With regard to PAF, there is still debate in the literature as to how much PAF 
is clinically important from the perspective of increasing stroke risk. Please 
see Chapter 6 for further discussion of the literature  
 
4.1.7 Echocardiography and the contribution of echocardiography to risk 
stratification 
Echocardiography was performed by a trained echocardiographer (MD) 
using a Sonosite TitanTM (Sonosite Ltd, UK) portable echo machine. 
Measurements were taken according to European Association of 
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Echocardiography guidelines as far as was possible given the limitations 
intrinsic to the setting and the capabilities of the echo machine (180). 
Importantly with regards to assessing for structural heart disease 
predisposing to AF, global LV function was noted in addition to LA size and 
MV structure and function. For the purposes of reporting LV function, EF was 
normal (≥55%), mildly impaired (45-54%), moderately impaired (35-44%), or 
severely impaired (<35%) and measured using fractional shortening and 
visual estimation (as Simpson’s biplane method was unavailable on this 
machine). Other limitations of the echo machine included only being able to 
record still images and not video loops (meaning function had to be 
assessed whilst performing the echo), battery life and memory card sufficient 
to record a maximum of 3 echocardiographs in the field, and lack of Tissue 
Doppler Imaging (TDI) facility to assess diastolic dysfunction in more detail. 
Limitations intrinsic to SSA included having to do many of the echos with the 
patient in a seated position due to lack of beds at health centres / village 
halls, and that dimmed / dark rooms were not always available for ideal 
visualisation of images. Having said this, I had to balance limitations with 
practicality and the machine produced good images for its size and 
portability, sufficient that following recording in the field, reporting and 
recording measurements were done the same evening on returning from the 
field. 
It was vital to perform echocardiography on all AF patients and controls. It is 
well recognised that structural heart disease, particularly LV dysfunction, 
increased LA size, and MV disease predispose to the development and 
maintenance of AF (38) (74) (75). In addition to identifying risk factors for 
development, it was also important to risk stratify patients with AF as to their 
subsequent risk of stroke. As previously mentioned, LV dysfunction 
(arbitrarily ≤40%) is a clinically significant risk factor for stroke in non-
rheumatic AF (147), and the identification of a patient with AF and mitral 
stenosis / rheumatic mitral valve disease immediately places this patient at 
high risk of thromboembolic problems (31). Therefore, echo was mandatory 
in order to assess risk in this population and decide on treatment. 
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4.1.8 Blood Sampling 
Blood samples were taken from AF patients and controls for biochemical 
analyses including urea and electrolytes, liver and thyroid function tests, 
glucose and lipid profile. These tests were done as they have either 
implications for the aetiology of AF (e.g. thyroid function tests looking for 
hyperthyroidism) or contribute to an assessment of overall cardiovascular 
risk (e.g. lipid profile and random blood glucose). eGFR was calculated and 
reported using a new equation called the CKD-EPI equation, which is 
claimed to be as accurate as the more traditional Modified Diet in Renal 
Disease – 4 (MDRD-4) equation for eGFR <60 ml/min/1.73 m2, and 
‘considerably more accurate’ than MDRD-4 in the group with eGFR >60 
ml/min/1.73 m2 (181). In addition, a recent study by Eastwood et al (182) 
looked at 944 black Africans from the Ashanti tribe in Ghana, and compared 
creatinine clearance using 24-hour urine samples to equations for calculating 
eGFR (Cockcroft-Gault, MDRD-4, CKD-EPI).The study found that the CKD-
EPI equation without the adjustment for race was the closest to that of 
creatinine clearance, outperforming MDRD-4 (with and without adjustment 
for race) and CKD-EPI (with adjustment for race) which overestimated eGFR 
and Cockcroft-Gault which underestimated eGFR. The CKD-EPI without race 
adjustment mirrored decline in GFR in the older age groups better than the 
other equations (although the study population had a maximum age of 75 
years), and therefore is the one I chose to use in my study population. I also 
calculated eGFR using more traditional measures, the Cockcroft-Gault and 
MDRD-4 formulae as comparisons. Cockcroft-Gault does not have an 
adjustment for race in its equation and is known to be inaccurate at both 
significant overestimation of eGFR in black African patients compared to 
isotope imaging (183), and significant underestimation compared to 
creatinine clearance (182). MDRD-4 has an adjustment for race in its 
equation, but like CKD-EPI, has been shown to be more accurate in black 
African patients at estimating GFR when using the equation without race 
adjustment (183). The figures reported therefore are without adjustment for 
race. 
In addition to these traditional tests, other electrolytes such as magnesium 
and calcium were measured because electrolyte imbalances may contribute 
to the development of atrial tachyarrhythmias by causing abnormal impulse 
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generation, which could initiate a re-entrant loop within the atria (184). 
Hypomagnesaemia was present in 20% of patients presenting with AF in one 
small study containing 45 patients (185), although it is difficult to estimate the 
contribution of hypomagnesaemia to AF / AFl given the lack of prospective 
studies, and the fact that serum magnesium represents only 1% of total body 
content in general (186). In addition, it is noted that full blood counts (FBC) 
were not performed in my Study Population despite anaemia potentially 
contributing to the development of AF through decreasing oxygen delivery to 
myocardial tissue thus creating an ischaemic substrate. The reason for this 
was purely economic in that the samples had to be analysed in Moshi and at 
US$19 each, were deemed prohibitively expensive.  
However, biochemistry samples were spun and frozen at the Duke University 
laboratory in Moshi on the day of collection, prior to transport on dry ice back 
to the UK, where they were analysed at North Tyneside General Hospital at 
a more affordable price. It is not possible to carry out FBC on frozen 
specimens. 
 
4.1.9 Patient Treatment 
AF cases identified were treated with aspirin to lower stroke risk (157) and 
older rate-control agents (digoxin, atenolol) to reduce symptoms and help 
improve functional status (187) (in the absence of contra-indication). The 
agents were chosen based on effectiveness, local availability and cost. 
Warfarin remains unavailable and unsuitable for stroke prevention in rural 
Tanzania due to a lack of infrastructure for monitoring INR levels. Potentially 
promising in the future are the newer anti-coagulants such as rivaroxaban 
and dabigatran that do not require monitoring, although they are only just 
beginning to appear on the market (recent FDA licensing in the USA) and are 
therefore currently very expensive. 
In addition to the treatment given for AF, I prescribed treatment to address 
risk factors such as HTN (bendrofluazide and nifedipine), diabetes mellitus 
(chlorpropamide) and heart failure (frusemide, captopril). Again, these 
treatments were chosen for sustainability reasons. 
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4.1.10 Controls 
Controls were selected from the list of those aged 70 years and above within 
the study villages who were found to have sinus rhythm on their 12-lead 
ECG. Anyone who had been previously diagnosed with AF or another 
cardiac arrhythmia requiring treatment was not considered as a potential 
control. Controls were age- and sex-matched as a group to those identified 
as having AF. I employed a pragmatic approach whereby a pool of controls 
was selected by convenience sampling from the background population and 
controls selected from this pool by use of a random number generator. The 
reasons for using this approach were multiple: 
1. If controls were identified completely at random, they would have been 
expected to return to the village health centre on a separate occasion, 
entailing a long walk and preventing them from working which they were 
often unwilling to do. 
2. I found there was more time first thing in the morning for doing more 
detailed histories, performing echocardiograms etc. before the majority of 
participants turned up. Often we were seeing >50 participants per day and 
therefore it was more pragmatic to identify the first 2-3 people per day as 
controls. 
3. Which village I visited on a day-to-day basis depended on accessibility 
during the prolonged rainy season as well as enumerator availability and it 
was difficult to plan too far in advance with regard to asking the enumerator 
to request that specific people return on specific days. 
 
4.1.11 Expected Prevalence Rates 
As mentioned previously, the main reason for conducting this study was to 
accurately document the prevalence of AF in a previously unstudied elderly 
SSA population. I was expecting prevalence rates to be similar to prevalence 
rates in African-Americans, with higher rates of rheumatic valvular heart 
disease in this population compensating for lower rates of IHD (with respect 
to AF risk factors). I also also felt that estimating population risk of AF based 
on one of the recently published risk prediction algorithms derived from large 
epidemiological studies in the US would be interesting (188, 189). This was 
done retrospectively given that the risk prediction tools were published after 
my data collection had finished and is a rough estimate of predicted 
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prevalence as these tools are risk prediction tools rather than prevalence 
prediction tools and risk of incident AF over 5 and 10 years has been 
estimated from them, rather than prevalence. 
I decided to compare my population and risk factors with the African-
American cohort in the CHS study, which was analysed using the 
Framingham risk prediction tool in the Schnabel paper (188). The reason for 
doing this is that whilst the ARIC prediction tool (189) appeared to predict AF 
risk with more accuracy than the Framingham AF score (c-statistic 0.76 
versus 0.68) in African-Americans, increasing age consistently comes out as 
the most important risk factor for AF and the ARIC tool has only been 
validated in a population of 45-64 year olds. It therefore has limited 
application to my Study Population. In addition, I felt I could be more 
accurate with the Framingham risk score as the ARIC tool relies on data from 
clinical examination, smoking status, presence of diabetes mellitus (for 
example), data which I did not collect. However, I had more risk factors for 
the Framingham risk score recorded. Unfortunately, the CHS African-
American cohort had missing data on valvular heart disease and had 
consequently been unable to estimate a hazard ratio. Therefore I have not 
included it in the table below. 
 
Table 16 Risk Factors for AF based on Framingham AF risk prediction tool - 
a comparison of the Study Population to African-Americans in the 
Cardiovascular Health Study (CHS AA) 
Risk Factor My Study 
(n=2232) 
CHS AA (n=1552) 
Risk Factor Hazard Ratio 
Mean Age 
(years) 
77.7 75.3 1.95 (per 10 
years) 
Gender (% men) 43.7 35.8 1.2 (being male) 
BMI (kg/m2) 21.6 28.5 1.29 (per 5kg/m2) 
SBP (mmHg) 160 141 1.17 (per 
20mmHg) 
HTN Treatment 94 (4.2%) 58.4% 1.58 
PR interval (ms) 152 173 1.12 (per 30ms) 
Heart Failure 0 7.8% 3.21 
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As can be seen, my Study Population was on average older, with more men, 
a lower BMI, yet a higher mean SBP, a significantly lower percentage of 
people on anti-hypertensives, a shorter mean PR interval and no-one with 
significant heart failure (i.e. either EF <45% or clinical heart failure). 
Therefore, if we look at the risk factors that would increase risk in my Study 
Population, older age by 2 years would increase risk by approximately 20%, 
increased mean SBP would increase risk by approximately 17%, and there 
were 8% more men in my population, increasing risk further. Countering this, 
it appears that reduced BMI would reduce risk by approximately 30%, PR 
interval by approximately 10% and my own feeling is that it is incredibly 
difficult to try to compare the 2 populations in terms of anti-hypertensive 
treatment (because as will be seen in chapter 7, very few very hypertensive 
people were on treatment due to under-diagnosis and lack of treatment 
resource) and heart failure (a value of zero people is likely to be an 
underestimate and of minimal help given I only had data from 75 'control' 
echocardiograms). Discounting the final two, and allowing for the fact that the 
prevalence of valvular heart disease is probably higher in my Study 
Population than in the CHS AA study, the population risk factor profile 
suggests I should be expecting a similar prevalence of AF to that seen in an 
African-American population. 
 
4.1.12 Statistical Analysis  
Statistical advice was sought from Dr Keith Gray from Northumbria Health 
Care Foundation Trust and a calculation of the power of the study performed 
(based on the Hai DSS study population). Statistical analyses were 
performed using Statistical Package for the Social Sciences SPSS software, 
version 17.0, and Microsoft Excel 2007. 
Age-standardisation was carried out using the direct method, with 
standardisation to the WHO world standard (190). Age specific rates for each 
five year age band were also calculated. Confidence intervals (CIs) for 
prevalence and for odds ratios were calculated based on the assumptions of 
the binomial distribution. CIs for continuous variables were calculated from 
the normal distribution. Due to the small number of AF and PAF cases 
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identified, significance tests for some data are not presented. Point estimates 
and proportions are given as appropriate. 
 
4.2 Results 
 
4.2.1 Prevalence of AF 
ECGs were performed on 2232 study participants. Of these, 1256 (563%) 
were women and 976 (437%) were men. There were 15 cases of AF (14 
fibrillation, 1 flutter) giving an overall crude prevalence rate of 067% (95% CI 
033 to 101) and an age-adjusted prevalence of 064% (95% CI 031 to 
097), as shown in Table 17. Rates were higher in women than men, though 
not significantly so, as shown in Table 18. There was a general trend 
towards increased prevalence with increasing age.  
 
Table 17. Age-specific prevalence of atrial fibrillation 
Age 
bands 
WHO world 
population 
(%) 
Combined sexes 
  Cases Denominator 
population 
Prevalence (%) (95% 
CI) 
70-74 221 4 877 046 (001 to 090) 
75-79 152 2 625 032 (0 to 076) 
80-84 091 4 344 116 (003 to 230) 
85+ 0635 5 386 130 (017 to 242) 
Total 5275 15 2232 067 (033 to 101) 
Age-
adjusted* 
- - - 064 (031 to 097) 
* To WHO world population.(190) 
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Table 18 Age- and sex-specific prevalence of atrial fibrillation 
Age bands Males Females 
 Cases Denominator 
population 
Prevalence per 
1000 (95% CI) 
Cases Denominator 
population 
Prevalence 
per 1000 
(95% CI) 
70-74 2 
384 
052 (0 to 124) 2 
493 
041 (0 to 
097) 
75-79 0 
285 
0 2 
340 
059 (0 to 
140) 
80-84 0 
135 
0 4 
209 
191 (006 to 
377) 
85+ 1 
172 
058 (0 to 172) 4 
214 
187 (005 to 
368) 
Total 3 976 031 (0 to 065) 12 1256 096 (042 to 
149) 
 
4.2.2 Clinical Correlates of AF 
Comparison of the clinical characteristics of those with AF and controls is 
shown in Table 19 for females and Table 20 for males, below. The results 
are further explained in individual sections below that. Again, data are 
missing for specific variables in a small number of cases, as detailed in the 
tables. 
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Table 19 Comparison of female patients and controls 
 Patients (n = 12) Controls (n= 60) 
Mean age (years) 815, n = 12 803, n = 60 
Mean BMI (kg/m2) 209 , n = 9 220 , n = 55 
Mean pulse rate (beats per minute) 1187, n = 12 816, n = 58 
Mean pulse pressure (mmHg) 598, n = 12 789, n = 60 
Mean diastolic BP (mmHg) 1051, n = 12 917, n = 60 
Mean systolic BP (mmHg) 1649, n = 12 1706, n = 60 
BP ≥ 140/90 9 (750%), n= 12 48 (800%), n = 60 
BP > 150/95 7 (583%), n= 12 43 (717%), n = 60 
BP > 160/100 7 (583%), n= 12 31 (517%), n = 60 
Mean serum cholesterol (mmol/L) 4.5, n= 10 4.8, n = 51 
Barthel index score 
No disability (19-20) 
Moderate disability (15-18) 
Severe disability (0-14) 
n = 8 
5 (625%) 
1 (125%) 
2 (250%) 
n = 31 
30 (968%) 
1 (32%) 
0 (0%) 
Palpations 6 (500%), n= 12 5 (83%), n = 60 
Pre-syncope 6 (500%), n= 12 6 (100%), n = 60 
Shortness of breath 5 (417%), n= 12 8 (133%), n = 60 
Reduced exercise tolerance / 
tiredness 
4 (333%), n= 12 5 (83%), n = 60 
Mean CHA2DS2-VASc risk score 4.27, n = 11 - 
Echocardiography   
Left ventricular function 
Normal (EF ≥55%) 
Mild impairment (EF 45-54%) 
Moderate impairment (EF 35-44%) 
Severe impairment (EF <35%) 
n = 12 
7 (583%) 
2 (167%) 
2 (167%) 
1 (83%) 
n = 60 
54 (900%) 
6 (100%) 
0 (0%) 
0 (0%) 
Mean left atrial size (cm) 44, n= 12 3.3, n = 49 
Left atrial dilation 
Normal 
Mild 
Moderate 
Severe 
n = 12 
1 (83%) 
3 (250%) 
5 (417%) 
3 (250%) 
n = 49 
37 (755%) 
10 (205%) 
2 (41%) 
0 (0%) 
Mitral valve stenosis 1 (83%), n = 12 2 (33%), n = 60 
Mitral valve regurgitation 7 (583%), n = 12 11 (183%), n = 60 
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Table 20 Comparison of male patients and controls 
 Patients (n = 3) Controls (n = 15) 
Mean age (years) 767 , n = 3 771, n = 15 
Mean BMI (kg/m2) 268, n = 3 217, n = 15 
Mean pulse rate (beats per minute) 1053, n = 3 699, n = 14 
Mean pulse pressure (mmHg) 517, n = 3 781, n = 15 
Mean diastolic BP (mmHg) 817, n = 3 849, n = 15 
Mean systolic BP (mmHg) 1333, n = 3 1631 , n = 15 
BP ≥ 140/90 1 (333%), n= 3 11 (733%), n= 15 
BP > 150/95 0 (0%), n= 3 10 (667%), n= 15 
BP > 160/100 0 (0%), n= 3 9 (600%), n= 15 
Mean serum cholesterol (mmol/L) 4.4, n= 3 51, n = 12 
Barthel index score 
No disability (19-20) 
Moderate disability (15-18) 
Severe disability (0-14) 
n = 3 
3 (100%) 
0 (0%) 
0 (0%) 
n = 6 
6 (100%) 
0 (0%) 
0 (0%) 
Palpations 1 (333%), n= 3 1 (67%), n = 15 
Pre-syncope 0 (0%), n= 3 0 (0%), n = 15 
Shortness of breath 2 (667%), n= 3 1 (67%), n = 15 
Reduced exercise tolerance / 
tiredness 
0 (0%), n= 3 0 (0%), n = 15 
Mean CHA2DS2-VASc risk score 133, n= 3 - 
Echocardiography   
Left ventricular function 
Normal (EF ≥55%) 
Mild impairment (EF 45-54%) 
Moderate impairment (EF 35-44%) 
Severe impairment (EF <35%) 
n = 3 
3 (100%) 
0 (0%) 
0 (0%) 
0 (0%) 
n = 15 
13 (867%) 
2 (133%) 
0 (0%) 
0 (0%) 
Mean left atrial size (cm) 41, n= 3 36, n = 9 
Left atrial dilation 
Normal 
Mild 
Moderate 
Severe 
n = 3 
1 (333%) 
2 (667%) 
0 (0%) 
0 (0%) 
n = 9 
9 (100%) 
0 (0%) 
0 (0%) 
0 (0%) 
Mitral valve stenosis 0 (0%), n = 3 0 (0%), n = 15 
Mitral valve regurgitation 1 (333%), n = 3 2 (133%), n = 15 
 
4.2.2.1 Symptoms 
The most common symptoms associated with AF in the Study Population 
were palpitations and pre-syncope, each affecting 6/15 (40%) of those with 
AF. Next most common was shortness of breath (5/15 – 33.3%), then limited 
exercise tolerance and tiredness (both 4/15 – 26.7%), and finally cardiac-
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sounding chest pain (3/15 – 20%). Of the 5 that had shortness of breath, all 
of them reported symptoms with moderate exertion and were therefore 
classified as NYHA class II. This corresponds to high-income country studies 
where up to 30% of AF patients have symptomatic heart failure of NYHA 
classes II-IV (191, 192) although it is to be noted that these patients were at 
the less severe end of the spectrum (NYHA II), as expected for otherwise 
well community-based patients. In addition, ≥20% AF patients have CAD 
according to these same studies (191, 192) which corresponds well to my 
study findings of patients with cardiac-sounding chest pain. However, 
‘anginal’ symptoms may not necessarily signal large vessel coronary disease 
and may be as a result of tachyarrhythmia and microvascular coronary 
perfusion abnormalities associated with AF (193). Interestingly, 5/15 (33%) 
were completely asymptomatic of their AF, again in keeping with studies in 
high-income countries that suggest approximately 30% of AF sufferers 
(particularly the elderly) are unaware of their diagnosis (43). This compared 
to the control group, whose most common symptom was SOB (19/114 – 
22%), followed by pre-syncope (11/114 – 13%) and limited exercise 
tolerance (9/114 – 10%), then palpitations and tiredness (both 7/114 – 8%). 
Cardiac-sounding chest pain and syncope were each only present in 2/114 
(2%). 
 
4.2.2.2 Signs 
Examination findings revealed an average pulse rate of 116bpm (range 60-
220) in AF patients. Females had a higher average pulse pate than males 
(118.7bpm vs. 105.3). This compared to a mean pulse rate of 77.5 in 
controls, with male controls having higher mean pulse rates than their female 
counterparts (83bpm vs. 73.4). 2/15 (13.3%) patients had a raised jugular 
venous pressure (JVP), but no patients had evidence of overt cardiac failure. 
2 patients had a raised JVP, and 2 other patients had mild pedal oedema, 
but the raised JVPs were secondary to tricuspid valve incompetence, and 
pedal oedema is very common in the elderly and was not considered 
pathological in these two cases due to the lack of supporting findings. 
Several AF patients and controls were found to have cardiac murmurs on 
auscultation of the praecordium but corresponded well with what was 
subsequently found on echocardiography.  
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4.2.2.3 Blood Pressure 
Mean systolic BP in AF patients was 158.6mmHg and diastolic 100.4mmHg. 
Females with AF had significantly higher systolic and diastolic BP than their 
male counterparts (164.9 vs. 133.3 systolic and 105.1 vs. 81.7). Using our 
pre-determined cut-off points, this equated to 9/12 (75%) female patients 
with a BP ≥140/90 but only 1/3 (33%) male. 7/12 (58.3%) female and 0/3 
male AF patients had BP ≥150/95 and 7/12 (58.3%) female patients had BP 
>160/100. Overall mean pulse pressure was 58.2mmHg, again with a larger 
pulse pressure in female AF patients (59.8 vs. 51.7). Comparisons to the 
control groups can be seen in Tables 19 and 20.  
 
4.2.2.4 Echocardiographic Findings 
Left ventricular systolic function was more commonly affected in AF patients 
than in controls. Overall, 10/15 (66%) AF patients had normal LV function, 
with 2/15 (13.3%) having mild LV dysfunction, 2/15 (13.3%) moderate LV 
dysfunction and 1/15 (6.7%) severe LV systolic dysfunction. 3/3 male AF 
patients had normal LV systolic function meaning female AF patients had 
lower average ejection fractions.  
AF patients had slightly higher mean pulmonary artery systolic pressures 
(PASP) than controls (25.22mmHg vs. 22.56). Female AF patients had a 
mean PASP of 25.28mmHg vs. male patients with a very similar mean value 
of 25mmHg. Whilst male controls were very similar with a mean of 25.86, 
female controls had much lower mean PASP of 16.37mmHg. None of our 
patients or controls had significant aortic stenosis. 
See Tables 19 and 20 for further echocardiographic indices with comparison 
to age-and sex-matched controls. No statistical analysis has been performed 
due to very low numbers of AF patients. 
 
4.2.2.5 Functional Status 
Functional status, as determined by the BI score, was lower on average in 
AF patients (16.9) than in controls (19.4). The mean BI score was 
significantly lower in 8 female AF patients (16.2) than 3 male AF patients 
(20), but were fairly similar in 31 female controls (19.5) and 6 male controls 
(19.3). 5 female patients (62.5%) had mild disability / no disability 
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(characterised by BI scores of 19-20), 1 (12.5%) had moderate disability (BI 
15-18) and 2 (25%) had severe disability (BI <15). All 3 male AF patients 
scored 19-20 on BI therefore having mild / no reduced functional status. The 
odds of a female AF patient having severe disability, based on BI score, 
were 1.31 (95% CI 0.90 to 1.92) those of a man. 
 
4.2.2.6 Body Mass Index 
The mean BMI of AF patients was 22.34, with men having higher values 
(26.8) than women (20.9). This compares to a mean control BMI of 21.9, with 
male controls having a very similar BMI (21.7) to female controls (21.9), and 
to the mean BMI of the background study population of 21.6 (men and 
women combined), 20.9 (men) and 22.2 (women) 
 
4.2.2.7 Blood Results 
AF patients had a mean eGFR of 67.9mL/min/1.73m2 using the CKD-EPI 
equation without adjustment for race, 70.9mL/min/1.73m2 using MDRD-4, 
and 49.1mL/min/1.73m2 with the Cockcroft-Gault formula. Male patients had 
a much higher average eGFR than females (82 vs. 63.7). This was a higher 
mean eGFR than in controls (see graph below), with mean GFR in controls 
being 58.1mL/min/1.73m2 using CKD-EPI (59.5mL/min/1.73m2 using MDRD-
4 and 42mL/min/1.73m2 for Cockcroft-Gault), and again GFR being better in 
males than females (78.7 vs. 52.4). 
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Graph 10 Comparison of eGFR (mL/min/1.73m2) in AF patients and controls, 
using 3 different equations 
 
 
With regards to electrolytes, AF patients had K+ (4.3mmol/L), Ca2+ (2.33) and 
Mg2+ (0.84) values that were well within the normal ranges, and this 
compared similarly to control patients with mean values of K+ (4.4mmol/L), 
Ca2+ (2.35mmol/L) and Mg2+ (0.86mmol/L).  
Two female controls were biochemically hyperthyroid yet clinically euthyroid, 
and no AF patients had significant thyroid abnormalities.  
With respect to risk factors for CVD, AF patients and controls had fairly 
similar mean total cholesterol (TC) and glucose levels. AF patients had a 
mean TC of 4.45, with controls being slightly higher at 4.69. Mean glucose 
levels were 5.18 (AF patients) and 5.22 (controls). No AF patients had a 
random blood glucose ≥11.0, but 2 male controls did (11.7 and 12.9). 
 
4.2.2.8 Risk Stratification for Stroke 
Mean CHA2DS2-VASc score was 3.64 (excluding 1 patient with rheumatic 
mitral valve disease). Female AF patients were at higher thromboembolic 
risk than their male counterparts, with a mean score of 4.3 (range 3-7) 
compared to 1.33 (range 1-2). Nevertheless, there were only 2/15 (13.3%) 
patients, both male, that scored 1 (and who would therefore be classified as 
intermediate risk). The other 13/15 (86.7%) would be classified as high 
thromboembolic risk (12 patients with a risk score >1, and 1 other patient 
with rheumatic MS classified as high risk). 
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4.2.2.9 Sequelae at Follow-up   
1/15 AF patients had died at follow-up but the village enumerator did not 
know any more details and it was felt inappropriate at that time to enquire 
further. Another  patient had been hospitalised with symptoms and signs of 
heart failure after discussion with the village enumerator (who was also a 
nurse at the village health centre). There are therefore missing data with 
regard to follow-up and blood results on these 2 cases. 
 
4.2.3 Treatment and Advice for AF 
Patients were given an information sheet regarding AF in Swahili (see 
appendix 5) and advised of symptoms, signs and potential sequelae. They 
were also given advice and education regarding the medication I prescribed 
for them. All 15 AF patients were prescribed aspirin 75mg od, given that they 
were all classified as at least intermediate risk of stroke sequelae. With 
regard to rate control, 9/15 (60%) were prescribed digoxin (125mcg or 
250mcg depending on size and frailty), 3/15 (20%) were prescribed 
propranolol (40mg bd or 80mg bd depending on BP and pulse rate), 2/15 
(13.3%) did not require rate control as their ventricular rate was adequate, 
and 1/15 (6.7%) was previously aware of her diagnosis of AF and was taking 
500mcg od of digoxin – this was halved by me to 250mcg as she was 
bradycardic. Digoxin was prescribed in the majority due to the fact that it was 
often the only rate-control drug available at the village dispensary, and was 
significantly cheaper than propranolol. Propranolol was the most widely 
available beta-blocker and was prescribed in 1 case where the patient was 
having frequent paroxysms of AF and in 2 cases where the patients had 
either accompanying angina or were quite symptomatic from AF with a fast 
ventricular response and therefore rapid ventricular rate control was 
important. 
Concomitant anti-hypertensive medications were prescribed in 5 patients, in 
the form of nifedipine (1/15), bendrofluazide (3/15) and lisinopril (1/15). 
Nifedipine and bendrofluazide were chosen primarily as they were most 
widely available and most effective. Bendrofluazide was the cheapest 
medication but I tried to avoid prescribing it with digoxin due to the risk of 
hypokalaemia and subsequent digoxin toxicity / proarrhythmia, and in these 
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patients we gave nifedipine instead. In the case of lisinopril, the patient was 
already on this relatively expensive drug, yet his hypertension was not 
adequately controlled and therefore the dose was increased, with advice 
regarding re-checking of renal function given. 
 
4.2.4 Follow-up 
2 patients were not seen at follow-up; 1 had died and 1 had been admitted to 
hospital. Of the remaining 13 AF patients, 2 had reverted to sinus rhythm and 
therefore their digoxin was stopped and 1 continued to have a fast ventricular 
response and therefore their digoxin was increased. Of the 8 patients that 
were followed-up and originally symptomatic, 4 (50%) had noticed an 
improvement in their symptoms since the commencement of treatment. 
Unfortunately, other than the patient who was previously aware of her AF 
diagnosis and already on treatment, not one of the patients had returned to 
the health centre for a repeat prescription, although 4/13 followed-up still had 
medication remaining from my initial prescription. Reasons cited for this 
included not having enough money, being too busy with work and having 
forgotten. Repeat education, advice and shorter prescriptions were given. 
 
4.3 Discussion 
4.3.1 AF Prevalence Data 
4.3.1.1 Comparison to Other Populations 
There have been a limited number of studies in SSA looking at AF (59, 60, 
62, 63). Most have looked at the incidence of AF (59, 60) and mortality due 
to AF (63) in hospital populations, or at stroke risk factors in the community 
(62). The study by Connor et al (62) in South Africa was based on a 
questionnaire sent to 200 general practices recruiting 9133 patients (mean 
age 507 years), of whom 23% were black. The reported prevalence rate of 
AF in black patients was 2%, although this is likely to be an overestimate 
given that patients with an irregular pulse were classified as having AF. 
Table 1 summarises AF prevalence from elsewhere in the world. All of the 
studies report a much higher prevalence of AF in equivalent age groups. In 
the UK, Majeed et al (194) looked at 1.4 million people on a GP research 
database, and found a prevalence of AF in the 70-74 age group of 4.6% in 
men and 3.3% in women, rising to >10% in both men and women aged 85+. 
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In Europe, Heeringa et al (37) found even higher rates, reporting a 
prevalence of 6.9% in men and 5.4% in women aged 70-74, rising to almost 
1 in 5 in both men and women aged 85+. Whilst ethnicity was not stated in 
either study, it is likely that the populations did not contain many black people 
of African origin. Go et al (39) reported on 1.89 million adults in the USA, with 
3.6% (68,040) being African-American. This study reported similar rates in 
white patients to Majeed’s study (194), but lower rates in black patients 
(4.4% 70-79 age group, 7.7% 80+). However, these rates were still 11 times 
(70-79 age group) and 6 times (80+) higher than those found in my study. 
Upshaw et al (40) found similarly lower rates in black patients presenting to a 
US hospital. Lower rates are also found in studies from Japan (49, 50), 
Korea (54) and China (52), although the only instances where these low 
rates truly compare to my data is in the female 80+ group in the study by 
Iguchi et al from Japan (50) (2.5% versus our 1.89% for the same age band) 
and in the Jeong study from Korea (54) in the female 75-79 age group (0.5% 
versus 0.59% in my study). 
Most of the above studies are epidemiological studies from high-income 
countries where data is available on the prevalence of PAF and 
consequently added to prevalence estimates. This study has primarily 
estimated prevalence rates solely from the findings of a 'one-off' 12-lead 
ECG, and consequently is likely to have under-estimated the prevalence of 
AF in a rural elderly SSA population. Having said this, as will be seen in 
chapter 6, there also appears to be a low prevalence of PAF in this 
population. Even if we use a generous definition of PAF of only 1 episode of 
irregular NCT >30 seconds in duration, the prevalence would only be 0.64% 
+ 2.6% = 3.24% in total, and thus still significantly lower than other 
populations studied. 
 
4.3.1.2 Reasons for Low Prevalence Rate 
Contemporary data are building up regarding the influence of genetic 
polymorphisms on the susceptibility of certain populations to AF. In a recent 
review, it has been suggested by Xiao et al (195) that 2 chromosomal loci 
and 17 causal genes had been identified in familial AF, with an additional 7 
common variants and single-nucleotide polymorphisms in 11 different genes 
indicated in non-familial AF. These mutations occur in genes coding for 
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potassium channels, sodium channels, connexins, atrial natriuretic peptides, 
calcium handling proteins and nucleoporins. In the 1st genome-wide 
association study (GWAS) of AF (196) a strong association between AF and 
2 single-nucleotide polymorphisms (SNPs) on chromosome 4q25 was 
identified. Approximately 35% of those of European descent have at least 
one of the DNA sequence variations and the risk of AF increases by 1.72 
and 1.39 per copy. Both SNPs are adjacent to the PITX2 gene, essential for 
cardiac development (in knockout mice, PITX2c is responsible for extension 
of left atrial myocardium into the pulmonary veins (197) and thus may be a 
candidate gene (198). Interestingly, in preliminary results from the 
Vanderbilt-Meharry registry, only 17.1% of African-American controls carried 
the common 4q25 variant (72). This suggests significant racial differences in 
polymorphisms, and either protective genetic factors in African-Americans or 
predisposing factors in Caucasians. Whilst African-Americans are 
predominantly of West African descent and again are likely to be genetically 
very different from the East African population that I studied, I feel the same 
underlying principles with regard to genetic differences are applicable, and it 
is likely that there are protective factors, either genetic factors, or novel 
environmental factors, present in my Study Population. In further support of 
the argument for a genetic basis/novel environmental factors for protection 
against AF is my initial attempt at a comparison with the CHS African-
American cohort with regard to population risk. From examining identified 
risk factors, whilst they differ to some degree in both studies, the population 
risks appear to be approximately the same yet, as has been explained 
above, the prevalence of AF in my Study Population is significantly lower 
than African-American populations, thereby suggesting an unmeasured risk 
(in the CHS AA population) which may well be a genetic difference in 
susceptibility to AF. 
Another reason for a lower AF prevalence in my Study Population is it is 
likely that there is a much lower contribution of ischaemic heart disease 
(IHD) to AF causation in blacks in SSA than in Western countries, given it 
accounts for <1% of deaths (80) (versus 20% deaths in other high-income 
countries (81)). This idea is supported by the lower prevalence of AF seen in 
Japan in combination with previously known lower prevalence of IHD (199) 
when compared to Western countries. One potential contributor to putative 
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lower rates of IHD in the Study Population could be the low mean serum 
cholesterol levels seen in patients (Tables 19 and 20). 
In addition, it has been noted previously that increased BMI and obesity 
increases risk of AF (90), possibly because of an associated increase in 
atrial volume. The mean BMI of the Study Population was low, being 20.9 in 
men and 22.2 in women. These BMI levels compare similarly to an elderly 
Chinese population, which were noted to be much lower than a Western 
Caucasian population (200), and tallies with lower AF prevalence rates found 
by Zhou et al (52). 
Patients with significant rheumatic valvular disease (which I initially 
hypothesised would increase prevalence rates in this population) and AF 
may die earlier because of AF or valve sequelae and this may, in part, 
explain the low mean age of people with AF from other studies in SSA (60, 
63). This idea is supported by the high 1-year mortality rate (29.5%) of AF 
patients from a study based in Cameroon by Ntep-Gweth et al (63) and by 
the fact that only one of my AF patients was felt to have rheumatic heart 
valve disease on echocardiography.  
It is also possible that AF may manifest differently in black Africans 
compared with other populations. It has been suggested that African-
Americans may have more paroxysmal AF, rather than persistent AF seen in 
Caucasians (153), and thus partially explain their increased stroke burden 
(201) despite the lower prevalence of AF in epidemiological studies  (39). As 
black Africans share this increased stroke burden, the same suggestion may 
be made regarding paroxysmal AF in this population. 
Finally, there was a shortfall between census number and people screened 
and I cannot exclude the possibility that AF was over-represented in people 
who refused to be screened. However, access to healthcare in Tanzania is 
limited and it seems unlikely that people with chronic ill-health would ignore 
the opportunity to be assessed. 
 
4.3.1.3 Gender and Age Differences 
I found AF to be more prevalent in women than men, supporting the findings 
of previous hospital-based studies in SSA (59, 60) and studies from Iran (55) 
and Turkey (56), although numbers were small and so drawing firm 
conclusions is difficult. In the Heart of Soweto study in South Africa, Sliwa et 
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al (60) suggested the higher prevalence in women was due to higher levels 
of obesity, with the real risk factor for AF being obesity rather than female 
gender per se. In my study, female patients had a mean BMI (20.9) less than 
the study population in general, although mean BMI in women was 
significantly higher than in men overall. Previous studies in high-income 
countries show that men are 50% more likely than women to develop AF (38) 
yet it has been shown to be a more common hospital presentation in women 
than men in South Africa (59, 60). It has previously been shown that the 
prevalence of IHD in Iran is higher in women than men (202) and that the 
prevalence of ischaemic ECG findings in Turkish adults is higher in women 
than men (203). This may explain in part reasons for higher AF prevalence in 
women in these populations and the Study Population. Other potential 
reasons for the majority of our AF cases being women include the larger 
overall female numbers in the study, and that the background population of 
women had significantly higher systolic, diastolic, and pulse pressure than 
men. The reasons for the gender differences in BP are not entirely clear, 
given that there was no difference in anti-hypertensive use between sexes in 
the background population, but it has been noted in Western populations that 
prevalence rates of hypertension are higher in women than men over the age 
of 70 (204). 
In my study of those aged 70 years and over there was a trend towards 
higher prevalence of AF with age, as noted in studies from other countries 
(all studies in Table 1). Again, I recognise that the small number of cases 
limits the generalisability of my findings.   
 
4.3.2 Clinical Correlates 
HTN has previously been shown to be the single biggest risk factor for AF, 
responsible for 14% of all cases (38). Systolic pressure (74) and pulse 
pressure (205) have been suggested as the driving factors behind AF 
development rather than diastolic pressure. However, these studies 
contained very few, if any, black patients and it has been noted that 
increased rates of HTN do not always translate into an increased incidence 
of AF in an African-American population (75). In my Study Population 60.0% 
of AF cases had a BP greater than or equal to 140/90, and 46.7% had a BP 
greater than 160/100. Surprisingly, mean systolic BP and pulse pressure 
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were higher in the control group than in those with AF. However, AF cases 
had significantly higher diastolic BP than controls. This could simply be a 
consequence of higher mean heart rates in AF patients. Alternatively, it could 
be that diastolic hypertension is more important than systolic BP in this 
population in relation to AF. A third and more likely explanation is the one 
alluded to in the methods, that of difficulties in accurate BP measurements in 
patients with irregular arrhythmias and as previously stated, whilst I tried to 
be as accurate as possible with measurements, the BP recordings in AF 
patients are likely to be less accurate than those of the control group in sinus 
rhythm. 
LV systolic dysfunction, increased left atrial size and mitral regurgitation were 
significantly more common in AF patients than in controls, in-line with other 
studies (38) (74) (75). 
 
4.3.3 Functional Status and Stroke Risk 
AF cases had lower Barthel Index scores reflecting reduced functional status 
and higher levels of disability. This may be due to the fact that AF patients 
not only had significantly more cardiac-related symptoms, but in addition one 
patient had a dense hemiparesis following stroke and was severely disabled 
(Barthel Index score 4). However, even after exclusion of this patient, mean 
BI scores remained lower in AF patients than controls (17.9 vs. 19.4). 
Overall, CHA2DS2-VASc scores were higher in women than in men. Even 
after adjustment for the extra point gained for being female, the 
thromboembolic risk remains higher, in keeping with the Heart of Soweto 
study findings (60). I feel this reflects not only increased average age and BP 
of female patients but also supports the idea that women with AF are at 
increased risk of thromboembolic disease (206). 
 
4.4 Conclusions 
I have shown that the prevalence of AF in elderly black Africans is strikingly 
low in comparison with elderly populations from other regions (even 
accepting a slightly higher rate with the addition of the prevalence of PAF), 
and in particular is up to 11 times lower than in a comparable elderly black 
American population (39), itself thought to have a lower prevalence than a 
matched Caucasian population.  
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Only one of 15 AF cases was previously aware of their diagnosis, and 
patients with AF need to be identified earlier in order to reduce the risk of 
serious medical complications arising from AF, such as stroke.  
In a country where rheumatic fever (and thus rheumatic valve disease) 
remains common and HTN is reaching epidemic proportions, we would 
expect AF prevalence to be high. The low prevalence of AF in elderly 
Tanzanians is likely to be multifactorial, with both genetic and environmental 
differences. 
Whilst currently the reasons for these differences are incompletely 
understood, the data suggests significant differences, both in a genetic 
sense (with the potential for protective polymorphisms) and an environmental 
sense, combining to lead to these differences in disease occurrence. Further 
work is needed to elucidate novel protective factors, and genetic sequencing 
in this population.
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Chapter 5. Electrocardiographic P wave Indices 
 
5.1 Methods 
5.1.1 Electrocardiograph Analysis and Quality Control 
This was conducted at the medical physics department of Freeman Road 
Hospital, Newcastle upon Tyne and is detailed below.  
 
5.1.1.1 P wave indices 
All study participants underwent 12-lead (ECG), performed according to the 
Society for Cardiological Science and Technology Guidelines (207). The 
standard 10-second, 12-lead ECG was acquired and processed using GE 
Medical Systems® CardioSoftTM and 12-SLTM analysis programs. The ECG 
data were sampled at 500 samples/s with an amplitude resolution of 5µV. 
The raw ECG data were stored together with the ECG measurements 
provided by the software, for further offline processing. The detection and 
analysis systems used on the GE MAC 1200 machines have been well 
validated, and median beats across the 12-leads are used to minimise 
artefact and noise, and maximise accuracy in measurement (208-210), a key 
feature in the machines use when in a challenging environment in a rural 
community in SSA. 
Digital records were visually assessed for technical errors and inadequate 
quality and, following exclusion of these records (n=198) along with those 
without P wave annotations (n=27) from the 12-SL program (including 
patients with AF), the number of ECG records suitable for further analysis 
totalled 2007. 
The P wave annotations (P onset, P offset and QRS onset) of signal-
averaged beats produced by 12-SLTM were adopted for further offline P wave 
parameter computation.  
P onset (PON) was automatically annotated as the earliest across the twelve 
leads, P offset (POFF) as the latest. The QRS onset (QRSON) was also 
automatically annotated as the earliest across the twelve leads.   
Based on the fiducial point markers (PON, POFF) for each lead, P wave 
amplitude (PAMP) and area (PAREA) were computed.  PAMP was calculated as 
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the peak-to-nadir amplitude difference on individual leads. Mean PAMP across 
12 leads (PAMP (avg)) and PAMP in lead II (PAMP (II)) were considered for 
statistical analysis. Defining a baseline reference as the horizontal line 
intercepting the ECG at PON, PAREA was computed on individual leads as the 
area underneath the curve with respect to the baseline, as shown in Figure 5 
(grey area). Mean PAREA across 12 leads (PAREA (avg)) and PAREA in lead II 
(PAREA (II)) were considered for statistical analysis. If the P wave was 
biphasic (Figure 5.d) the positive and negative contributions to the area were 
summed. In lead V1, the P wave terminal negative force (PTNF) was also 
computed as the product between the (right-most) negative lobe amplitude 
(Figure 5.d, dotted vertical line) in units of µV and its time interval (Figure 5.d, 
dotted horizontal line) in units of seconds between the (right-most) negative 
zero-crossing of the baseline and POFF. 
P wave duration (PD) was computed as the time interval between PON and 
POFF. P wave dispersion was not calculated due to the global definition of 
PON and POFF by the 12-SL
TM program. The PR interval was calculated as the 
time interval between PON and the annotated QRSON. RR interval was also 
calculated and thus a normalised PR interval was calculated as PR / RR * 
100 and reported as a percentage of RR (PR%). 
 
Figure 5: P wave area computation for different P wave morphologies: positive (a), negative 
(b), positive notched (c), biphasic (d). P wave area is total shaded area. Arrows in (d) show 
duration and amplitude for PTNF computation. Solid vertical lines show PON and POFF. 
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5.1.2 P wave Indices Analysis 
Statistical advice was obtained from Dr. Luigi DiMarco and Dr. Philip Langley 
in the Medical Physics department of Freeman Road Hospital. PWI were 
computed for each record and statistical analysis was carried out according 
to the age and gender groupings, with median and interquartile ranges 
reported. Further, Lilliefors test was performed on all age-gender groups to 
test the null hypothesis of normal data distribution. The test rejected the null 
hypothesis in a substantial number of cases therefore a non-parametric test 
was adopted to perform the one-way analysis of variance (ANOVA). The 
Kruskal-Wallis (KW) rank-sum test (an extension of the Wilcoxon rank-sum 
test for more than two groups) was employed, setting a confidence level of 
95% (α=0.05), and post hoc analysis for multiple comparisons was then 
carried out according to Tukey’s honestly significant difference (HSD) 
criterion. 
 
5.2 Results 
5.2.1 Description of P wave Indices 
Table 21 summarises the record count and the age-gender grouping. 
 
Table 21 – Age-gender grouping of records 
Gender \ 
Age 
70-74 
years 
75-79 
years 
80-84 
years 
85+ 
years 
Unknown Total 
Male 346 261 116 160 4 887 
Female 437 310 184 171 18 1120 
Total      2007 
 
Effects of Age 
PWI statistics with respect to age-bands are reported in Table 22, with p 
values representing a difference between two age groups for each PWI. 
Figure 7 displays the box-plot of the indices (first quartile, median, third 
quartile and whiskers representing the farthest sample from the box within a 
distance equal to the inter-quartile range) by age-band, showing multiple 
group comparisons for each PWI. PAMP (lead II and average) was 
significantly lower in the 85+ age group than in the other 70-74, 75-79, and 
80-84 age groups. PAREA (lead II and average) was significantly higher in the 
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70-74 age group compared to the other 3 age groupings. Both PAMP and 
PAREA suggested a decrease in value with age. Normalised PR interval was 
significantly higher in the 85+ than the 70-74 and 75-79 age groups 
suggesting an increase with age, and RR interval significantly lower in the 
85+ than 70-74 and 75-79 age groups. There were no significant differences 
in PD or PTNF across age groups. 
 
Table 22 – PWI for each age-band. Median (inter-quartile range) reported 
 Age Group 
Parameter 70-74 Years  
(n=783) 
75-79 Years  
(n=571) 
80-84 Years  
(n=300) 
85+ Years  
(n=331) 
p value (*) 
PD [ms] 112 
(104-120) 
112 
(104-120) 
111 
(102-120) 
110 
(102-122) 
N.S. 
 
PAMP(avg) [µV] 115 
(97-140) 
113 
(92-137) 
111 
(93-135) 
103 
(87-124) 
p<0.001 
PAMP(II) [µV] 195 
(155-250) 
185 
(145-240) 
180 
(143-235) 
165 
(125-210) 
p<0.001 
PAREA(avg) 
[mV*ms] 
4.92 
(3.86-6.04) 
4.60 
(3.72-5.83) 
4.60 
(3.72-5.43) 
4.26 
(3.36-5.33) 
p<0.001 
PAREA(II) 
[mV*ms] 
8.97 
(6.71-11.36) 
8.38 
(6.59-10.49) 
8.18 
(6.21-10.06) 
7.39 
(5.56-9.49) 
p<0.001 
PTNF(V1) 
[µV*s] 
1.25 
(0.53-2.16) 
1.28 
(0.34-2.55) 
1.25 
(0.47-2.14) 
1.62 
(0.93-2.89) 
N.S. 
RR [s] 0.76 
(0.69-0.87) 
0.76 
(0.67-0.86) 
0.75 
(0.66-0.84) 
0.74 
(0.63-0.84) 
p<0.01 
PR [ms] 150 
(138-166) 
152 
(138-168) 
154 
(142-168) 
158 
(142-173) 
p<0.01 
Normalised    
PR [%] 
19 
(17-22) 
20 
(17-23) 
21 
(18-24) 
21 
(18-25) 
p<0.001 
(*) p-value from KW test, referring to null hypothesis of all samples drawn 
from same population 
Abbreviations: PD = P duration, PAMP = P amplitude (avg=average, II=lead II), 
PAREA = P area, PTNF = P terminal negative force in lead V1. N.S. = not 
significant.  
 
Effects of Gender 
Table 23 details background characteristics of mean age, BP and BMI in 
addition to gender-specific PWI. Women had a significantly higher systolic 
and diastolic BP and BMI than men (p<0.001). There was no significant 
difference in age between genders. Men had significantly greater PD, PAREA 
(average and lead II), RR and PR interval (p<0.001) (yet the difference in 
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normalised PR interval between genders was not significant). Women had a 
significantly greater PTNF than men (p=0.030). 
 
Table 23 – P wave indices and background clinical characteristics (Median 
(Inter-quartile Range)) for male vs. female patients. Statistical significance (p 
value) of group difference (KW test, α = 0.05) reported. 
Parameter Male (n = 887) Female (n = 1120) p value 
Mean Age (years) 
Blood Pressure 
77.9 
N=884 
77.5 
N=1116 
 
Systolic [mmHg] 151(132 - 175) 162(141 - 190) M<F (p<0.001) 
Diastolic [mmHg] 82(73 - 93) 88(79 - 99) M<F (p<0.001) 
Body Mass Index N=824 N=1020  
BMI [Kg/m2] 20.0(18.0-23.0) 21.0(19.0-24.0) M<F (p<0.001) 
P Wave Indices N=887 N=1120  
PD [ms] 112(104 - 122) 110(102 - 118) M>F(p<0.001) 
PAMP(avg) [µV] 113(95 - 136) 111(93 - 136) N.S. 
PAMP (II) [µV] 185(145 - 235) 185(145 - 240) N.S. 
PAREA (avg) [mV*ms] 4.89(3.97 – 6.00) 4.52(3.59 – 5.51) M>F(p<0.001) 
PAREA (II) [mV*ms] 8.65(6.70 – 11.13) 8.21(6.08 – 10.25) M>F(p<0.001) 
PTNF (V1) [µV*s] 1.19(0.35 - 2.13) 1.49(0.79 - 2.42) M<F(p=0.030) 
RR [s] 0.80(0.71 – 0.90) 0.73(0.64 – 0.82) M>F(p<0.001) 
PR [ms] 156(144 - 172) 150(136 - 164) M>F(p<0.001) 
Normalised  PR [%] 20(17 - 22) 20(18 - 24) N.S. 
Abbreviations: BP = blood pressure, BMI = body mass index, PD = P 
duration, PAMP = P amplitude (avg=average, II=lead II), PAREA = P area , PTNF 
= P terminal negative force in lead V1. N.S. = not significant. M>F = median 
value in Male population significantly higher than in Female population.  
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Figure 6 – Multiple comparison (Tukey HSD criterion) post hoc analysis of P wave indices, normalised-PR interval, and RR interval with respect to age band, combined for male and female 
subjects. Box-plot represents median (notched), 1
st
 and 3
rd
 quartile. Whiskers represent the farthest sample from the box within the inter-quartile range.  Horizontal lines connect groups with 
significant difference (p<0.05). Triangle pointing up (∆) at the end of the line indicates group whose median is significantly higher, and down if group median significantly lower.
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5.3 Discussion 
5.3.1 ECG P wave Indices Descriptors / Predictors of AF 
5.3.1.1 Effect of Age 
PAREA and PAMP in both men and women exhibit a significant decrease in 
value with age. It has been previously suggested that autonomic tone may 
be related to P wave area and that during periods of sleep when autonomic 
tone is reduced, this is reflected by decreased P wave area (151). Autonomic 
tone is known to reduce with age (211) and this would be a potential 
explanation for a decrease in P wave area seen with age in our population. 
Age-related loss of atrial myocytes and thus decreased volume of 
electrically-active atrial tissue, reflected in smaller velocity P waves may 
further explain the decline in values with age.  
With the knowledge that advancing age (37, 39)) and increased P wave area 
(153) increases the risk of AF, it seems paradoxical that P wave area 
decreases with age in the Study Population. However, it should be 
remembered not only that P wave area predicted AF in a population of 45-64 
year olds in a high-income country (153) and therefore may not be applicable 
to our population, but also that age and PR interval (which increases with 
age and is also known to increase risk of AF (156)) are likely to be more 
potent risk factors in the Study Population.  
Normalised PR interval increases in both men and women with age in my 
study and this is likely to be because of gradual fibrosis of intra- and inter-
atrial conduction fibres. It has previously been noted that the prevalence of 
1st degree heart block increases with age (212). The prevalence of 1st degree 
heart block (PR >200ms) in the Study Population was 3.6% (73/2007), 
similar to another community-based study in the elderly (75-85 years) in the 
US (213) reporting a prevalence of 2.1%, but lower than a hospital-based 
elderly (70+ years) population (11.7%) (212). 
In the Study Population, P duration did not change significantly with age.  
Previous work has suggested an increase in PD with age when looking at a 
broader age range in smaller numbers of people (214), although examining 
this data more closely reveals that in similar age groups (i.e. 66-75 and 76-
85 year olds) there was no significant change in PD, as in my study. 
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5.3.1.2 Effect of Gender 
My study also demonstrates significant differences in PWI with respect to 
gender. Men had higher values than women for P duration and P area. Men 
are known to have larger atrial diameters than women (215). Furthermore, 
median BMI was lower in men (20.0 (18-23) kg/m2) than women (21.0 (19-
24) kg/m2) in my study overall, potentially reflecting lower impedance of body 
mass between electrodes and cardiac signals, and these are potential 
reasons for larger PWI in men.  
The finding of generally larger PWI in men provokes discussion around the 
effect of hypertension on PWI, given the fact that women had a higher mean 
BP than men. Hypertension has been shown to increase PD (216), yet 
women had a smaller PD than men. However, PTNF was greater in women 
than men, and is likely to be a more sensitive predictor of systemic 
hypertension, having been well-validated for inclusion in criteria for 
assessing left ventricular hypertrophy (217).  
Median PR interval was longer in men than women, consistent with a 
previous large multi-centre study (218), although, unlike in my study, that 
study did not normalise PR for heart rate. In doing so, I found that, because 
women had higher heart rates than men overall, when PR was normalised 
for RR interval, there was no gender difference. 
 
5.3.1.3 Comparison with Other Populations 
I have not directly compared my numerical data to other studies, either 
because of a lack of age-specific data, or a difference in measurement 
methodology, particularly with regards calculating P wave area (153). The 
latter point has been noted as a particular problem in comparing studies 
(219), and I have focused on presenting new data from elderly Tanzanians 
and, in comparing to other studies, looked simply at trends with respect to 
age and gender. What is clear is that my Study Population is different 
genetically and environmentally from other populations studied and further 
work is needed to look at ‘normal values’ in my Study Population. It is known 
that factors such as chronically elevated atrial pressure, ischaemia and 
metabolic stress lead to atrial remodelling and thus changes in atrial 
conduction and P wave morphology on the surface ECG (219). It is also 
known that ischaemic heart disease is less common in black Africans in SSA 
111 
 
than in high-income countries (80). Furthermore, hypertension prevalence 
rates are approaching that of high-income countries and yet detection, 
treatment and levels of control are much lower (220). These points suggest 
the prevalence of factors influencing PWI in an elderly SSA population are 
likely to be very different from those of other populations already studied and 
thus that reference ranges for PWI derived from other populations are not 
valid for my Study Population. 
 
5.3.1.4 Strengths and Limitations 
My study has several strengths. It contains a large sample size that has been 
randomly selected within a rural African community-based population. All 
study variables were ascertained uniformly, and of particular note, the ECGs 
were analysed with computer assistance, thus minimising intra- and inter-
observer variability. My analysis did not exclude outliers and thus gives a 
more balanced overall picture of PWI. 
There are also several limitations noted. Specifically with regard to my study, 
as I only surveyed approximately 25% of the 70+ population, there is a 
possibility of sample bias, despite the randomly-selected nature of the Study 
Population. 
The measurement method meant my data produced PWI calculated from a 
median P wave, rather than each individual P wave on the 12-lead ECG. The 
reason for doing this is that PON and POFF were more reliably identified as the 
production of a median beat eliminates a significant amount of baseline 
‘noise’. This comes at the expense of data from each individual lead and the 
ability to calculate PWI such as maximum and minimum PD and P wave 
dispersion. 
The median differences with age and gender were all fairly small in a clinical 
sense. Whilst many were statistically significant, it should be remembered 
that the differences are unlikely to be clinically significant. However, my 
primary aim for this study was not to look at clinical impact of the changes, 
but simply initially to report them. I foresee that these results will be the 
precursor to the production of reference ranges for an elderly SSA population 
and in the future be used to predict disease states such as AF. 
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5.4 Conclusions 
To my knowledge, this will be the first published report of PWI in a large 
community-based elderly population in SSA. There are significant differences 
in PWI with gender and age in my study. This population is geographically 
and genetically different from other populations studied and thus it will be 
interesting to note whether PWI predict diseases such as AF and stroke in 
this population. However, in a low-income country such as Tanzania, where 
healthcare resources are limited, yet the number of elderly with chronic 
disease continues to grow exponentially, measurement of PWI may form an 
important, accessible and ultimately affordable part of risk assessment for 
these diseases in the future. 
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Chapter 6. Ambulatory Monitors 
 
6.1 Methods 
6.1.1 Longer-term Cardiac Monitoring 
For the purposes of ambulatory ECG monitoring, the study used 2 Holter 
(full-disclosure, 24 hour) monitors, and 10 event (selective disclosure with 
limited memory, up to 7 day) recorders. The first Holter monitor was a 
Mortara H-ScribeTM (Mortara Instruments, Milwaukee, US) 12-lead Holter 
monitor, and the second a Darwin Medilog AR12 HRVTM (Schiller, Australia) 
3-lead Holter monitor. The longer-term event recorders were Novacor R-test 
EvolutionTM (Novacor, France) monitors. The recorders were chosen as they 
have been shown to be superior to 24-hour monitors in identifying episodes 
of PAF (221) over longer periods, are automated and therefore particularly 
useful in identifying asymptomatic episodes of PAF (222) and have been 
shown to have good accuracy at detecting episodes of PAF (223), with a 
sensitivity of 96.1% and specificity 92.6%. The monitors have a total 
recording time of 20 minutes and were programmed to store irregular R-R 
intervals that could correspond to paroxysms of AF. The parameters for 
event-triggered recordings were: 50 s for absolute pauses (RR interval 
>2.5s); 175s for relative pauses (RR interval >150% previous RR interval); 
500s for premature beats (RR interval <[mean RR-12.5% x mean RR]); 60s 
for bradycardia (R frequency <50 minutes-1); 250s for runs (RR interval <RR-
12.5% x RR] for > 3 beats); and 30s for ST shift (<1mm or >3mm). 120s 
were devoted to patient-triggered recording but as the majority of patients 
were asymptomatic this was under-utilised.  These settings have been 
previously validated for the detection of PAF (224). The enumerators were 
given an introduction to these ambulatory monitors and were shown how to 
do basic troubleshooting such as changing electrode stickers that may 
become detached during monitoring. Whilst the event recorders have been 
previously shown to increase AF detection rates, they do not have full 
disclosure as with the 24-hour tapes. The memory of the event recorders 
extends to 20 minutes for the purposes of recording arrhythmias. If the 
memory becomes full, then the most recent arrhythmias (i.e. later in the 
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recording) will be stored. However, whilst the recorder may not formally 
‘record’ an arrhythmia, it can give an idea of arrhythmia burden as it will 
record the number of arrhythmia events ‘seen’ in each category. Because the 
recording strips are of 30 seconds length, if the arrhythmia is longer than 
that, it will not necessarily trigger a further ‘seen event’, so may 
underestimate arrhythmia burden. Of course the arrhythmia may well last 
less than 30 seconds but there is no way of analysing this from the 
recordings. Because I cannot say exactly how long each person had 
arrhythmia for, I feel the most useful way of presenting the results is to say 
how many 30 second periods per 24 hours of recording had arrhythmia 
present, and in this context I will focus mainly on irregular narrow complex 
tachycardia (NCT) i.e. PAF and PAFl. Whilst I will be unable to document an 
accurate delineation of how much PAF each person has, this will not be the 
primary aim of this section. This will be to further examine whether P wave 
indices influence / predict occurrence of PAF in these patients. From a 
clinical importance perspective, as I am adopting a conservative time of 5 
minutes in any 24 hour period being clinically important (as delineated from 
the literature, see introduction), this will equate to anyone who has more than 
10 thirty-second periods with irregular NCT per 24 hours. 
 
6.1.2 Choice of Participants 
The study aimed to perform ambulatory monitoring in a sub-group of the 
Study Population. With regard to 24-hour monitoring, participants were 
chosen primarily on a pragmatic basis using convenience sampling. It was 
not possible to choose these patients entirely at random given the logistics of 
being in different villages on a daily basis, and participants’ reluctance not 
only in wearing the monitors but also coming back to the health centre to 
have the monitor detached when they often lived long distances from the 
health centre and were busy with work. With regard to the R-test monitors, I 
produced a scoring system for P wave predictors, meaning each ECG could 
be classified as having a low, intermediate or high number of P wave 
predictors for subsequent AF development. The scoring system was based 
primarily on the paper by Soliman et al (153) in Stroke, with scores for each 
P wave predictor weighted according to their hazard ratio in that paper. In 
addition to these measurements, I also included PDISP (225) and PR 
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interval (156) in the scoring system. The table below shows which P wave 
measurements were used and their weighted scoring. 
 
Table 24: Scoring System for P wave Indices 
P wave Predictor Weighted 
Scoring 
P wave duration lead II 4 
P wave terminal force V1 2 
Maximum P wave duration  4 
P wave dispersion (maximum – minimum 
P wave duration) 
3 
Maximum P wave area 2.5 
PR duration 1.5 
Max Total 17 
 
This scoring system enabled me to divide the ECGs into low, intermediate 
and high numbers of P wave predictors. The divisions were arbitrary, with <6 
points scoring low, 6-12 points intermediate and >12 points high. The idea 
behind this scoring system is that P wave predictors are on a continuum, 
rather than being absolute values and if I split the ECGs up solely into those 
with and those without P wave predictors, I would have been likely to miss 
out on a lot of detail within the group with P wave predictors. The other idea 
behind the system was to enable me to try and perform equivalent numbers 
of event recordings on those in all 3 groups. I did not however have the 
luxury of taking ECGs back from the field and analysing them on the 
computer prior to putting the event recorders on because of the 
aforementioned problems of getting participants back to the health centre on 
more than one occasion. Therefore, the initial screen of the ECG was an 
examination by me in the field for known P wave predictors. 
 
6.1.3 Case definition of PAF 
Short runs of regular and irregular narrow-complex tachycardia are common 
in the elderly, and hence the suggested cut-off for describing AF of a 
minimum of 30 seconds continuous irregular narrow-complex tachycardia.  
Paroxysmal AF is self-terminating, usually within 48 hours. Although AF 
paroxysms may continue for up to 7 days, the 48-hour time point is clinically 
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important—after this the likelihood of spontaneous conversion is low and 
thromboembolic risk rises substantially. In the results and discussion I use 
the terms ‘irregular NCT’ and ‘AF’ interchangeably, acknowledging the fact 
that according to the strict definition, the irregular NCT has to be >30 
seconds in length to be classified as AF, yet the episodes that I will be 
discussing are often <30 seconds in length. This is due to the generally 
smaller burden of AF seen on ambulatory monitoring. 
 
6.1.4 How Much PAF is Clinically Important? 
Data from the Italian AT500 registry looking at PAF detected by anti-
tachycardia pacemakers and the subsequent risk of thromboembolism in 725 
patients (226) suggest that episodes of AF lasting >24 hours increase risk of 
arterial embolism by 3.1 times in elderly patients. Episodes >5 minutes and 
<24 hours made no difference to risk. This concurs with data from the AIDA 
study (227). Data from the more recent TRENDS study (228) looking at 2486 
patients with dual-chamber pacemakers and at least 1 risk factor for stroke, 
found that a burden of atrial tachycardia or AF ≥5.5 hours per 24-hour period 
doubled risk of thromboembolism. The 5.5 hours was cumulative and did not 
have to occur in 1 single episode.  
However, 2 further trials have demonstrated much lower levels of detected 
atrial tachycardia are needed to increase stroke risk. In the Mode Selection 
Trial (MOST) (229), atrial high rate episodes (AHREs) detected by 
pacemaker in 312 patients with sinus node dysfunction were looked at in 
correspondence with the subsequent risk of stroke and death. Of the 312 
patients, 160 (51.3%) had at least 1 AHRE >5mins over a median 27 months 
of follow-up. The presence of 1 AHRE >5mins increased risk of mortality by 
2.48 times and stroke 2.79 times. In the Asymptomatic AF and Stroke 
Evaluation in Pacemaker Patients and the AF Reduction Atrial Pacing Trial 
(ASSERT) (230), 2580 patients were followed-up for a mean of 2.8 years. 
AHREs were common, occurring in 36% overall. AHREs >6 minutes were 
associated with a 2.5-fold increase in the risk for stroke and systemic 
embolism. It should be noted that whilst numbers in the MOST trial were 
fairly small, the number in ASSERT and length of follow-up was much better. 
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The reason for use of 5 and 6 minutes cut-off is that these are the accepted 
cut-off values for the respective pacemakers in accurately detecting AHREs. 
Suggestions arising from these study results include whether even shorter 
episodes may predispose to arterial embolic events and that AHREs appear 
to be an appealing surrogate for PAF to facilitate such studies (231).  
 
6.1.5 Treatment Decisions for PAF 
Based on the above data, I decided that a pragmatic cut-off for treatment 
with aspirin for PAF would be >5minutes in every 24-hour period, and the 
treatment dose was 75mg od.  
 
6.1.6 Analysis 
As previously mentioned, the 24-hour monitors were full-disclosure, whilst 
the event recorders had a finite memory for automatic arrhythmia detection. 
Manual analysis of the recordings was combined with automatic reports 
generated by the recorders themselves, and the results are presented below, 
with mean values and 95% confidence intervals reported for the more 
important results. 
 
6.2 Results 
3 different ambulatory monitors were used to collect data on longer term 
cardiac rate and rhythm monitoring in a sub-set of patients chosen during the 
main study, as detailed in the methods. They were mainly used to identify the 
burden and prevalence of paroxysmal AF in the background population and 
this results section will concentrate mainly on that, but will also report other 
interesting findings.  
 
6.2.1 24-Hour Tapes 
47 patients, chosen on a pragmatic basis, underwent Holter recording with 
the Mortara H-ScribeTM (H-Scribe) and 49 with the Medilog Darwin AR12 
HRVTM (Medilog). With regard to the H-Scribe, 35 patients were women and 
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12 were men, with a mean age of 77.7 years. With regard to the Medilog, 34 
patients were men and 15 were women, with a mean age of 79.6 years. This 
totalled 50 women and 47 men undergoing full disclosure Holter monitoring. 
The table below details mean recordings for duration, heart rate, supra-
ventricular ectopics (SVEs) and ventricular ectopics (VEs) and pauses. 
 
Table 25 Overall Averaged Results of Holter monitoring 
Recorder Number 
of 
Records 
Duration Heart Rate (bpm) SVEs VEs 
  minutes Min Mean Max Runs 
<3 
Runs 
≥3 
Max Run Runs 
<3 
Runs 
≥3 
Max 
Run 
H-Scribe 47 1282.7 52.5 78.3 128.7 869.1 20.7 108.4 678.4 0.17 2.42 
Medilog 49 1701.2 51.2 77.7 137.7 513.1 5.9 8.2 203.1 0.14 1.75 
 
Of the patients undergoing monitoring with H-Scribe, 5 patients had evidence 
of irregular runs of narrow-complex tachycardia (NCT) that looked like AF. 
However, the burden of this arrhythmia was low, as detailed in the table 
below. 
 
Table 26 Burden of irregular NCT in individual patients undergoing H-Scribe 
monitoring 
Patient Recording 
Duration 
Heart Rate (bpm) SVEs Pauses 
(gender 
+ age) 
minutes Min Mean Max <3 beats ≥3 
beats 
Max 
run 
(beats) 
seconds 
1 (F 71) 1390 40 65 136 40 3 11 1.7 
2 (F 73) 1293 46 70 127 66 3 5 1.47 
3 (M 84) 1318 58 78 132 3418 6 23 1.34 
4 (M 76) 1440 42 69 135 87 3 4 1.84 
5 (F 86) 1440 48 70 131 1163 48 33 1.64 
  
Patient 5 appeared to have the heaviest burden of irregular NCT, but whilst 
her longest run of NCT was 33 beats (15 seconds), the remaining 47 runs ≥3 
beats were all <5 secs, meaning she had <5 minutes in total of irregular NCT 
over a 24-hour period. 
Of those undergoing Medilog monitoring, there were also 5 patients who 
suffered irregular NCT, details of which are in the table below. 
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Table 27 Burden of irregular NCT in individual patients undergoing Medilog 
monitoring 
Patient Recording 
Duration 
Heart Rate (bpm) SVEs Pauses 
(gender 
+ age) 
minutes Min Mean Max <3 
beats 
≥3 
beats 
Max run 
(beats) 
seconds 
1 (F 72) 1390 46 72 143 148 6 40 0 
2 (M86) 1279 57 83 137 110 1 15 0 
3 (F 76) 2487 46 90 170 2553 147 101 1.45 
4 (F 72) 1605 66 98 164 327 41 13 0 
5 (F 83) 2206 51 73 127 167 7 11 0 
 
As can be noted, again the burden of irregular NCT was light, apart from for 
patient 3, who had a significant burden of paroxysmal AF. Whilst it should be 
noted that her recording was longer than others (totalling over 41 hours) the 
147 runs of AF were mostly up near the max run of 101 beats (approx 40 
secs at a rate of 150 bpm), thus giving her a burden much higher than our 
proposed cut-off of 5 minutes in 24 hours. 
In addition to the irregular NCTs, there were 4 cases with regular runs of 
NCT in the H-Scribe group (none in the Medilog group), although none of 
which resembled atrial flutter.  The burden is detailed in the table below. 
 
Table 28 Burden of regular NCT in individual patients undergoing H-Scribe 
monitoring 
Patient Recording 
Duration 
Heart Rate (bpm) SVEs Pauses 
(gender + 
age) 
minutes Min Mean Max <3 beats ≥3 beats Max run 
(beats) 
seconds 
1 (F 86) 1349 45 82 163 7420 526 13 2.34 
2 (F 80) 1440 49 105 159 79 75 157 1.6 
3 (F 101) 1440 50 82 163 15277 195 51 1.39 
4 (F 70) 1440 68 106 203 49 41 4628 1.22 
 
Whilst trying to classify further the regular NCT, it appeared patient 1 had 
multi-focal atrial tachycardia, patients 2 and 4 appeared to have AV nodal re-
entrant tachycardia and it was difficult to further classify patient 3 due to 
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quality of recording. Clearly, patient 4 appears to have the heaviest burden of 
SVT, and she was the only one of the 4 to be symptomatic from her 
arrhythmia.  
 
6.2.2 Event Recorders 
137 event recordings were performed on 75 men and 62 women with an 
average age of 77.0 years. The following table shows mean values for 
recording time, total number of SVEs and VEs (isolated, short runs 2-5 beats 
and longer runs >5 beats) recorded AND seen (see methods) and longest 
pause. 
Table 29 Overall mean values for event recordings 
Number of 
recordings 
Length of 
recording 
(hours) 
SVEs 
isolated 
SVE 
short 
runs 
SVE 
long 
runs 
VEs 
isolated 
VE 
short 
runs 
VE 
long 
runs 
Pauses 
(seconds) 
137 90.03 1410 296 34 1073 167 6 1.20  
 
Of the 137 recordings performed, 29 (21.2%) showed evidence of irregular 
NCT (including Atrial Flutter) of which 17 were men and 12 were women. 
The table below shows further details of this group. 
 
Table 30 Characteristics of group with irregular NCT on event recording, 
mean values 
Reco
rding 
numb
er 
Recordi
ng 
Length 
(hours) 
SBP DBP BMI BI SVEs 
isolat
ed 
SVEs 
short 
run 
SVEs 
long 
run 
No. 30 
sec 
periods 
containi
ng AF 
(total) 
No. 30 
sec 
periods 
containi
ng AF / 
24 hours  
Longe
st 
Pause 
(secs) 
29 104.25 166.4 89.1 21.5 19.6 3050 969 131 130.7 23.25 1.55 
 
It should be noted that only 5 (3.6%) recordings had a potential burden of 
PAF >5 minutes / 24 hours i.e. 10 thirty-second periods that contained 
irregular NCT. These 5 recordings are responsible in the main for the 
relatively high mean value of 23.25 for number of 30 second periods 
containing AF / 24 hours. Without these 5 recordings, the mean values for 
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total number of 30 second periods containing AF and number per 24 hours 
would reduce dramatically to 5.96 and 0.82 respectively. 
Further details of these 5 patients are contained in the table below. 
 
Table 31 Patients with >10 thirty-second periods containing AF in 24 hours 
Patient 
(Gender 
/ Age) 
Recording 
Length 
(hours) 
SBP DBP BMI BI SVEs 
isolate
d 
SVEs 
short 
SVEs 
long 
No. 30 
sec 
period
s 
contai
ning 
AF 
(total) 
No. 30 
sec 
periods 
containi
ng AF / 
24 
hours 
Max 
Pause 
(secs) 
1 (M77) 141.52 147 74 17.6 20 3851 363 115 115 19.4 2.0 
2 (F80) 138.24 221 125 26.6 19 655 380 104 104 18.06 1.76 
3 (M73) 134.56 120 72 20.2 20 25877 1447
6 
1481 1481 264 2.08 
4 (F85) 142.4 156 104 23.3 20 7282 6896 1307 1307 220.4 5.2 
5 (M77) 136 130 66 18.8 20 15986 3023 640 640 112.86 1.44 
  
As previously mentioned, I attempted to put event recorders on patients with 
an even spread of degree of P wave ‘predictors’ of AF. This was initially done 
fairly crudely in the field as specified in the methods section, with subsequent 
manual measurement on a computerised screen with a cursor through the 
Cardiosoft V4.2TM program. Of the 137 recordings, 100 were manually 
measured, with 29 considered to have a high score on the P wave predictors 
scoring system (methods), 39 a medium score and 32 a low score, which 
provides an even spread given the limitations of the initial method of visual 
measurement. Reasons for non-measurement via CardiosoftTM were either 
that the ECG was not stored digitally, the quality was not deemed sufficient 
for accurate measurement, or the digital ECG file was corrupt at the time of 
attempted measurement. 
 
6.2.3 Overall Prevalence of PAF 
The prevalence of PAF, using a definition of ≥1 episode of irregular NCT >30 
seconds in length, in this study would be 5/137 (3.6% (95% CIs 0.5 to 6.7)) 
for the event recorders and 1/96 (1% (95% CIs -2.1 to +3.1)) for the Holters. 
If we combine these numbers then the overall prevalence of PAF in this 
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study totals 6/233 which is 2.6% (0.6 to 4.6). The percentage of people with 
no PAF therefore is 227/233 which is 97% (94.8 to 99.2) of the cohort. 
 
6.2.4 Relationship of P wave Indices to Ambulatory Monitor Findings 
Subsequent to the ‘rough’ delineation of ‘P wave predictors’ in the field, the 
ECGs of patients undergoing both Holter and Event Recorders were 
analysed digitally through CardiosoftTM and 12-SLTM to look more closely at P 
wave indices. A comparison was made between the P wave indices of those 
patients with evidence of irregular NCT (i.e. AF) and those without, on both 
Holter and Event recorder, as shown in the tables below. Records with 
missing P wave annotations have been excluded, as detailed in the tables. 
 
Table 32 – P wave parameters (Median (Inter-Quartile Range)) for patients 
undergoing Holter monitoring with and without evidence of AF. 
Parameter  Irregular NCT  
N = 9  
Others  
N = 79  
p value  
Pd [ms]  112(107 - 129)  112(102 - 122)  N.S.  
Pamp(avg) [μV]  115(94 - 134)  113(98 - 144)  N.S.  
Pamp(II) [μV]  170(150 - 228)  190(135 - 240)  N.S.  
Parea(avg) 
[μV*ms]  
4978(3699 - 
5957)  
4898(3988 - 
5955)  
N.S.  
Parea(II) 
[μV*ms]  
8380(6435 - 
9820)  
8480(6575 - 
11225)  
N.S.  
Ptnf(V1) [μV*s]  1.76(0.00 - 0.00)  1.37(0.42 - 
2.39)  
N.S.  
PR [ms]  142(129 - 156)  158(142 - 179)  N.S.  
RR [ms]  807(682 - 921)  770(689 - 899)  N.S.  
Norm. PR [%]  18(16 - 20)  20(17 - 24)  N.S.  
Pd = P duration, Pamp(avg) = mean P wave amplitude (across 12 leads), 
Parea(avg) = mean P wave area (across 12 leads), Ptnf = P wave terminal 
negative force, PR = PR interval (Pon to QRSon). P value reported for KW 
test (α=0.05), N.S. = not significant.  
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Table 33 – P wave parameters (Median(Inter-Quartile Range)) for patients 
undergoing Event Recording with and without evidence of AF 
Parameter  Irregular NCT  
N = 26  
Others  
N = 104  
p value  
Pd [ms]  117(106 - 130)  112(105 - 122)  N.S.  
Pamp(avg) [μV]  119(82 - 153)  119(100 - 151)  N.S.  
Pamp(II) [μV]  208(120 - 275)  210(160 - 273)  N.S.  
Parea(avg) 
[μV*ms]  
5245(3535 - 
6164)  
5224(4111 - 
6991)  
N.S.  
Parea(II) 
[μV*ms]  
9485(6030 - 
11830)  
9770(7275 - 
12325)  
N.S.  
Ptnf(V1) [μV*s]  0.87(0.39 - 2.44)  0.98(0.19 - 2.96)  N.S.  
PR [ms]  158(146 - 170)  158(146 - 170)  N.S.  
RR [ms]  736(637 - 841)  759(674 - 843)  N.S.  
Norm. PR [%]  22(18 - 27)  21(18 - 24)  N.S.  
Pd = P duration, Pamp(avg) = mean P wave amplitude (across 12 leads), 
Parea(avg) = mean P wave area (across 12 leads), Ptnf = P wave terminal 
negative force, PR = PR interval (Pon to QRSon). P value reported for KW 
test (α=0.05), N.S. = not significant  
 
As can be seen from the tables, none of the P wave indices appeared to be 
significantly different between the group suffering from irregular NCT and 
those without. 
However, if we look in more detail at those patients undergoing event 
recordings and divide the group having irregular NCT (n=26) into those with 
>5 minutes of PAF / 24 hours (n=4 as 1 ECG not analysable) and those with 
<5 minutes PAF / 24 hours (n=22), then, comparing the group with clinically 
significant PAF to those with <5minutes per 24 hours (Table 33) or those 
without any evidence of irregular NCT (Table 34), it can be seen that the 
group with >5 minutes of PAF per 24 hours has a significantly longer PD than 
the other 2 groups, and a non-significant increased PR interval. In 
comparison to the group with <5 minutes PAF, there is also a significantly 
larger PTNF, and a significantly smaller PAMP and PAREA in lead II. In 
comparison with the group with no irregular NCT, there is a significantly 
smaller PAMP average and in lead II, and significantly smaller PAREA in lead II. 
 
124 
 
Table 34 PWI (Median (Inter-Quartile Range)) for patients undergoing event 
recorders with >5minutes PAF / 24 hours of recording versus those <5 
minutes / 24 hours 
Parameter  <5mins PAF / 24 
hours 
N = 22  
>5mins PAF / 24 
hours 
N = 4  
p value  
Pd [ms]  113(105 - 125)  134(127 - 136)  NCT<NCT5+(p=0
.027)  
Pamp(avg) 
[μV]  
121(86 - 155)  74(58 - 111)  N.S.  
Pamp(II) [μV]  213(143 - 280)  80(68 - 155)  NCT>NCT5+(p=0
.028)  
Parea(avg) 
[μV*ms]  
5344(3829 - 6483)  3655(2347 - 5338)  N.S.  
Parea(II) 
[μV*ms]  
9710(7255 - 11995)  4525(3170 - 6925)  NCT>NCT5+(p=0
.016)  
Ptnf(V1) 
[μV*s]  
0.63(0.39 - 1.20)  2.97(2.44 - 0.00)  NCT<NCT5+(p=0
.017)  
PR [ms]  156(146 - 168)  184(155 - 212)  N.S.  
RR [ms]  736(637 - 841)  732(594 - 836)  N.S.  
Norm. PR [%]  22(18 - 25)  29(22 - 31)  N.S.  
Pd = P duration, Pamp(avg) = mean P wave amplitude (across 12 leads), 
Parea(avg) = mean P wave area (across 12 leads), Ptnf = P wave terminal 
negative force, PR = PR interval (Pon to QRSon). P value reported for KW 
test (α=0.05). NCT= <5minsPAF/24hours. NCT5+= >5minsPAF/24hours  
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Table 35 PWI (Median(Inter-Quartile Range)) for patients undergoing event 
recorders with >5minutes PAF / 24 hours of recording versus those with no 
irregular NCT 
Parameter  Clinically 
Significant PAF 
N = 4  
No Irregular 
NCT 
N = 104  
p value  
Pd [ms]  134(127 - 136)  112(105 - 122)  NCT5+>NC
T-(p=0.007)  
Pamp(avg) [μV]  74(58 - 111)  119(100 - 151)  NCT5+<NC
T-(p=0.037)  
Pamp(II) [μV]  80(68 - 155)  210(160 - 273)  NCT5+<NC
T-(p=0.014)  
Parea(avg) 
[μV*ms]  
3655(2347 - 5338)  5224(4111 - 
6991)  
N.S.  
Parea(II) 
[μV*ms]  
4525(3170 - 6925)  9770(7275 - 
12325)  
NCT5+<NC
T-(p=0.011)  
Ptnf(V1) [μV*s]  2.97(2.44 - 0.00)  0.98(0.19 - 
2.96)  
N.S.  
PR [ms]  184(155 - 212)  158(146 - 170)  N.S.  
RR [ms]  732(594 - 836)  759(674 - 843)  N.S.  
Norm. PR [%]  29(22 - 31)  21(18 - 24)  N.S.  
 Pd = P duration, Pamp(avg) = mean P wave amplitude (across 12 leads), 
Parea(avg) = mean P wave area (across 12 leads), Ptnf = P wave terminal 
negative force, PR = PR interval (Pon to QRSon). P value reported for KW 
test (α=0.05). NCT- = no NCT, NCT5+ = >5minsPAF/24hours  
 
6.2.5 Other Findings of Note 
With respect to the Holter monitors, there was 1 patient who had Wenkebach 
(Mobitz type I) and 2 patients with Mobitz type II. There was also 1 patient 
who had ventricular standstill (i.e. non-conducted P waves with no escape 
rhythm) for 9.9 seconds. Surprisingly, particularly with the last case, the 
patients were asymptomatic and the bradyarrhythmias were mainly 
nocturnal. This clearly raises ethical issues in a resource-poor country about 
doing Holters on asymptomatic patients and this is discussed in section 2.10. 
With respect to the Event Recorders, 1 patient had Wenkebach and 1 patient 
had complete heart block. Latterly, the patient had a regular ventricular 
escape rhythm of 32 bpm. Again, the patients both denied having any 
symptoms and were given advice as in section 2.10. 
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6.3 Discussion 
The two main reasons for performing ambulatory monitoring in a subgroup of 
my Study Population was to document the prevalence of PAF (i.e. that which 
is not picked up on 12-lead ECG), and also to look at P wave indices in the 
ambulatory monitor group to see if there were any PWI that might predict 
PAF. I will focus on the former in this section and the latter is discussed 
below in section 6.3.2. 
The first thing to say about reporting prevalence of PAF is that it is difficult. 
Up to 90% of episodes of PAF may be entirely asymptomatic (232) (233), 
including some lasting >48 hours (233), yet PAF may be responsible for up 
to 25% of all AF (234). Thus the patient is unaware of the episode and 
therefore does not present for 12-lead ECG. In addition, no single 
ambulatory monitor, be it internal or external, is perfect. There is a trade-off 
between length of recording and disclosure i.e. a full disclosure monitor, 
when examined by a trained operator, is more likely to be able to detect all 
episodes and be able to quantify AF burden over a 24 hour – 7 day period 
whereas, if it is not full-disclosure, it becomes more difficult to quantify exact 
amounts of PAF. However, we also know that the longer the recording, the 
greater the chance of actually detecting some PAF in the first place, usually 
requiring a monitor that does not provide full disclosure and relies upon 
computer algorithms to ‘detect’ and record PAF. Neither method is perfect 
and it has been estimated that PAF may be documented in ~70% of patients 
suffering from the arrhythmia with ambulatory monitoring, with a fairly poor 
negative predictive value (for the absence of AF) of 30-50% (32).  
Despite these problems and the fact that performing ambulatory monitoring 
tends to be time-consuming and expensive with regard to resources, there 
are several epidemiological studies reporting on PAF but mainly in smallish 
numbers and reporting mainly on general ambulatory monitor findings rather 
than specifically on PAF.  
 
6.3.1 Comparison to other populations 
A study from Greece (235) looked at AF incidence in patients presenting to 
hospital with AF that lasted <7 days and was not associated with any acute 
illness. They found an incidence of 7.2/10,000/year in men and 
5.3/10,000/year in women. There were more incident cases in men and they 
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occurred at a younger age on average. The incidence increased with age. It 
must be pointed out that this is likely to be a significant under-estimation 
given they only included patients who were symptomatic and therefore 
presented to hospital. 
 A UK study (236) looking at almost 2000 patients aged 40-89 years with AF 
in a GP research database, found that 525 (27.8%) on further classification 
had PAF. The authors calculated this to be equivalent to an incidence rate of 
1.0 per 1000 patient years.  
A study looking at the prevalence of PAF post-acute stroke using different 
methods of detection looked at 149 patients (224). AF was detected in 22 
patients overall (14.8%), with 12 (8% of total stroke patients) of these having 
PAF and thus only being identified using either Holter (7 patients – 4.7%) or 
external loop recorder (5 patients – 3.3%). A further study looking at 413 
stroke / TIA patients undergoing Holter monitoring (237) found that PAF 
occurred in 39 (9.2%) patients, but only lasted >30 seconds in 11 (2.5%) 
patients, with the remaining 26 having PAF <30 seconds over a mean 
recording length of 22.6 hours. 
A study in Chest in 1982 (238) looked at 98 healthy elderly patients aged 60-
85 undergoing 24-hour Holter recording. They noted that paroxysmal atrial 
tachycardia occurred 22 times in 13 (13%) patients, with only 1 patient 
showing a 2 second run of atrial flutter and no observed PAF. 
The Bronx Aging Study (213) looked at 423 independent, community-
dwelling subjects aged 75-85 undergoing 24-hour ambulatory cardiac 
monitoring. They noted 17 patients (4%) with evidence of AF on their 
recording, although 14 subjects had evidence of AF on their 12-lead ECG 
and therefore only 3 patients (0.6%) of the sample had PAF unidentified on 
12-lead ECG. The authors do not further describe the burden of that PAF. 
A community-based study from Finland (239) performed ambulatory 
monitoring on an elderly population (aged 65+) of 162 subjects and found AF 
in 5 (3.1%) but it is not clear how many patients were known to have AF on 
12-lead ECG and therefore how much of the AF was paroxysmal, as the 
focus of the paper was more towards general findings on ambulatory 
monitoring and risk of death.  
The Cardiovascular Health Study (240) looked at 1512 randomly selected 24 
hour monitors in participants aged 65+. Sustained AF (i.e. already identified 
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on 12-lead) was present in 1.7% of women and 2.5% of men, whilst 
intermittent AF (just picked up on 24 hour monitoring) was present in 1.1% of 
women and 0.8% of men. 
It is difficult to compare my Study Population directly to these other studies 
given differences in methodology, particularly with respect to ambulatory 
monitors used and background characteristics of the populations studied. 
Having said this, it would appear that my results are fairly similar to these 
other studies when comparing Holter monitors, given 1/96 (1.0%) of patients 
undergoing 24-hour recording demonstrated runs of irregular NCT >30 
seconds in length that would be classified as PAF.  
There are very few studies in the literature reporting prevalence of PAF using 
non-invasive event recorders such as the ones I used (Novacor R-test 
EvolutionTM) and, again, it is therefore difficult to see how my results 
compare to other populations. However, the majority of studies are in post-
stroke patients and have reported an increased prevalence / detection rate of 
PAF in event recorders over 24 hour monitors (224). It would therefore stand 
to reason that the prevalence of PAF in patients undergoing event recordings 
is higher, at 3.6% (5/137), than those undergoing Holter. Obviously my 
results are limited to a degree by the low overall number of recordings.  
With regard to how much PAF is clinically significant from the point of view of 
increasing stroke risk sufficiently that formal anticoagulation should be 
considered, again it is difficult to say. Studies come mainly from cohorts of 
patients with permanent pacemakers (226, 228-231, 233) with  AF detection 
algorithms, using a surrogate of atrial high rate episodes (AHRE) for AF, 
shown to be ‘tantamount’ to AF (231). These cohorts are by nature a fairly 
specific, self-selecting group with known cardiac conducting disease, and 
there have been no community-based studies looking at PAF and stroke risk 
in the general population. In addition, these studies differ with how much 
PAF they consider to be clinically important. The range is from 5 minutes in a 
24 hour period (i.e. 1 AHRE detected) (229) up to >24hours continuous 
paroxysm (226) (227). I decided beforehand to adopt the more conservative 
estimate from the MOST trial of 5 minutes in a 24 hour period as a treatment 
threshold for aspirin, given the fact that my patients were elderly and the 
majority were hypertensive, and thus at high risk of stroke (anti-
hypertensives were also prescribed in patients with BP>160/100). As 
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mentioned previously, because the event recorders were not ‘full disclosure’, 
the 5 minute period was estimated from the number of 30 second periods in 
24 hours that irregular NCT was observed. If there were >10 periods, they 
received treatment if there were no contraindications. I aim to follow up my 
ambulatory monitor patients as currently I have no data on how much PAF 
increases stroke risk in the Study Population and, as mentioned above, it 
may be that elderly black Africans are more susceptible to a lower burden of 
PAF. 
Comparing the results of the two Holter monitors, the mean recording length 
was 419 minutes (33%) longer with the Medilog monitor than H-Scribe.  The 
mean heart rates were very similar, yet there were many more SVEs 
(isolated and runs) and VEs (runs <3 beats) in the H-Scribe population. It is 
noted that there were more women than men in this group and this is one 
potential reason for the difference but it is probably more likely to reflect the 
differences in the detection algorithms for each monitor. 
 
 6.3.2 P wave Indices and PAF 
It is interesting to note that in the group of patients with evidence of >5mins 
in 24 hours of PAF, that P wave duration was significantly longer than in the 
groups with <5mins/24 hours (21ms) and also those without evidence of NCT 
(22ms). It is also interesting to note that only the group with >5mins PAF per 
24 hours had a median value >120ms (134ms). The other 2 groups had 
median values <120ms (113ms for the group <5mins PAF per 24 hours and 
112ms for group without PAF). It has been previously noted by Soliman et al 
(153) that maximum PD and PD in lead II are the strongest predictors of 
incident AF (HR 4.07 and 3.90 respectively) in their study looking at PWI and 
prediction of PAF and stroke. There are several other papers (225, 241, 242) 
that agree with my finding of an increased PD being more common in 
patients with evidence of PAF. The DeBacquer study notes, similarly to mine, 
that a cut-off of 120ms seems to separate patients with AF (PD ≥120ms 
present in 71%) and without (present in 41%). However, they also note that 
this is only when combined with morphologic changes such as notched or 
deflected P waves, whereas other studies (153, 225, 241) comment on the 
effect of PD alone. It is also worth making clear at this stage that the other 
studies have used maximum PD and PD in lead II, whereas in my study it was 
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a signal averaged- median beat averaged over the 12 leads that predicted 
PAF, not previously noted in the literature. 
With regard to PR interval, it was noted there was a longer PR interval in the 
group with >5mins PAF per 24 hours by 28 ms over the group with <5mins 
PAF per 24 hours (184 vs 156ms), and 26ms over the group with no PAF 
(184 vs 158ms). The differences did not reach statistical significance in either 
group comparison but again these results agree with other suggestions from 
the literature indicating an increased risk of PAF with prolonged PR interval 
(153, 156). In the Cheng study (156) a 20ms increase in PR interval resulted 
in an 11% increase in risk of AF. 
Interestingly, with regards P wave amplitude and area, the patients with 
>5mins per 24 hours of NCT had significantly lower values in lead II than the 
group with <5mins PAF per 24 hours (PAMP 80 vs. 213µV, PAREA 4525 vs. 
9710µV*ms) and the group with no PAF (PAMP 80 vs. 210µV, PAREA 4525 vs. 
9770µV*ms). This suggests a difference from the Soliman study (153) and is 
likely to be a result of small numbers in each group rather than a true 
difference. 
When discussing these differences, it is important to maintain a clinical 
perspective. Realistically speaking, it will be difficult in routine clinical 
practice, without the aid of callipers etc., to accurately measure differences in 
PWI and determine an individual’s potential risk. The concept of a cut-off 
point, such as is suggested by 120ms for PD, may be useful but these PWI 
must be used in conjunction with other clinical variables when assessing risk. 
 
6.4 Conclusions 
My findings show a similar burden of PAF in a sub-group of my Study 
Population to that in other populations studied in high-income countries. It 
suggests either that PAF does not appear to be a major contributory factor to 
the increased stroke burden seen or that, potentially, black Africans are more 
susceptible to a lower burden of PAF than other populations. 
P wave duration and PR interval may be predictive factors for PAF in my 
Study Population, but should be taken in context of the patient’s overall risk 
factor profile. 
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Chapter 7. Hypertension 
 
7.1 Methods 
7.1.1 Blood Pressure and standardisation of measurements 
I had 2 BP machines available for use. Both were newly calibrated A&D UA-
767TM (A&D Instruments Ltd, UK) automated monitors, that conform to the 
accuracy standards of the British Hypertension Society and have been 
previously validated for use as automated monitors (243). The enumerators 
were given a further session with initial demonstration and then subsequent 
practice, with instruction sheet as aide memoire given. In accordance with 
the World Health Organization (WHO) STEPS protocol (244) and similar to 
protocols used in large hypertension trials (229, 230), BP was performed 3 
times in the right arm with the arm supported at the level of the heart with the 
participant in the sitting position after at least 5 minutes of resting quietly, and 
then once after standing for 3 minutes in a similar fashion. The participant’s 
sitting BP was recorded as an average of the 2nd two recordings. An 
appropriately sized cuff was employed and the participant was given a full 
explanation as to the procedure in order to try and allay anxiety and potential 
'white-coat' hypertension (noted to be a particular problem in the elderly, but 
also in elderly that may well never have had their BP taken before). If there 
was a greater than 10mmHg difference in either systolic +/- diastolic BP 
between the 2nd and 3rd recordings, then further recordings were taken until 
2 consecutive readings were concordant within this range. The study 
performed sitting and standing BP readings in all study participants (disability 
allowing). 
 
7.1.2 Case Definition of Hypertension 
HTN was defined as BP ≥140/90mmHg for the purposes of reporting 
prevalence. I further classified hypertensives according to suggested 
treatment guidelines for SSA of BP >150/95mmHg (245), my own pre-
determined cut-off for immediate commencement of treatment for HTN of 
>160/100mmHg, and those with severe (Grade 3) HTN of ≥180/100mmHg. 
Isolated systolic hypertension (ISH) was defined as a systolic BP 140-
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159mmHg (Grade 1) or ≥160mmHg (Grade 2) with a diastolic BP <90mmHg. 
Pulse pressure (systolic minus diastolic) was also recorded. 
 
7.1.3 Electrocardiographic criteria of left ventricular hypertrophy 
As with the measurement of P wave indices in Chapter 5, this was performed 
digitally using 12-SL analysis software available on the GE MAC 1200TM 
machines I was using to look at participants with ECG LVH and how well this 
correlated with whether they were found to be hypertensive. In addition, I 
also looked at how well ECG LVH correlated with echo LVH in the 
participants that underwent an echocardiogram (i.e. cases and pool of 
controls from the AF prevalence study). With the 12-SL system, median 
beats are produced to help eliminate noise, and the Sokolow-Lyon index is 
reported. This index measures the product of the S wave in lead V1, added 
to the larger of the R waves in either V5 or V6. The cut-off for ECG LVH is 
≥3.5mV. All electrocardiographic criteria for LVH have been shown 
recurrently to be specific but not overly sensitive with regard to true LVH 
(when compared to imaging such as echo or MRI). However, according to a 
recent study comparing multiple ECG LVH criteria to CMR findings, the 
Sokolow-Lyon index is the best performing criteria overall, with a sensitivity 
of 26% and specificity of 92.6% (246). In the significant percentage of the 
total overall study population that was African-American (25.7% - 1241 
participants), the sensitivity of Sokolow-Lyon increased to 36.7%, at the 
expense of the specificity which dropped slightly to 86.8%. This therefore 
seemed the most suitable and appropriate ECG criteria to report. Of 2130 
digital ECG records, 1350 (63.4%) had ECGs suitable for calculation of 
Sokolow-Lyon index, after exclusion of records without annotation and 
visually inadequate quality. Basic statistics were applied to the results, 
including 95% CIs for percentages and p values for differences between 
some groups using the Mann-Whitney test. Of the AF case-control group, 53 
had all three of  
1. an ECG with LVH index annotation 
2. echocardiographic measurement of septal and posterior wall thickness 
and LA diameter 
3.BP recording 
and were compared in a sub-group analysis. 
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7.1.4 Echocardiographic criteria for left ventricular hypertrophy 
LV wall thickness and left atrial diameter were measured and classified 
according to British Society of Echo guidelines (247), such that normal LV 
wall thickness was defined as 0.6-1.2cm, with mild, moderate and severe 
hypertrophy defined as wall thicknesses 1.3-1.5cm, 1.6-1.9cm, and ≥2.0cm 
respectively. LA diameters were gender specific. 
 
7.2 Results 
7.2.1 Prevalence of Hypertension 
Of the 2223 participants able to have their BP taken, only 670 (30.1%) 
people had an average BP of <140/90 (i.e. were normotensive), 1553 
(69.9%) had an average BP ≥140/90, 1289 (58.0%) had an average BP over 
150/95 and 993 (44.7%) had an average BP over 160/100. Therefore, more 
than 2 out of every 3 study participants were hypertensive with a BP 
≥140/90, and almost 2 of every 3 hypertensives identified had BP >160/100 
(993/1553 or 63.9%). 653 participants (29.4%) had Grade 3 ‘severe’ HTN 
(≥180/110). It was not possible to take 9 people’s BP. This was either 
because they refused to have it done, stated that it was painful or they were 
felt to be too physically or mentally unwell for it to be appropriate. 
 
Table 36 Frequency and Crude Prevalence of hypertension at varying 
diagnosis and treatment cut-offs  
Blood Pressure Frequency  Crude Prevalence (95% 
CI) 
< 140/90 670 30.1 (28.2 – 32.1) 
≥140/90 1553 69.9 (68.0 – 71.8) 
>150/95 1289 58.0 (55.9 – 60.0) 
>160/100 993 44.7 (42.6 – 46.7) 
≥180/110 653 29.4 (27.5 – 31.3) 
 
The following table reports age-adjusted (to WHO world population) 
prevalence rates (95% CI) for n=2196 because 27 patients had missing data 
for age, as I was unable to establish accurately enough their year of birth 
beyond saying they were over the age of 70 and are therefore excluded from 
analysis. 
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Table 37 Age-adjusted prevalence rates for hypertension bands 
Blood Pressure Age-Adjusted Prevalence (95% 
CI) 
< 140/90 30.7 (28.8 – 32.6) 
≥140/90 69.7 (67.8 – 71.6) 
>150/95 57.7 (55.6 – 59.8) 
>160/100 44.3 (42.2 – 46.4) 
≥180/110 29.0 (27.1 – 30.9) 
 
7.2.2 Gender and Age Differences 
The mean pulse pressure and diastolic and systolic blood pressures of the 
Study Population are described in the table below, according to sex 
category. As can be noted, all 3 measures were significantly higher in 
women than men in the Study Population. In fact, despite making up only 
56% of the total study population, almost 2 out of every 3 hypertensives 
(61%) were women. 
 
Table 38 Mean BP results of the Study Population by Gender 
 Males (n = 972) Females (n= 1251) 
Mean pulse pressure (95% 
CI) 
713 (69.9 to 727) 766 (753 to 780) 
Mean diastolic BP (95% 
CI) 
831 (821 to 840) 893 (884 to 902) 
Mean systolic BP (95% CI) 1543 (1523 to 1564) 1660 (1641 to 1679) 
 
When each hypertensive band was broken down by gender, there were a 
significantly higher number of women than men in each band, as can be 
seen in the table and graph below. What can also be noted, particularly in 
the graph, is that there was a higher percentage of women that were 
hypertensive overall and an increased percentage of women making up the 
group with very high BPs i.e. ≥180/110. 
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Table 39 Number of study participants in each hypertensive band by gender 
(percentage is of total hypertensive population for each band) 
BP Men (95%CI) Women (95% CI) Total 
 Frequency %age Frequency %age Frequency %age 
≥140/90 603 39 (36.4 – 41.3) 950 61 (58.8 – 63.6) 1553 100 
>150/95 487 38 (35.1 – 40.4) 802 62 (59.6 – 64.9) 1289 83 
>160/100 357 36 (33.0 – 38.9) 636 64 (61.1 – 67.0) 993 64 
≥180/110 216 33 (29.5 – 36.7) 437 67 (63.3 – 70.5) 653 42 
 
Graph 11 Percentage of study participants in each hypertensive band by 
gender (percentages are of total study population by gender with available 
BPs i.e. 972 men and 1251 women) 
 
With respect to HTN prevalence and age, the following tables and graph 
illustrate the frequency and prevalence in men and women by 5-year age 
bands. The total population with age and BP recorded is 2196 (965 men and 
1231 women). 
 
Table 40 Frequency of hypertension by gender and age-band 
Age 70-74 75-79 80-84 85+ 
Sex Men Women Men Women Men Women Men Women 
Normotensive 147 129 112 75 48 48 59 44 
BP ≥140/90 233 355 170 258 85 156 111 166 
BP >150/95 190 295 131 227 66 127 96 142 
BP >160/100 147 224 91 183 50 101 65 117 
BP ≥180/110 84 146 62 130 38 63 30 87 
Total 
Population 
380 484 282 333 133 204 170 210 
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Table 41 Prevalence (95% CI) of hypertension by gender and age-band 
Age 70-74 (95% CI) 75-79 (95% CI) 80-84 (95% CI) 85+ (95% CI) 
Sex Men Women Men Women Men Women Men Women 
Normotensive 38.7 
(33.8 – 
43.6) 
26.7 
(22.8 – 
30.6) 
39.7 
(34.0 – 
45.4) 
22.5 
(17.6 – 
27.4) 
36.1 
(27.9 – 
44.3) 
23.5 
(17.7 – 
29.3) 
34.7 
(27.6 – 
41.9) 
21 (15.4 
– 26.5) 
BP ≥140/90 61.3 
(56.4 – 
66.2) 
73.3 
(69.4 – 
77.3) 
60.3 
(54.6 – 
66.0) 
77.5 
(72.6 – 
82.4) 
63.9 
(55.7 – 
72.0) 
76.5 
(70.6 – 
82.3) 
65.3 
(58.1 – 
72.4) 
79 (73.5 
– 84.6) 
BP >150/95 50 (45.0 
– 55.0) 
61 (56.6 
– 65.3) 
46.5 
(40.6 – 
52.3) 
68.2 
(62.7 – 
73.6) 
49.6 
(41.1 – 
58.1) 
62.3 
(55.6 – 
68.9) 
56.5 
(49.0 – 
63.9) 
67.6 
(61.3 – 
73.9) 
BP >160/100 38.7 
(33.8 – 
43.6) 
46.3 
(41.8 – 
50.7) 
32.3 
(26.8 – 
37.7) 
55 (49.1 
– 60.8) 
37.6 
(29.4 – 
45.8) 
49.5 
(42.6 – 
56.4) 
38.2 
(30.9 – 
45.5) 
55.7 
(49.0 – 
62.4) 
BP ≥180/110 22.1 
(17.9 – 
26.3) 
30.2 
(26.1 – 
34.3) 
22.0 
(17.2 – 
26.8) 
39.0 
(33.8 – 
44.3) 
28.6 
(20.9 – 
36.2) 
30.9 
(24.5 – 
37.2) 
17.6 
(11.9 – 
23.4) 
41.4 
(34.8 – 
48.1) 
 
Table 42 Levels of hypertension by age band and gender (M=male, 
F=female), by percentage of each age band 
Age 
band 
70-74 75-79 80-84 85+ 
Gender M F M F M F M F 
BP 
<140/90 
38.7 (33.8 
– 43.6) 
26.6 (22.8 
– 30.6) 
39.7 (34.0 
– 45.4) 
22.5 (17.6 
– 27.4) 
36.1 (27.9 
– 44.3) 
23.5 (17.7 
– 29.3) 
34.7 (27.6 
– 41.9) 
21 (15.4 – 
26.5) 
BP 140-
149/90-
95 
(Grade 
1) 
11.3 (8.2 
– 14.4) 
12.4 (9.5 
– 15.3) 
13.8 (9.8 
– 17.8) 
9.3 (6.2 – 
12.4) 
14.3 (8.3 
– 20.3) 
14.3 (9.4 
– 19) 
8.8 (4.6 – 
13.1) 
11.4 (7.1 
– 15.7) 
BP 150-
159/95-
99 
(Grade 
1) 
11.3 (8.2 
– 14.4) 
14.7 (11.6 
– 17.8) 
14.2 (10.1 
– 18.3) 
13.2 (9.6 
– 16.8) 
12 (6.5 – 
17.5) 
12.7 (8.1 
– 17.3) 
18.2 (12.4 
– 24.0) 
11.9 (7.5 
– 16.3) 
BP 160-
179/100-
109 
(Grade 
2) 
16.6 (12.9 
– 20.3) 
12 (9.1 – 
14.9) 
10.3 (6.7 
– 13.8) 
15.9 (12.0 
– 19.8) 
9.0 (4.1 – 
13.9) 
18.6 (13.3 
– 24.0) 
20.6 (14.5 
– 26.7) 
14.3 (9.0 
– 19.6) 
BP 
≥180/110 
(Grade 
3) 
22.1 (17.9 
– 26.3) 
30.2 (26.1 
– 34.3) 
22.0 (17.2 
– 26.8) 
39.0 (33.8 
– 44.3) 
28.6 (20.9 
– 36.2) 
30.9 (24.5 
– 37.2) 
17.6 (11.9 
– 23.4) 
41.4 (34.8 
– 48.1) 
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Graph 12 Levels of hypertension by age band and gender (M=male, 
F=female), by percentage of each age band 
 
 
Table 43 Age-adjusted prevalence rates (95% CI) by age band (male and 
female combined) and level of hypertension 
 70-74 years 75-79 years 80-84 years 85+ years 
BP 140-
149/90-95 
12.7 (10.5 – 14.9) 11.7 (9.2 – 14.2) 16.0 (12.1 – 19.9) 7.1 (4.5 – 9.7) 
BP 150-
159/95-99 
14.1 (11.8 – 16.4) 14.1 (11.3 – 16.9) 14.0 (10.3 – 17.7) 10.2 (7.2 – 13.2) 
BP 160-
169/100-
109 
17.4 (14.9 – 19.9) 13.7 (11.0 – 16.4) 16.7 (12.7 – 20.7) 11.8 (8.6 – 15.0) 
BP 
≥180/110 
28.4 (25.4 – 31.4) 32.2 (28.5 – 35.9) 33.7 (28.7 – 38.7) 21.3 (17.2 – 25.4) 
BP 
≥140/90 
OVERALL 
 
72.6 (69.6 – 75.6) 
 
71.7 (68.1 – 75.3) 
 
80.4 (76. – 84.6) 
 
50.4 (45.4 – 55.4) 
 
Isolated Systolic Hypertension 
733 of 1553 hypertensives (47.2%) had isolated systolic hypertension (ISH). 
This works out as an overall crude prevalence rate of 33.0% (733/2223) and 
an age-adjusted prevalence rate of 31.6%. The table below shows the 
frequency breakdown by gender and SBP band. 411 (52.6% women) had 
Grade 1 ISH (SBP 140-159) and 322 (61.5% women) had Grade 2 ISH (SBP 
≥160). The crude prevalence rates of Grade 1 and 2 ISH were therefore 
18.5% (411/2223) and 14.5% (322/2223) respectively. 
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Table 44 Levels of systolic BP by gender 
Gender SBP ≥180 SBP ≥160 but <180 SBP ≥140 but <160 Total 
Male 41 83 195 319 
Female 76 122 216 414 
Total 117 205 411 733 
 
7.2.3 Participant Awareness of Hypertension, Treatment and Adequate 
Control 
586 (26.3% of total and 37.7% of the hypertensive group) of the Study 
Population (189 (32.3%) men, 397 (67.7%) women) were aware that they 
had HTN but only 94 of these (16% of participants aware of their 
hypertension, 6.1% of total who were hypertensive) were on regular 
treatment (48 (51%) men, 46 (49%) women).  
Of the 94 people on treatment for HTN, 14 (11 (79%) men, 3 (21%) women) 
had controlled blood pressure of <140/90, 21 had an average blood pressure 
of less than or equal to 150/95 and 34 had an average blood pressure of less 
than or equal to 160/100. Therefore 60 had an average blood pressure of 
>160/100, and 80 still had uncontrolled blood pressure, i.e. a blood pressure 
of ≥140/90. Therefore, of the hypertensive population overall, only 0.9% 
(14/1553) had adequately controlled BP. 
To suggest a rough pattern for HTN in this population therefore would be as 
follows – a ‘rule of sixths’: 
 4/6 of the total Study Population (1553/2232) were hypertensive 
 2/6 of the total Study Population (653/2232) had Grade 3 (severe) HTN 
 2/6 of the Study Population had ISH  
 4/6 of the hypertensive group (950/1553) were women 
 4/6 of the hypertensive group (993/1553) had moderate/severe HTN 
with BPs >160/100 
 4/6 of the group with moderate/severe HTN (636/993) were women 
 2/6 of the hypertensive group (586/1553) were previously aware of 
their HTN  
 1/6 of the group previously aware of their HTN (94/586) were on 
current treatment 
 1/6 of the group on current treatment (14/94) were adequately 
controlled 
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7.2.4 Functional Status and Co-morbidities 
As noted previously, functional status in women overall is worse than men, 
with an OR of 1.31 of being severely disabled (BI <15) if female. This is 
reflected in the BI scores for the different bands of HTN between the 
genders, with women having lower BI than men in each BP band. However, 
there appears to be little difference in levels of disability between BP bands, 
as shown in the table below. 
 
Table 45 Barthel Index scores by gender and BP level 
Blood Pressure Barthel Index Score 
 Male Female Overall 
<140/90 19.35 19.12 19.27 
≥140/90 19.37 19.22 19.28 
>150/95 19.32 19.23 19.26 
>160/100 19.27 19.12 19.18 
 
7.2.5 Advice and Treatment  
Of 1553 hypertensive subjects, 993 had a BP >160/100, my cut-off for 
commencement of treatment. Of these 993, 855 (86.1%) were given a 
prescription for bendroflumethiazide, 21 (2.1%) a prescription for nifedipine, 
and 25 (2.5%) a prescription for propranolol (usually due to concomitant 
angina or benign essential tremor). Of 52 patients (5.2%) taking medication 
in this BP band already, 38 (3.8%) were asked to continue their current 
medication (and usually reminded of the importance of taking on a daily 
basis), 10 (1.0%) were asked to increase their current medication, and 4 
(0.4%) were changed to more effective agents. Of the remaining 40 patients 
(4.0%), 26 patients (2.6%) refused to take medication and 14 (1.4%) were 
considered too frail. The 560 participants that had a BP between 140-160/90-
100 were given detailed advice regarding diet and lifestyle and it was 
recommended to them that they returned to their local health centre for BP 
monitoring on a regular basis. All patients with HTN were given education 
regarding non-pharmacological intervention such as stopping smoking and 
reducing salt and alcohol intake. Physical activity was discussed but I quickly 
realised that participants spent the majority of the day either working in their 
‘shamba’ / cleaning the homestead, or were too frail / disabled to work.  
 
140 
 
7.2.6 Electrocardiographic criteria of left ventricular hypertrophy 
Of the 1350 ECGs with digital Sokolow-Lyon index annotations, 576 were 
men and 774 women. The number with LVH criteria was 342 in total (25.3% 
(95% CI 22.9-27.7)). As a percentage, there were more men with ECG LVH 
(29.2%(25.1-33.3)) than women (22.5%(19.6-25.4) (see Table 45). This was 
statistically significant with a p value <0.001. 
 
Table 46 Distribution of LVH Index 
 Sokolow-Lyon Index  
 <3.5mV ≥3.5mV Total 
Male 408 168 576 
Female 600 174 774 
Total 1008 342 1350 
 
On comparing ECG LVH to systolic and diastolic BP, I found that both 
systolic and diastolic BP was significantly higher in participants with ECG 
LVH criteria, and BMI was significantly higher in participants without ECG 
LVH criteria, as in Table 47 below. 
 
Table 47 Descriptive statistics of LVH Covariates (mean +- SD) 
Covariate No. Recordings Sokolow-Lyon Index P value (*) 
<3.5mV ≥3.5mV 
BMI 1237 22.2±4.7 20.8±3.5 <0.005 
Systolic BP 1344 156±32 175±35 <0.0001 
Diastolic BP 1344 85±16 91±17 <0.0001 
(*) Mann-Whitney test, α=0.05 
 
When I looked at the sub-group of 53 participants (23 men, 30 women) who 
had undergone echocardiography, only 9 (17%) fitted criteria for ECG LVH. 
Covariate analysis in Table 47 shows again a significantly higher SBP in 
those with ECG LVH, and whilst there is a suggestion that septal and 
posterior wall thicknesses are higher in the ECG LVH group, these results do 
not reach significance. 
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Table 48 Subgroup analysis of LVH covariates for those undergoing 
echocardiography (mean±SD) 
Covariate Sokolow-Lyon LVH index P value (*) 
<3.5mV (n=44) ≥3.5mV (n=9) 
BMI 20.6±6.7 19.1±2.1 0.144 
SBP 162±33 199±34 0.007 
DBP 91.7±20 104±18 0.080 
Septal wall 
thickness (cm) 
1.27±0.25 1.34±0.34 0.699 
Posterior wall 
thickness (cm) 
1.15±0.18 1.29±0.34 0.218 
LA diameter (cm) 3.62±0.7 3.58±0.44 0.89 
* Mann-Whitney test, α=0.05 
 
On examining the ECG LVH group, only 4 of 9 (44%) had echocardiographic 
evidence of LVH. Of these 4, 2 had concentric hypertrophy (1 mild, 1 
severe), with the other 2 being isolated septal hypertrophy (mild) and 
asymmetric hypertrophy (moderate septal and mild posterior wall 
hypertrophy). Of the group without ECG LVH, 18/44 (41%) had evidence of 
some degree of LVH. Of those with concentric hypertrophy, 5 had mild and 1 
had moderate. 3 had asymmetric hypertrophy, with moderate septal and mild 
posterior wall hypertrophy. 9 had evidence of isolated septal hypertrophy, 
with 6 measured as mild, 2 as moderate and 1 as severe. 
Therefore, the sensitivity of the Sokolow-Lyon index in my population is 18% 
(identifying 4/22 with LVH) and the specificity 59% (identifying 26/44 without 
LVH either on ECG or echo). 
 
7.3 Discussion 
7.3.1 Comparison of Prevalence Rates to Other Populations 
HTN prevalence (BP ≥140/90) from the National Health Survey of England in 
1998 (204) examined 11,529 adults ≥16 years old, finding an overall 
prevalence of 37%. This rate increased with age, and HTN was more 
common in men than women up until the age of 70, when it became more 
prevalent in women. The prevalence in men aged 70-79 was 77.6%, and 
81.8% in the 80+ group, compared to 82.7% and 83.8% respectively in 
women. 
An overview of HTN trends in the USA (248) found a prevalence rate of 
28.9% in 2004, with ethnic and gender differences. Prevalence was highest 
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in non-Hispanic black women at 40.8%, and was lowest in Mexican-
American men at 26.2%.  In those aged ≥70 years, the prevalence was 
63.3% in white men and 78.8% in white women. This compared to 83.4% in 
black men and 83.1% in black women, and 69.1% in Hispanic men and 
78.8% in Hispanic women. 
There are more data in SSA regarding HTN than there are for AF, although it 
has been noted that very few studies provide age-standardised data and 
thus comparison of studies is more difficult (220). Also, there are no studies 
dedicated to HTN in the elderly, with most studies containing small numbers 
of over 70s. Cut-off values for HTN are taken as ≥140/90 unless mentioned 
otherwise, as these values differ in SSA studies.  
It it helpful to begin by mentioning data from Tanzania. A study by Swai et al 
from almost 20 years ago (249) looked at 8581 adults (aged 15+) in 3 distinct 
regions in rural Tanzania. Prevalence was low at 10.9%, 3.6% and 2.3% for 
men in the regions of Kilimanjaro, Morogoro and Mara respectively, and 
9.6%, 5.2% and 3.6% for women in the same regions. In the 65+ group, 
prevalence was higher in women than men in all three regions and again 
highest in Kilimanjaro region in both men and women at 27.2% and 27.3% 
respectively. The mean BPs in the 65+ group in Kilimanjaro were 141/83 for 
men and 142/84 for women. Another study by Edwards et al published 11 
years ago (250) looked at HTN prevalence in rural (Kilimanjaro region) 
versus urban (Dar-es-Salaam) Tanzania. The prevalence in older men (>54 
years) was 77.8% in the urban area and 54.0% in rural area, versus 69.0% 
and 61.0% in women in these respective areas. The mean BPs were 
149.3/89.3 and 143.2/88.5 for urban and rural men >54 years, and 
148.6/92.0 and 144.1/88.1 for urban and rural women in the same age 
group. It is interesting to note from this not only that average mean BP is 
higher in urban versus rural, that HTN prevalence appears to be higher in 
more affluent / ‘less poor’ rural areas (i.e. Kilimanjaro) but also how difficult it 
is to look at temporal trends in the prevalence of HTN, given that in the Swai 
study the BP cut-off for hypertension was ≥160/95, and in the Edwards study 
was ≥140/90. 
Elsewhere in SSA, a review by Opie et al (251) suggests that the prevalence 
of HTN in the 65+ age group is ~30-40% in rural West Africa, ~50% in semi-
urban West Africa and 50-60% in a mixed South African population. At the 
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time (2005) these compared to slightly higher rates of 60-70% for black 
Americans of a similar age (252). 
A more recent review by Addo et al (220) found difficulty comparing temporal 
trends in BP due to differences in methodology. However, picking out studies 
in the review that have been mentioned to have data on elderly patients, 
prevalence of HTN in those aged 65+ was ~60% (men and women) in a 
Liberian study (253) and ~70% (men) to ~80% (women) in a study from 
Senegal (254). 
Summarising these prevalence rates in comparison to my Study Population, 
it would appear that prevalence rates in both elderly men (27.2% rising to 
62%) and elderly women (27.3% rising to 76%) in Kilimanjaro region have 
increased significantly since 2000 when the study by Edwards et al was 
performed, although it is noted that the population is not exactly the same 
because their rates are in the 65+ age group and mine are in the 70+. In 
addition, mean systolic BPs in both men and women have increased 
significantly, from 143.2 in men and 144.1 in women to 154.3 in men and 
166.0 in women. In the same period, diastolic BP has stayed fairly level in 
women (88.1 in 2000 versus 89.3 in 2010) and has actually decreased in 
men (88.5 in 2000 versus 83.1 in 2010). Compared to other populations in 
SSA, it would appear that my prevalence rates are on the higher side, being 
similar to rates reported from Senegal (254) and significantly higher than 
from other parts of West Africa (255) or South Africa (256). These rates are 
approaching HTN prevalence rates in the 70+ age group reported from high-
income countries, from ~75-85% for a mainly Caucasian / Asian population in 
England, to >80% in black Americans. 
With regard to isolated systolic hypertension (ISH), there are few data from 
SSA (251) and yet it is known to be an important problem in the elderly and 
in my Study Population ISH comprised almost half (47.2%) of all 
hypertension seen. This is similar to prevalence rates from the UK, where 
46.1% of men and 57.3% of women aged 70-79 with HTN had ISH, and 
49.8% and 53.1% for men and women in the 80+ age group (204).   
 
7.3.2 Reasons for Prevalence Rates 
There are many proposed ethnicity-related causes of HTN. These include 
low plasma renin values in blacks, increased intracellular sodium levels with 
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depression of sodium pump, and genetic differences in epithelial sodium 
channels and the renin-angiotensin-aldosterone system (251). In addition, it 
has been noted that black Americans have increased peripheral vascular 
resistance(251), and in a South African study (257), low birth weight and thus 
an ‘underweight phenotype’ has been associated with increased BP in adult 
life.  
In addition to the above factors, there is also a link between socioeconomic 
status and BP in SSA (258). The general trend appears to be that as 
socioeconomic status increases, so do obesity and BP. The Kilimanjaro 
region is a ‘relatively affluent’ rural area due to its favourable climate and 
proximity to major tourist attractions such as Mount Kilimanjaro and the 
Serengeti National Park which may be why HTN may be similarly prevalent 
to urban African areas and increasing at such a rapid rate.  This is linked to 
the idea of increasing ‘Westernisation’, meaning a change in lifestyle to more 
sedentary and the increase in availability (geographically and economically) 
of unhealthy foods. 
The prevalence of HTN in the elderly in Tanzania is yet to reach levels seen 
in high-income countries, and certainly in black Americans. This may be due 
to the fact that people in SSA who develop HTN earlier in life remain 
undetected and untreated for much longer than in high-income countries, 
and thus are more likely to suffer hypertensive sequelae such as strokes, 
and die earlier. Consequently, proportionately more people with less severe 
HTN would make it to old age and into our demographic population studied. 
 
7.3.3 Gender and Age Differences 
BP is known to increase with age in high-income country studies (204) (248). 
Proposed mechanisms in the elderly include increased sodium sensitivity, 
increased aortic stiffness due to loss of elasticity, increased atherosclerosis, 
endothelial dysfunction and reduced organ perfusion (particularly renal) 
(259). There is a general trend in my Study Population population in both 
men and women of an age-related increase in BP. The percentage of 
hypertensive patients in the Study Population rises between the ages of 70-
74 to 85+ from 61.3% to 65.3% in men and 73.3% to 79.0% in women 
(although these changes do not reach statistical significance).  
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It is noted in the Study Population that BP in women is greater than that in 
men. This correlates to high-income country studies showing both that HTN 
is more prevalent in women overall in the USA (248), and particularly in the 
elderly in England (204). 
 
7.3.4 Participant Awareness of Hypertension, Treatment and Adequate 
Control 
Detection, treatment and adequate control of HTN in SSA, and particularly 
the Hai District of northern Tanzania, remain poor. In my study, 37.7% of 
hypertensives were aware of their diagnosis, 6.1% were treated and 0.9% 
were adequately controlled. In the study by Edwards et al (250) in the Hai 
District in 2000, 17% were aware, 11% treated and 0.7% controlled. It should 
be remembered that the latter study included all adults, not just the elderly. 
These results suggest either that there has been very little improvement in 
detection, treatment and control of HTN in the Hai District in the last 10 
years, or that there may have been an improvement in the adult population 
overall but that the elderly population has been neglected. Both possibilities 
are equally feasible but the results are even more surprising and 
disappointing given the fact that the same research group instituted several 
health interventions at the time to improve detection, control and treatment of 
NCDs, specifically hypertension, diabetes, asthma and epilepsy (260). These 
interventions included development of local treatment guidelines, sustainable 
local clinics for detection and treatment and health promotion at a national 
level.  
Elsewhere in Africa, a study from Ghana in West Africa (261) found in an 
adult population with a prevalence of hypertension of 29.4% overall, only 
34% were aware of their HTN, but 28% were receiving treatment and 6.2% 
were adequately controlled. Clearly this is not ideal, but it is slightly better 
than in Tanzania. The authors interestingly found that, whilst knowledge of 
one’s own HTN increased with age, treatment and adequate control was 
worse than in younger age groups. It was felt that, whilst older people may 
be more interested in looking after their health, they were less likely to have 
the financial means with which to finance long-term treatment.  
A study from South Africa (256) reported much better levels of detection, 
treatment and control from a demographic and health survey in 1998. Using 
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a BP cut-off of 160/95, they reported 41% of men were aware of their 
hypertension, 39% were on treatment and 26% had their BP controlled. The 
figures for women were 67%, 55% and 38% respectively. This is just inferior 
to rates found in the USA (248) with overall awareness at 71.8%, treatment 
61.4% and control 35.1%, although it should be remembered that the cut-off 
for the US study was 140/90mmHg. In the 65+ age group in the UK, only just 
over half of cases were being identified in 1998 (56.5%), of whom 45.6% 
were treated and 11% were adequately controlled (204). 
Most of these figures are inferior even to Wilber and Barrow’s classic 
suggestion of a ‘rule of halves’ (262) in that only half of the hypertensives 
were being detected, and only half of those were treated, of which only half 
were adequately controlled (N.B. using a cut-off of 160/95mmHg). My figures 
equate more to a rough ‘rule of sixths’, with only 2 sixths of hypertensives 
aware, 1 sixth of those aware treated, and 1 sixth of those treated 
adequately controlled.   
It has previously been suggested that adult women in SSA (and high-income 
countries) have been reported to have better detection, treatment and control 
rates than men (220). The authors suggest this may be due to increased 
contact with health services when of child-bearing age. It is clear from my 
study of the elderly that men have better rates of treatment and control than 
women. Elderly women do not have the same reasons as younger women to 
seek healthcare services and from my experience it tended to be men that 
travelled around more as women who tended to stay around the homestead, 
with men having a more important status in society. Thus men are more 
likely to come into contact with health services through word-of-mouth, 
advertising etc., and have their health valued more than female members of 
the family. 
Overall, the low levels of detection, treatment and control emphasise the 
challenges of non-communicable disease management in SSA from the 
perspectives both of difficulty in accessing healthcare in a resource-poor 
country and also ensuring patients are aware of the dangers of undetected / 
untreated diseases (such as hypertension) that are asymptomatic in the 
majority of cases and yet require lifelong treatment.  
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7.3.5 Hypertension and AF 
One of my most interesting and surprising findings is that my Study 
Population had such a high prevalence of HTN, yet such a low prevalence of 
AF. The two conditions are intrinsically linked, given a pathophysiological 
mechanism of sustained high BP increasing LA pressure and thus 
encouraging LA stretch over time, leading to heterogeneity of atrial 
conduction and encouragement of multiple re-entrant wavelets, a substrate 
primed for AF development. As has been mentioned previously in section 
1.3.1, HTN is the most common condition associated with AF in population-
based studies (73) and has been said to be the single biggest risk factor for 
AF, responsible for 14% of all cases (38). However, it has also been shown 
that increased rates of HTN do not always translate into increased incidence 
of AF (188). With HTN prevalence rates similar to high-income countries, my 
study suggests that HTN in itself may not be such a risk factor for the 
development of AF, as in other populations or that other influencing factors 
such as ischaemic heart disease (which may well be subclinical in high-
income countries and thus prevalence under-estimated) are often overlooked 
when considering causative risk factors in other populations. There is also 
the potential for genetic polymorphisms in this East African population that 
are as yet undiscovered, that may protect against AF. 
 
7.3.6 Treatment and Advice 
The vast majority (86.1%) of my hypertensive patients were given 
bendrofluazide, the cheapest, most readily available, and one of the most 
effective agents in lowering BP in the elderly. They were also advised of 
side-effects and recommended they have their renal function checked within 
a month of starting the drug (whilst accepting that the majority will not). 
Thiazide diuretics (hydrochlorothiazide, chlorthalidone, and bendrofluazide) 
are recommended by the American College of Cardiology for initiating 
therapy. They cause an initial reduction in intravascular volume, peripheral 
vascular resistance, and BP, and are generally well tolerated (259). The 
price per 5mg tablet was 35TzS (i.e. 1.75 pence) and therefore a patient on 
2.5mg bendrofluazide could be treated for a month for <30 pence. Those 
with contraindication to bendrofluazide were given nifedipine, slightly more 
expensive and less available, but the calcium channel blocker of choice in 
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this part of Africa. Results of controlled trials have demonstrated the safety 
and efficacy of calcium antagonists in elderly patients with HTN. They appear 
well suited for elderly patients, whose hypertensive profile is based on 
increasing arterial stiffness, decreased vascular compliance, and diastolic 
dysfunction (259). The price per 10mg tablet was 45TzS (2.25 pence) and 
therefore a patient on 10mg bd of nifedipine could be treated for a month for 
£1.50. After this, the price of anti-hypertensives rose fairly rapidly, and 
combined with lower levels of effectiveness / more side-effects, meant our 
treatment policies and guidelines were confined mainly to bendrofluazide and 
nifedipine. ACE-Inhibitors were not used by me given their reduced 
effectiveness in elderly black people (259), their lack of availability in many of 
the villages and their price making them prohibitively expensive for most 
patients.  
With respect to the 38 patients who said they were actually taking anti-
hypertensive medication regularly, it transpired that in a significant number of 
cases this did not mean on a daily basis. What it often meant was that the 
patient had been prescribed medication at one point after presenting with 
some likely unrelated symptom such as headache, been prescribed 
bendrofluazide as they had concomitant HTN, and taken a tablet 
subsequently only when they felt unwell or had a headache. They were 
reminded of the importance of taking daily tablets and educated as to why 
this was the case. 
Only 1.4% of patients with a BP >160/100 were considered too frail for 
treatment. It would be interesting to know similar levels of frailty in high-
income countries but this seems to be a fairly low figure in an over-70s 
population. When we look at levels of disability, a marker of frailty, we can 
compare BI scores with a European population. Using the BI, 4.3% and 6.9% 
of the Study Population were severely and moderately disabled respectively, 
compared to 9% and 26% in an equivalent European population (263). This 
supports the idea that the Study Population had fewer patients who were too 
frail to be treated than may be found in other populations. 
During my time in Tanzania, I produced HTN guidelines to try and 
standardise treatment across the district (see Appendix 6). There was a huge 
disparity with regard to the quality of health assessment and the availability 
of drugs across the district, generally showing a trend to increased quality of 
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assessment and drug availability with size of health centre and accessibility 
by road. The guidelines were produced using a combination of best 
evidence, local availability of drugs and Tanzanian national guidelines in 
conjunction with the District Medical Officer. 
 
7.3.7 Electrocardiographic criteria of left ventricular hypertrophy 
The main findings from this section are that the prevalence of ECG LVH in 
this elderly population is 25%, ECG LVH correlates well with both systolic 
and diastolic BP readings, but doesn't appear to correlate particularly well 
with echo findings, providing a sensitivity and specificity of 18% and 59% 
respectively when compared to the 'gold standard' for measuring LVH of 
echocardiography. ECG LVH is more common in men and also in those with 
a lower BMI. 
ECG LVH has previously been shown to be an ominous sign. It is associated 
with an 8-fold increase in cardiovascular mortality and has been shown to be 
more common in stroke and MI patients. Hypertension predisposes, and at 
systolic pressures >180mmHg evidence of ECG LVH is seen in 50 percent in 
other studies (264). However, the precise pathologic and anatomic meaning 
of ECG LVH remains unclear, as it is only modestly related to actual findings 
on echo and MR. It has been suggested that the ECG 'aberrations' are as 
much to do with myocardial damage as hypertrophy itself (264). The fact that 
1 in 4 of this elderly population has evidence of ECG LVH suggests that 
there is a significant number at risk of cardiovascular sequelae. 
Whilst there is a good correlation between ECG LVH and SBP, this 
relationship is not so good for echo parameters of hypertrophy. The numbers 
in this section of the study were small and thus make it more difficult to 
comment confidently but may suggest that LV geometric patterns in elderly 
black Africans, particularly those that are hypertensive, may be different from 
other populations studied i.e. this population does not see classic 
hypertrophied myocardium as a result of hypertension and may see 
myocardial 'damage' as previously mentioned but with normal wall 
thicknesses. In retrospect, what would have been enlightening would have 
been to measure troponin and BNP levels to look for chronic myocardial 
damage and wall stretch. 
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It is little surprise that the ECG LVH group had a lower mean BMI, and 
contained more men as a percentage. The sensitivity of ECG LVH criteria is 
known to be reduced in obese patients, thought to be because of attenuating 
effects of increased tissue mass between praecordial electrodes and the 
heart itself (265). My study cohort revealed women to have a higher BMI 
than men, and with extra breast tissue in a significant number of patients, it 
stands to reason that men would have a greater percentage fitting criteria for 
ECG LVH. 
With regard to numbers of ECGs with an LVH index annotation, 1350 is 
lower than I was expecting, particularly when compared to the number of 
ECGs with P wave annotations. However, LVH index relies on specific leads 
(V1, V5/V6) for its measurement, whereas the P wave is a 'global' 
measurement, taken over 12 leads. This may explain this fact to a degree, 
but on visual inspection of ECGs without LVH index annotations, whilst some 
display a sub-optimal baseline, one would be confident of measuring LVH 
index manually and reliably. This has not been done on the remainder as I 
felt it would give more accurate results just using one analysis technique and 
not to introduce measurement bias between techniques. 
 
7.4 Conclusions 
My results suggest that HTN prevalence rates are high in the elderly in 
Tanzania and are approaching (if not having caught up with) rates seen in 
high-income countries, having rapidly increased in recent years. 
Despite this, the rates of detection, treatment and control remain very low 
and rather than the classic ‘rule of halves’, my study conforms more to a ‘rule 
of sixths’, despite attempts at education, community awareness programs 
and increased availability of medication over recent years. 
My findings of a very low prevalence of AF and a high prevalence of HTN 
suggest that HTN remains overwhelmingly the largest risk factor for stroke, 
and poor rates of detection and control the reason for increased incidence 
rates in the Study Population compared to Caucasian populations in high-
income countries.  
ECG LVH correlates well with BP, particularly SBP, but this does not always 
translate into true ventricular hypertrophy. 
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Chapter 8. Overview of Discussion 
 
8.1 Strengths 
Overall strengths of the project are that I have collected a large amount of 
data from an elderly African cohort. Methodologically robust in the random 
choice of villages to reflect the population spread across the whole district, 
with the use of census data collected by experienced enumerators and a 
sound infrastructure, my study has enabled the collection of important NCD 
data in an elderly population. 
Specifically with respect to AF, I used the gold standard of 12-lead ECG to 
identify my cases and, likewise with respect to HTN, I used an automated 
machine minimising inter-observer variability and validated to British 
Hypertension Society standards (243). 
With respect to PWI, all study variables were ascertained uniformly and, of 
particular note, the ECGs were analysed with computer assistance, thus 
minimising intra- and inter-observer variability. My analysis did not exclude 
outliers and thus gives a more balanced overall picture of PWI. 
 
8.2 Limitations 
The study was limited by a number of factors. I was expecting to find a 
similar AF prevalence rate to that found in elderly African-Americans but the 
low overall numbers of patients with AF made it difficult for me to comment 
confidently on different sub-groups. It is possible but unlikely that people with 
AF were under-represented in the 25.1% of the 70 and over population that I 
screened, given the random choice of villages accurately reflecting 
topographic and demographic differences within the DSS. There is a 
mismatch in numbers from the census and those I actually saw and it is also 
possible that AF was over-represented in those who refused to be screened. 
Again, this is unlikely given poor access to healthcare and thus patients with 
chronic ill health are unlikely to pass up the opportunity to see a doctor. The 
use of historical events to determine participants’ year of birth reduces the 
reliability of the ages quoted and there is a possibility that the population was 
younger than quoted. However, this is a well recognised problem of research 
in SSA and the techniques I used are well-validated. Whilst I had excellent 
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interpreters who were medically trained, it was difficult at times to ascertain 
the finer points of a patient’s symptom burden, given the lack of medically 
descriptive words in Swahili and other local tribal languages spoken by 
village elders.  
With respect to PWI, the measurement method meant my data produced 
PWI calculated from a median P wave, rather than each individual P wave on 
the 12-lead ECG. The reason for doing this is that PON and POFF were more 
reliably identified as the production of a median beat eliminates a significant 
amount of baseline ‘noise’. This comes at the expense of data from each 
individual lead and the ability to calculate PWI such as maximum and 
minimum PD and P wave dispersion. 
The median differences with age and gender were all fairly small in a clinical 
sense. Whilst many were statistically significant, the differences are unlikely 
to be clinically significant. However, my primary aim for this part of the study 
was not to look at clinical impact of the changes but simply initially to report 
values and trends. I foresee that these results will be the precursor to the 
production of reference ranges for an elderly SSA population and in the 
future be used to predict disease states such as AF. 
With respect to the ambulatory monitors, there was no truly random choice of 
patients. With respect to the Holter monitors, if I was in a certain village for 
several consecutive days, it was often the patients that turned up earlier in 
the morning who were asked to wear the monitors. This allowed them to 
wear them for as close to 24 hours as possible, return them and for me to 
download the data to a laptop and then place them on someone else the 
following day. Thus, truly random choice was sacrificed for extra patient 
numbers and may well have biased the results in favour of patients who were 
fitter and more mobile (and less likely to have cardiac problems?) and thus 
likely to get to the health centre earlier, or patients who live closer to the 
health centre and thus possibly look after their health more closely. With 
respect to the event recorders, again it was not a truly random choice given I 
looked at the ECG to attempt a rough calculation of P wave ‘predictors’ for 
the purposes of getting an even spread of patients in each group. All 10 (or 8 
following 2 having malfunctioned!) monitors were put on patients in 1 village 
on a Tuesday with the aim of returning to that village the following Monday to 
collect the recorders to allow the data to be downloaded on a Monday night 
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and recorders placed back on patients the following day in a different village. 
It was sometimes the case that I struggled to find 10 patients willing to wear 
the monitor in one village and other participants aged over 70 were therefore 
selected. 
With respect to the HTN data, there are obvious limitations inherent in 
epidemiological surveys with assessing BP on only one visit. This has been 
shown previously to overestimate prevalence and underestimate those 
adequately controlled on treatment (266). In addition, there are problems 
inherent to BP measurement in the Tanzanian elderly. Firstly, most will never 
have had their BP taken before, and this will exacerbate anxiety levels and 
‘white-coat hypertension’, already known to be a significant issue in the 
elderly. Secondly, there is the idea of ‘pseudohypertension’, a problem 
whose prevalence is not really known, but suggested to be an issue in the 
elderly due to stiffening of the arteries and thus decreased compliance. Both 
of these problems are likely to have overestimated prevalence, despite my 
trying to minimise effects of the former with a clear explanation of what 
having BP recorded involved and discarding the first measurement of three. 
Another issue with my HTN data is the fact that I found it very difficult to 
assess dietary and social contributory factors. The rural Tanzanian diet is 
very healthy in that it consists of a lot of rice and vegetables but also often 
lacking in taste for the same reason. There is a liberal usage of salt therefore 
to flavour food but I found it very difficult to quantify exact amounts and felt 
my data may suffer due to the inaccuracies of this and therefore I made a 
conscious decision to stop collecting this data. Likewise, estimating alcohol 
intake proved beyond our means, as most elderly people enjoy social 
drinking, where they will pass around a container of 'mbege', or local brew, 
and each person will imbibe in turn. Therefore, when I asked about alcohol, 
the reply came 1 or 2 litres per night, but as this was shared often between 
several people and the exact percentage of alcohol was unknown as it had 
been brewed locally, I could not estimate number of units drunk. I did not 
collect data on smoking as very few elderly people smoked as they could not 
afford it. The data comparing ECG and echo LVH is limited due to small 
numbers that had a complete data set for comparison. 
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8.3 What does this study add? 
I began with the hypothesis that AF would be more common in the elderly 
population of Tanzania, primarily because of rheumatic mitral valve disease, 
and was keen to perform a robust community-based prevalence study of AF 
in the elderly, given its causal link with stroke and the substantially increased 
stroke burden seen in Tanzanians (267). What is clear from this study is that 
elderly Tanzanians appear to have a strikingly low prevalence of persistent / 
permanent AF and a similar prevalence of PAF to other populations, 
suggesting that the increased burden of stroke is either due to other risk 
factors such as hypertension, or that black Africans are more susceptible to 
smaller amounts of PAF. It tells us that AF does not appear to be a large 
health burden in elderly Tanzanians and is thus important when assessing 
healthcare planning for NCDs in this area in the future. 
What is particularly interesting is the finding of HTN prevalence rates similar 
to high-income countries in the setting of such low prevalence rates of AF. 
Currently this is difficult to explain but suggests that HTN does not 
predispose to AF in black Tanzanians as it does elsewhere in the world. 
However, it also tells us that HTN is likely to be the major risk factor for the 
increased stroke burden seen in Tanzanians and that, whilst the elderly 
population are particularly at risk, detection, treatment and control rates 
remain dangerously low. 
 
8.4 What further research does it suggest? 
It will be interesting to know whether the low prevalence of AF is confined to 
the elderly, or whether this phenomenon extends across all adult age groups, 
and prevalence in young and middle-aged adults needs to be determined.  
Future research into whether genetics play a role in the low prevalence of AF 
despite the high prevalence of HTN will be important. Studying AF candidate 
gene differences between this population and other populations, both in 
other areas of Africa and in high-income countries will be interesting. Is there 
some degree of genetic 'protection' from developing AF, or the myocardial 
substrate that predisposes to AF in this population? Further research may 
even be directed towards developing a novel risk prediction algorithm for AF 
in this population, thereby identifying those at highest risk for monitoring / 
treatment. 
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Further confirmation of HTN prevalence rates and the effects of ‘white-coat 
hypertension’ and arterial stiffness will ideally be determined in future studies 
using 24-hour ambulatory BP monitoring and assessing pulse wave 
velocities. In addition further work is needed, particularly in the elderly, to 
look at reasons for such low levels of detection, treatment and control of 
hypertension and identify possible solutions. 
With respect to PWI, rural elderly Tanzanians appear to have different 
‘normal’ values to other populations studied. Hopefully, work done here will 
lead on to identification of reference ranges in this population and may be of 
some use clinically, in the future (with some refinement) in order to identify 
people at risk of NCDs such as AF and stroke. 
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Appendix I: Information sheet for recording a 12-lead ECG 
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Appendix II: a. Demographic Data Collection Proforma 
 
KIBALI CHA KUTAFITI MATATIZO YA MISHIPA YA FAHAMU NA KUCHUNGUZA KISABABISHI KATIKA 
WILAYA YA HAI 
 
Tarehe ya uchunguzi        Eneo la uchunguzi 
Date of assessment: __ __/ __ __/ __ __     Assessment site: __________________________________ 
 
DEMOGRAPHIC DETAILS/TAARIFA ZA WATU 
Jina     Tarehe ya kuzaliwa Umri        Miaki Jinsia: Me/Ke 
Name: ____________________________DOB: ___/___/___  Age: |__|__|__| Yrs   Sex: M / F   
 (Jina)             kijiji (Jina) 
Balozi (name) :__________________________ Tawi/Village(name):____________________ 
           (nyumba 10)        No. yanyumba        No. yasimu 
Shina (10 cell no.)|__|__|__| House code  |__|__|__| Cell phone no.:_______________ 
Mgonjwa anaweza kutembea    Umbali/muda wa kwenda kwenye kituo cha afya 
Ambulant:     Yes/Ndiyo No/Hapana    Distance/Time to Health Centre:________________  
 
HISTORIA YA ZIADA INAHITAJIKA  Yes/Ndyiyo  No/Hapana 
 
FURTHER DEMOGRAPHIC DETAILS/ TAARIFA ZA ZIADA ZA WATU  
 
Tribe/kabila|____| Religion/Dini |____| Marital status/Hali ya ndoa |___| Household comp’n/Muundo wa kaya |___| 
1. Mzaramo  1.    Christian/Mkirsto 1. Married/Ameoa/olewa 1. Lives Alone/Anaishi mwenyewe 
2. Mndengereko 2.    Muslim/Mwislam 2. Widowed/Mjane  2. With spouse/Anaishi na mwenza 
3. Mchagga   3.    Hindu/Mhindi  3. Divorced/Mtalikiwa               3. Spouse/others/ Na mwenza na  
4. Mmasai   4.    Pagan/Mpagani 4. Single/Kapera       wengineo 
5. Mpare   5.    Other – state   5. Separated/Ametengana 4. W son/daughter/ Na watu wazima 
6. Mnyamwezi        Nyingine – taja_____________   5. W grandchildren/ Na watoto wengine 
7. Msukuma        6. Other state Nyingine - taja ________ 
8. Other – state/ Nyingine - taja _____________      
        
Age when married/Umri alipoowa/olewa |__|__| YRS Number of children/Idadi ya watoto  |__|__| 
 
Patient born in Hai/Mgonjwa mzawa wa Hai: Yes/Ndiyo No/Hapana Details/Maelezo_______________ 
 
Ever lived outside Hai/Alishawahi kuishi nje ya Hai:  Yes/ Ndiyo No/HapanaDeta ils/Maelezo_________ 
 
BLOOD PRESSURE/ SHINIKIZO LA DAMU Tulia kwa dakika 5 kabla ya kusoma kipimo na dakika 1 kati ya kila kipimo, kasha simama 
kwa dakika 3 kabla ya kusoma kipimo cha mwisho                            AKIWA AMESIMAMA/ 
STANDING 
Systolic     
Diastolic     
 
Kimo/Height/demispan (cm)_______________Uzito/Weight(measured/estimate)(kg)________________ 
 
SCREENING QUESTIONNAIRE Answered positively/ DODOSO LA UCHUNGUZI/Lililojibiwa kwa mtazamo chanya  
Swali Mtazamo 
Chanya 
Mtazamo 
Hasi 
Elezea 
1    
 
2    
 
3    
 
4    
 
5    
 
6    
 
7    
 
8    
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9    
 
10    
 
11    
 
12    
 
13    
 
14    
 
15    
 
16    
 
17    
 
18    
 
19    
 
20    
 
21    
 
22    
 
23    
 
24    
 
 
 
 
Kazi za kila siku (za maisha) 
Question 
no 
Alama/Score 3 2 1 0 
1 Kula  Anajilisha Anahitaji msaada wa 
kula 
Analishwa 
2 Kuoga  
 
 Anajitegemea Anategemea mtu 
3 Kujiweka katika hali 
ya usafi kwa mfano 
kusugua meno 
  Anajitegemea Anategemea mtu 
4 Kuvaa  Anajitegemea Anahitaji msaada 
mdogo  
Anategemea mtu 
5 Kinyesi  Anaweza kuzuia 
kinyesi 
Kinatoka mara moja 
moja kwa bahati 
mbaya 
Kinyesi kinatoka 
bila kufahamu 
(hawezi kuzuia) 
6 Mkojo  Havuji mkojo Unavija mara moja 
moja kwa bahati 
mbaya 
Anavuja mkojo 
7 Kutumia choo  
 
Anajitegemea Anahitaji msaada 
mdogo 
Anategemea mtu 
8 Anahamishwa na 
watu wangapi? Kwa 
mfano kutoka 
kitandani kwenda 
kwenye kiti 
Anajitegemea Anahitaji msaada 
mdogo 
Anahitaji msaada 
mkubwa/sana 
Anategemea mtu 
9 Kutembea Anajitegemea Anatembea kwa 
msaada wa mtu 
mmoja 
Anajitegemea 
wheelchair 
Hawezi 
kutembea 
10 Anatembea kilimani  Anajitegemea Anahitaji msaada 
mdogo 
Anategemea mtu 
 Vifaa vya 
kutembelea? 
Ndio 
Elezea 
 
 
 
Hapana Angetumia kama 
ingekwepo/ 
ingepatikana 
 
 Anamatatizo ya 
kuona? 
Ndio Hapana   
 Umeambiwa kwamba 
una kisukari? 
Ndio Hapana   
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b. Patient / Control Data Collection Proforma  
 
HAI ATRIAL FIBRILLATION PREVALENCE STUDY (2009/2010) 
 
STUDY SELECTION.  
 
DETAILS OF AF 
History: 1. Totally from patient 
2. Patient with collateral help (specify who)___________________ 
3. Totally from collateral (specify who)_______________________ 
  
                                                        
Symptoms yes No Details 
Palpitations    
SOB     
NYHA I (no Sx / limitation)    
NYHA II (mild Sx)    
NYHA III (mod Sx)    
NYHA IV (severe /rest Sx)    
PND    
Orthopnoea    
Pedal Oedema    
Chest Pain    
CCSAC 0 (asymptomatic)    
CCSAC I (strenuous)    
CCSAC II (moderate)    
CCSAC III (mild)    
CCSAC IV (rest)    
Pre-syncope    
Syncope    
Tiredness    
Limited ET    
Other please specify    
 
When did symptoms start? Year:____________ Age:__________ 
 
Details:____________________________________________________________________________ 
 
Any event illness prior to first Sx? Yes  No Details__________________________ 
 
History: Free Text (please continue on reverse as required) 
 
 
 
 
 
 
 
 
 
  
D: TREATMENT HISTORY 
 
Help Sought for Cardiac Symptoms: Yes   No  Age/Year when help sought_________ 
 
1.   Self-medication using modern drug |___|  7.    Government hospital  |___| 
2.   Family members or friends |___|  8.    Private dispensary  |___| 
3.   Traditional healers/medicines |___|  9.    Private health centre  |___| 
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4.   Village health worker  |___|  10.  Private hospital   |___| 
5.   Government dispensary  |___|  11.  Private Pharmacy, shop  |___| 
6.   Government health centre  |___|   
 
Details:________________________________________________________________________ 
 
Known AF/Reason Given for the Symptoms?  Yes  No    
      
Diagnosis/Reason? ______________By Who?___________________When? ___________________ 
 
Follow up? Yes No Details___________________________________________________ 
 
Treatment for AF symptoms 
Treatment   Drug Dose/
Freq 
From 
who 
Since 
when 
Compliance Afford 
Reg 
Effective Side 
Effects 
Why stopped 
Current 
 
Y / N 
    Daily 
From time to time  
When available 
 
Y / N 
Very Good 
Good 
No effect 
Bad  
Very Bad 
Dizziness 
Tiredness 
Headache 
Nausea 
Rash 
Other 
 
N/A 
 
 
Traditional Healer Intervention?: Yes No Length of trad. Healer treatment: 
 
1. Oral medication   |___|    
2. Bath     |___|   1.  Less than one week   |___| 
3. Inhalation   |___|   2.  1 – 2 weeks    [___] 
4. Topical    |___|   3.  2 weeks – 1 month   [___] 
5. Roots/leaves (state type if known) |___|   4.  More than one month   [___] 
6. Scarification   |___|    
7. Other (state):________________  |___| 
 
Effective? Yes  No  Cost________________________________________ 
 
Explanation/Diagnosis_________________________________________________________________ 
 
Details:_____________________________________________________________________________ 
 
Other Medications?   Yes  No 
 
Details:_____________________________________________________________________________ 
 
PAST MEDICAL HISTORY 
 
Any current/past severe/chronic illnesses Yes   No 
 
1.   Angina / IHD  |___|  6.   Rheumatic Fever   |___| 
2.   Hypertension  |___|  7.   Heart Failure    |___| 
3.   Stroke  |___|  8.   Hyper/Hypothyroidism   |___| 
4.   Diabetes  |___|  9.   Congenital Cardiac Problem    
5.   Hypercholesterolaemia |___|  10. Other (state)    |___| 
 
Details______________________________________________________________________________ 
If Stroke, impaired ADLs?  Yes   No 
 
1.   Mobility  |___|  6.   Toilet Use    |___| 
2.   Continence  |___|  7.   Feeding    |___| 
3.   Washing  |___|  8.   Transfer    |___| 
4.   Dressing  |___|  9.   Walking Aids    
5.   Grooming  |___|  10. Other (state)    |___| 
 
Details: ____________________________________________________________________________ 
 
In the previous twelve months: 
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Admitted to: hospital? Yes No  Attended health centre/dispensary? Yes No 
 
1.   Once     1.  Once    
2.   Twice     2.  Twice 
3.   More than twice (state) ____________ 3.   More than twice (state)____________       
 
Details/diagnosis:_____________________________________________________________________ 
 
FAMILY HISTORY 
 
Is there a family history of Cardiac disorders?    Yes  No                                                              
 
 1. Brother  |___|  7. Grandmother  |___|                            
 2. Sister  |___|  8. Grandfather  |___| 
 3. Father  |___|  9. Maternal aunt  |___| 
 4. Mother  |___|  10. Paternal  aunt  |___| 
 5. Son  |___|  11. Maternal uncle  |___|                                 
 6. Daughter  |___|  12. Paternal uncle  |___| 
 
State what _______________________________________________________________________________________________ 
 
SOCIAL HISTORY 
 
Alcohol Intake Yes No    1.   Mainly local brew  1.   Light (weekends and on holiday 
2.   Mainly bottled beer  2.   Average (<4 days/week)  
3.   Mainly spirits  3.   Heavy (4 + days/week) 
 
More heavily in the past?   Yes   No  
Details:_____________________________________________________________________________ 
 
Occupation Past/Present:____________________________ 
Had to stop because of symptoms? Yes No 
Details____________________________________________________________________________ Smoking / 
Snuff / Chewing Tobacco Yes No  Pack Years____________________ 
 
Caffeine (>4 cups / day) Yes No Amount____________________ 
  
 
CLINICAL EXAMINATION                                                         
 
General Inspection 
 
Comfortable at Rest Yes No 
Details______________________________________________________ 
 
Pedal Oedema  Yes  No 
Details______________________________________________________ 
 
Other Obvious Diagnoses / Signs Yes No 
Details______________________________________________________ 
 
Pulse 
Rate__________________________ 
 
Regular  Yes No 
Details:__________________________________________________________________ 
 
Normal Character Yes No 
If No, Details:_____________________________________________________________ 
JVP 
Raised   Yes No  
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Description:______________________________________________________________ 
 
Facial Features     
Arkus   Yes No 
Xanthelasma  Yes No 
Anaemia  Yes No 
Malar Flush  Yes No 
Cyanosis  Yes No 
Angular Stomatitis Yes No 
  
 
Fundoscopy       
L Eye  Normal   Abnormal  Impossible 
R Eye  Normal   Abnormal  Impossible 
Details:__________________________________________________________________ 
 
Chest Inspection 
Scars  Yes  No 
Details:_________________________________________________________________ 
Deformity Yes  No  
Details:_________________________________________________________________ 
 
Chest Palpation 
Apex Beat  Normal  Abnormal Impalpable 
Details:_________________________________________________________________ 
RV Heave  Yes  No 
Thrill   Yes  No 
Details:_________________________________________________________________ 
 
Chest Auscultation 
S1 + S2 Normal  Yes  No 
Details:_________________________________________________________________ 
Murmurs  Yes  No 
Systolic   Yes  No 
Diastolic  Yes  No 
Details:_________________________________________________________________ 
Added Sounds  Yes  No 
Details:_________________________________________________________________ 
Basal Creps  Yes  No 
Details:_________________________________________________________________ 
 
 
Miscellaneous 
Carotid Bruit  Yes  No 
Details:___________________________________________________________________ 
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Renal Bruit  Yes  No 
Details:___________________________________________________________________ 
Peripheral Pulses Yes  No 
Details:___________________________________________________________________ 
Thyroid Normal  Yes  No 
If no, details:_______________________________________________________________ 
Summary 
 
 
 
 
 
 
 
 
 
 
INVESTIGATIONS 
 
ECG Done?  Yes No 
 
Rhythm Strip  Yes No 
 
P Wave analysis Yes No 
 
Electrocardiogram / Rhythm Strip 
Atrial Fibrillation   Yes No 
Details________________________________________________________________________________________
__________________________________________________________________ 
 
Minnesota Coding System (for ischaemia) Definite  Equivocal Other 
Details (code)___________________________________________________________________ 
 
AF Predictors     Yes No 
 
P Wave Terminal Force (mcV/s)____________________________________________________ 
 
Maximum P Wave Duration (ms)___________________________________________________ 
 
Mean P Wave Duration (ms)______________________________________________________ 
 
P Wave Dispersion (Pmax-Pmin) (ms)______________________________________________ 
 
P Wave Duration in Lead II (ms)___________________________________________________ 
 
Maximum P Wave Area (mcV/ms)_________________________________________________ 
 
Mean P Wave Area (mcV/ms)____________________________________________________ 
 
PR Duration (ms)_______________________________________________________________  
 
Other Abnormalities_____________________________________________________________ 
_____________________________________________________________________________ 
 
 
Echocardiogram 
 
Left Ventricle 
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LV Function Normal Yes  No 
Estimated EF <35% (severe)  36-44% (mod)  45-54% (mild)  >55% 
Details:_____________________________________________________________________ 
RWMAs  Yes  No 
Details:_____________________________________________________________________ 
LV Wall Thickness Normal Yes  No 
Details:_____________________________________________________________________ 
IV Septal Thickness Normal Yes  No 
If No, degree hypertrophy Mild  Moderate  Severe 
Details:_____________________________________________________________________ 
Posterior Wall Thickness NormalYes  No 
If No, degree Hypertrophy Mild  Moderate  Severe 
Details:_____________________________________________________________________ 
LV Diameter Normal  Yes  No 
LVIDd Normal   Yes  No 
If No, How Dilated  Mild  Moderate  Severe 
Details:_____________________________________________________________________ 
LVIDs Normal   Yes  No 
If No, how Dilated  Mild   Moderate  Severe 
Details:_____________________________________________________________________ 
Any Other Abnormality_________________________________________________________ 
___________________________________________________________________________ 
 
Right Ventricle 
RV Function Normal Yes  No 
If No, Degree Impairment Mild  Moderate  Severe 
Details:_____________________________________________________________________ 
RV Size Normal Yes  No 
If No, Degree Dilated  Mild  Moderate  Severe 
Details:_____________________________________________________________________ 
 
Atria 
LA size Normal Yes  No 
If No, Degree Dilated  Mild   Moderate  Severe 
Details:_____________________________________________________________________ 
RA Size Normal Yes  No 
If No, Degree Dilated  Mild  Moderate  Severe 
Details:_____________________________________________________________________ 
 
Aortic Valve 
AoV Normal  Yes  No 
Appearance of Valve:___________________________________________________________ 
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AoStenosis  Yes  No 
Peak Velocity (m/s)_____________ Mild  Moderate  Severe 
Peak Pressure Drop (mmHg)_______ Mild  Moderate  Severe 
Valve Area (cm2)________________ Mild  Moderate  Severe 
Overall Impression Severity AS  Mild  Moderate  Severe 
AoRegurgitation Yes  No 
P1/2T___________________  Mild  Moderate  Severe 
Overall Impression Severity AR  Mild  Moderate  Severe 
 
Mitral Valve 
MiV Normal  Yes  No 
Appearance of Valve:___________________________________________________________ 
MiStenosis  Yes  No 
MiV Area (cm2)_____________  Mild   Moderate  Severe 
MiV P1/2T(msec)___________  Mild   Moderate  Severe 
Mean Pressure Drop (mmHg)________ Mild  Moderate  Severe 
Overall Impression Severity MS:  Mild   Moderate  Severe 
MiRegurgitation  Yes  No 
Jet Area(cm2):_______________ Mild  Moderate  Severe 
Jet Area / LA (%)____________  Mild  Moderate  Severe 
Overall Impression Severity MR: Mild  Moderate  Severe 
Tricuspid Valve 
TV Normal  Yes  No 
TR   Yes  No 
Severity TR  Mild  Moderate  Severe 
Details:_____________________________________________________________________ 
PASP (RAP+RVSP mmHg)________________ 
TS   Yes  No 
Severity TS  Mild  Moderate  Severe 
 
Pulmonary Valve 
PV Normal  Yes  No 
Details:_____________________________________________________________________ 
 
Miscellaneous 
Aorta Normal  Yes  No 
Details:_____________________________________________________________________ 
Diameter of Sinus of Valsalva__________ 
Dilatation   Mild   Moderate  Severe 
Pericardial Effusion Yes  No 
Details (+ other pericardial problems):_______________________________________________ 
IVC Normal  Yes  No 
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Details:_____________________________________________________________________ 
 
Summary Echo Findings 
 
 
 
 
 
 
 
 
 
Bloods 
 
Blood taken?  Yes No Location of samples:___________________________ 
 
 Haematology  Serum   
 
Date Blood Taken:__________________________________________________ 
    
RESULTS 
Record 000 if the blood tests are not carried out 
 
Haematology 
2 Haemoglobin (g/dl)      |___||___|.|___| 
3 Haematocrit (fl)       |___||___||___| 
4 MCV        |___||___|.|___| 
5 Blood glucose (mmol/L)      |___|___| 
6 Platelets       |___|[___] 
7 White Cell Count      |___|[___] 
8 Neutrophils       [___][___]  
Biochemistry 
1 Sodium (134-147 mmol/L)     |___||___||___| 
2. Potassium (3.5-5.0mmol/l)     [___][___][__] 
3 Urea (3.1-7.9 mmol/L)      |___|.|___| 
4 Creatinine (75-155 umol/L)     |___|___|___| 
5 Calcium (2.12-2.60 mmol/L)     |___|.|___|___| 
6 Corrected calcium – calcium +0.1(40-albumin value)     |___|.|___|___| 
(If albumin value >40 corrected calcium = calcium +0.1(albumin value-40)  
7. Magnesium       |___|.|___|___| 
8.  Total protein (60 – 80 g/L)     |___|___| 
9.  Albumin (34-50 g/L)      |___|___| 
10. Bilirubin       [___][___][___]  
11.         Alkaline phosphatase (35-120 IU/L)    |___|___|___| 
12.         Alanine transaminase (<45 IU/L)     |___|___|___| 
13.      TSH (0.35-4.90 mU/L)      |___|.|___|___| 
14. Lipid Profile        
 Triglycerides       [___][___][___] 
 HDL Cholesterol      [___].[___][___] 
 Non-HDL Cholesterol      [___].[___][___] 
 
24 Hour Tape / R - Test  Yes  No 
Paroxysmal AF  Yes  No 
Details:_____________________________________________________________________ 
Other Arrhythmias Yes  No 
Details:_____________________________________________________________________ 
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Appendix III: Follow-up Data Collection Proforma 
FOLLOW UP PROFORMA 
 
Name________________________________Balozi_______________________________Age_______ 
 
 
 
 
 
 
 
 
 
DETAILS OF FOLLOW UP 
 
History: 1.From patient / 2.Patient with collateral_____________ /3.From collateral_________________ 
 
Medication for AF/Hypertension. Drug/Dose/Frequency:  
Effective: ?reduction of symptoms  
Side effects:  
Treatment ongoing? If not why stopped: Side effects/Can’t Afford/Didn’t renew prescription 
 
 
 
 
 
Blood Pressure 
 
 
 
Plan (?further treatment needed) 
 
Diagnosis: 
Details: 
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Appendix IV: Prescription / Referral Form 
 
Northumbria Healthcare Foundation Trust, Newcastle, England Neurological Disorders and Risk Factors 
 
I AM A DOCTOR FROM ENGLAND, I HAVE REVIEWED THE BELOW NAMED 
PATIENT TODAY AS PART OF A STUDY LOOKING INTO NEUROLOGICAL 
DISORDERS AND THEIR RISK FACTORS, I HAVE DIAGNOSED THE FOLLOWING 
CONDITION AND WOULD SUGGEST THE FOLLOWING TREATMENT. I WOULD 
BE GRATEFUL IF YOU COULD SUPPLY THIS. THANK YOU. 
NAME OF PATIENT:      DATE OF BIRTH OF 
PATIENT: 
BALOZI:       VILLAGE: 
DIAGNOSIS MADE: 
TREATMENT SUGGESTED 
 
SIGNATURE OF DOCTOR:    DATE: 
NAME OF DOCTOR:     GMC NUMBER: 
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Appendix V: Atrial Fibrillation Information sheet and Consent Form 
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Appendix VI: Hypertension Guidelines for Diagnosis and Treatment in the Hai District 
Blood Pressure Assessment and When to Initiate Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Target Organ 
Damage* 
CV Risk Factors** Associated Clinical 
Conditions*** 
Non-Pharmacological 
Therapy**** 
1.Left Ventricular 
Hypertrophy 
2.Renal Impairment 
(proteinuria / raised 
Creatinine 
3.Grade 2 
Hypertensive 
Retinopathy  
1.Men>55, Women>65 
2.Diabetes Mellitus 
3.Smoker 
4.Family History 
Premature CV Disease 
(stroke / Myocardial 
Infarction) 
1.Stroke / TIA 
2.Angina / Myocardial 
Infarction 
3.Congestive Cardiac 
Failure 
Chronic Renal Failure 
4.Grade 3/4 
Hypertensive 
Retinopathy 
1.Stop Smoking 
2.Decrease Salt Intake 
3.Decrease Alcohol 
Intake 
4.Weight Loss 
5.Increase Physical 
Activity 
6.Increase 
Fruit/Vegetables 
 
Raised BP (≥140/90) from 3x BP (take average of last 2) 
after sitting quietly for 5 minutes. 
 
Clinical Evaluation For 
1. Target Organ Damage (TOD)* 
2. Cardiovascular (CV) Risk Factors** 
3. Associated Clinical Conditions (ACC)*** 
4. Consider Investigation For Causes 2° Hypertension 
(<55 years old) 
Counselling Regarding Non-Pharmological Treatment 
(NPT)**** 
BP 160 – 179 
100 – 110 
+ 
<3 CV Risk 
Factors 
BP ≥180 
110 
Any Grade 
Hypertension with 
any TOD, ACC or ≥3 
CV Risk Factors 
BP 140 – 159 
90 – 99 
+ 
1 or 2 CV Risk 
Factors 
BP 140 – 159 
90 – 99 
+ 
No CV Risk 
Factors 
Monitor NPT 3 – 6 months Monitor NPT 
6 – 12 
months 
Start Drug Treatment if BP ≥140/90 Start Drug 
Treatment if 
BP ≥150/95 
 
 
Start Drug Treatment 
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Drug Treatment For Hypertension 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Guidance Notes 3rd Line Agents 
*treatment includes Isolated Systolic 
Hypertension (i.e. Raised Systolic BP with 
Normal Diastolic BP, and vice-versa) 
**Good Practice to monitor Renal Function 
initially and with every dose titration 
***Care in Elderly (>70 years), frail or those with 
Postural BP drop (>20/10mmHg or Symptomatic) 
1.Methyldopa initially 250mg three times daily 
increased to maximum 1g tds (elderly 125mg 
twice daily initially, max 1g bd) 
2.Propranolol initially 80mg twice daily, max 
160mg twice daily 
3.Captopril** initially 12.5mg twice daily, max 
50mg twice daily (elderly initially 6.25mg bd) 
 
Decision To Treat 
Hypertension Counselling 
1. Need For Daily AND Lifelong Treatment 
2. Adverse Consequences of Hypertension and Non-
Compliance with Medication 
3. Drug Regime 
4. Reinforce Non-Pharmocological Therapy 
Nifedipine 20mg twice daily for 
1 week, then increase to 40mg 
twice daily if no side-effects*** 
Bendrofluazide** 2.5mg 
once daily for 1 week, then 
increase to 5mg if no side-
effects*** 
Bendrofluazide** 2.5mg once 
daily 
OR 
Nifedipine 20mg twice daily 
BP ≥180 
110* 
BP 140 – 180 
90 – 109* 
 
Review BP 1 month Review BP 1 month Review BP 1 month 
BP ≥140/90 
Start 
Nifedipine 
20mg twice 
daily 
BP <140/90 
1.Continue 
Treatment 
2.Review 3-
6 months 
BP ≥140/90 
Start 
Bendrofluazi
de** 2.5mg 
once daily 
BP <140/90 
1.Continue 
Treatment 
2.Review 3-6 
months 
 
BP ≥140/90 
Increase 1st 
Agent to 
Maximum 
Dose or Add 
2nd Agent 
BP <140/90 
1.Continue 
Treatment 
2.Review 3-6 
months 
 
Review BP 1 month 
If BP remains ≥140/90, either increase 2nd Agent to Maximum Dose 
OR Add 3rd Agent 
Review BP 1 month 
If BP remains ≥140/90, add 2nd 
agent / increase to maximum 
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Appendix VII: Fieldwork Photographs 
 
 
 
 
 
 
 
 
 
 
 
 
 
Traditional homestead in Hai district (Mount Kilimanjaro in 
background) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Hai district research team 
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Examining a patient with AF 
 
 
 
 
 
 
 
 
 
 
 
 
 
Running Repairs to the Project Car (a common sight!) 
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